Document:

CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2  	Exhibit 10.1

 

Certain confidential portions of this Exhibit, indicated by
[*], have been omitted pursuant to Rule 24b-2 of the Securities Exchange Act of 1934. The omitted materials have been filed separately
with the U.S. Securities and Exchange Commission 

 

 

TERM LOAN AGREEMENT

 

dated as of

 

May 8, 2015

 

between

 

Navidea
Biopharmaceuticals, Inc.

as Borrower,

 

The SUBSIDIARY GUARANTORS from Time to
Time Party Hereto,

 

and

 

Capital Royalty Partners II L.P., Capital
Royalty Partners II – Parallel Fund “A” L.P. and Parallel Investment Opportunities Partners II L.P.

 

as Lenders

U.S.
$60,000,000

 

 

    	 

    	 

    

 

Table
of Contents

 

	 	 	Page
	 	 	 
	SECTION 1	DEFINITIONS	1
	 	 	 
	1.01	Certain Defined Terms	1
	 	 	 
	1.02	Accounting Terms and Principles	20
	 	 	 
	1.03	Interpretation	21
	 	 	 
	1.04	Changes to GAAP	21
	 	 	 
	SECTION 2	THE COMMITMENT	22
	 	 	 
	2.01	Commitments	22
	 	 	 
	2.02	Borrowing Procedures	22
	 	 	 
	2.03	Fees	22
	 	 	 
	2.04	Notes	22
	 	 	 
	2.05	Use of Proceeds	22
	 	 	 
	2.06	Defaulting Lenders	23
	 	 	 
	2.07	Substitution of Lenders	24
	 	 	 
	SECTION 3	PAYMENTS OF PRINCIPAL AND INTEREST	24
	 	 	 
	3.01	Repayment	24
	 	 	 
	3.02	Interest	25
	 	 	 
	3.03	Prepayments	25
	 	 	 
	SECTION 4	PAYMENTS, ETC	28
	 	 	 
	4.01	Payments	28
	 	 	 
	4.02	Computations	28
	 	 	 
	4.03	Notices	28
	 	 	 
	4.04	Set-Off	28
	 	 	 
	SECTION 5	YIELD PROTECTION, ETC	29
	 	 	 
	5.01	Additional Costs	29
	 	 	 
	5.02	Illegality	30
	 	 	 
	5.03	Taxes	30
	 	 	 
	SECTION 6	CONDITIONS PRECEDENT	33
	 	 	 
	6.01	Conditions to the First Borrowing	33
	 	 	 
	6.02	 Conditions to the Second Borrowing	36
	 	 	 
	6.03	Conditions to Each Borrowing	36
	 	 	 
	SECTION 7	REPRESENTATIONS AND WARRANTIES	37
	 	 	 
	7.01	Power and Authority	37

  

    	-i-

    	 

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	7.02	Authorization; Enforceability	37
	 	 	 
	7.03	Governmental and Other Approvals; No Conflicts	37
	 	 	 
	7.04	Financial Statements; Material Adverse Change	38
	 	 	 
	7.05	Properties	38
	 	 	 
	7.06	No Actions or Proceedings	41
	 	 	 
	7.07	Compliance with Laws and Agreements	41
	 	 	 
	7.08	Taxes	41
	 	 	 
	7.09	Full Disclosure	42
	 	 	 
	7.10	Regulation	42
	 	 	 
	7.11	Solvency	42
	 	 	 
	7.12	Subsidiaries	42
	 	 	 
	7.13	Indebtedness and Liens	42
	 	 	 
	7.14	Material Agreements	42
	 	 	 
	7.15	Restrictive Agreements	43
	 	 	 
	7.16	Real Property	43
	 	 	 
	7.17	Pension Matters	43
	 	 	 
	7.18	Collateral; Security Interest	44
	 	 	 
	7.19	Regulatory Approvals	44
	 	 	 
	7.20	Small Business Concern	44
	 	 	 
	7.21	Update of Schedules	44
	 	 	 
	SECTION 8	AFFIRMATIVE COVENANTS	45
	 	 	 
	8.01	Financial Statements and Other Information	45
	 	 	 
	8.02	Notices of Material Events	46
	 	 	 
	8.03	Existence; Conduct of Business	48
	 	 	 
	8.04	Payment of Obligations	48
	 	 	 
	8.05	Insurance	49
	 	 	 
	8.06	Books and Records; Inspection Rights	49
	 	 	 
	8.07	Compliance with Laws and Other Obligations	50
	 	 	 
	8.08	Maintenance of Properties, Etc	50
	 	 	 
	8.09	Licenses	51
	 	 	 
	8.10	Action under Environmental Laws	51
	 	 	 
	8.11	Use of Proceeds	52

 

    	-ii-

    	 

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	8.12	Certain Obligations Respecting Subsidiaries; Further Assurances	52
	 	 	 
	8.13	Termination of Non-Permitted Liens	53
	 	 	 
	8.14	Intellectual Property	53
	 	 	 
	8.15	Small Business Documentation	53
	 	 	 
	8.16	Post-Closing	53
	 	 	 
	SECTION 9	NEGATIVE COVENANTS	54
	 	 	 
	9.01	Indebtedness	54
	 	 	 
	9.02	Liens	55
	 	 	 
	9.03	Fundamental Changes and Acquisitions	56
	 	 	 
	9.04	Lines of Business	56
	 	 	 
	9.05	Investments	56
	 	 	 
	9.06	Restricted Payments	57
	 	 	 
	9.07	Payments of Indebtedness	58
	 	 	 
	9.08	Change in Fiscal Year	58
	 	 	 
	9.09	Sales of Assets, Etc	58
	 	 	 
	9.10	Transactions with Affiliates	59
	 	 	 
	9.11	Restrictive Agreements	59
	 	 	 
	9.12	Amendments to Material Agreements	59
	 	 	 
	9.13	Preservation of Borrower Lease; Operating Leases	59
	 	 	 
	9.14	Sales and Leasebacks	60
	 	 	 
	9.15	Hazardous Material	60
	 	 	 
	9.16	Accounting Changes	61
	 	 	 
	9.17	Compliance with ERISA	61
	 	 	 
	SECTION 10	FINANCIAL COVENANTS	61
	 	 	 
	10.01	Minimum Liquidity	61
	 	 	 
	10.02	Minimum EBITDA or Revenue	61
	 	 	 
	10.03	Cure Right	61
	 	 	 
	SECTION 11	EVENTS OF DEFAULT	63
	 	 	 
	11.01	Events of Default	63
	 	 	 
	11.02	Remedies	66
	 	 	 
	SECTION 12	MISCELLANEOUS	66
	 	 	 
	12.01	No Waiver	66

 

 

    	-iii-

    	 

    

 

Table
of Contents

(continued)

 

	 	 	Page
	 	 	 
	12.02	Notices	66
	 	 	 
	12.03	Expenses, Indemnification, Etc	67
	 	 	 
	12.04	Amendments, Etc	67
	 	 	 
	12.05	Successors and Assigns	68
	 	 	 
	12.06	Survival	70
	 	 	 
	12.07	Captions	70
	 	 	 
	12.08	Counterparts	70
	 	 	 
	12.09	Governing Law	70
	 	 	 
	12.10	Jurisdiction, Service of Process and Venue	70
	 	 	 
	12.11	Waiver of Jury Trial	71
	 	 	 
	12.12	Waiver of Immunity	71
	 	 	 
	12.13	Entire Agreement	71
	 	 	 
	12.14	Severability	71
	 	 	 
	12.15	No Fiduciary Relationship	72
	 	 	 
	12.16	Confidentiality	72
	 	 	 
	12.17	USA PATRIOT Act	72
	 	 	 
	12.18	Maximum Rate of Interest	72
	 	 	 
	12.19	Certain Waivers	72
	 	 	 
	SECTION 13	GUARANTEE	74
	 	 	 
	13.01	The Guarantee	74
	 	 	 
	13.02	Obligations Unconditional	74
	 	 	 
	13.03	Reinstatement	75
	 	 	 
	13.04	Subrogation	75
	 	 	 
	13.05	Remedies	75
	 	 	 
	13.06	Instrument for the Payment of Money	75
	 	 	 
	13.07	Continuing Guarantee	75
	 	 	 
	13.08	Rights of Contribution	76
	 	 	 
	13.09	General Limitation on Guarantee Obligations	76

  

    	-iv-

    	 

    

 

Table
of Contents

 

SCHEDULES AND EXHIBITS

 

	Schedule 1	-	Commitments
	Schedule 7.05(b)	-	Certain Intellectual Property
	Schedule 7.05(c)	-	Material Intellectual Property
	Schedule 7.06	-	Certain Litigation
	Schedule 7.08	-	Taxes
	Schedule 7.12	-	Information Regarding Subsidiaries
	Schedule 7.13(a)	-	Existing Indebtedness of Borrower and its Subsidiaries
	Schedule 7.13(b)	-	Liens Granted by the Obligors
	Schedule 7.14	-	Material Agreements of Obligors
	Schedule 7.15	-	Restrictive Agreements
	Schedule 7.16	-	Real Property Owned or Leased by Borrower or any Subsidiary
	 	 	 
	Schedule 7.17	-	Pension Matters
	Schedule 9.05	-	Existing Investments
	Schedule 9.10	-	Transactions with Affiliates
	Schedule 9.14	-	Permitted Sales and Leasebacks
	 	 	 
	Exhibit A	-	Form of Guarantee Assumption Agreement
	Exhibit B	-	Form of Notice of Borrowing
	Exhibit C-1	-	Form of Term Loan Note
	Exhibit C-2	-	Form of PIK Loan Note
	Exhibit D	-	Form of U.S. Tax Compliance Certificate
	Exhibit E	-	Form of Compliance Certificate
	Exhibit F	-	Form of Opinion
	Exhibit G	-	Form of Landlord Consent
	Exhibit H	-	Form of Subordination Agreement
	Exhibit I	-	Form of Security Agreement

  

    	-i-

    	 

    

 

CONFIDENTIAL TREATMENT REQUESTED PURSUANT
TO RULE 24B-2

 

TERM LOAN AGREEMENT, dated as of
May 8, 2015 (this “Agreement”), among Navidea
Biopharmaceuticals, Inc., a Delaware corporation (“Borrower”), the SUBSIDIARY
GUARANTORS from time to time party hereto and the Lenders from time to time party hereto.

 

WITNESSETH:

 

Borrower has requested the Lenders to make
term loans to Borrower, and the Lenders are prepared to make such loans on and subject to the terms and conditions hereof. Accordingly,
the parties agree as follows:

 

SECTION
1

DEFINITIONS

 

1.01       Certain
Defined Terms. As used herein, the following terms have the following respective meanings:

 

“Accounting Change Notice”
has the meaning set forth in Section 1.04(a).

 

“Act” has the
meaning set forth in Section 12.17.

 

“Acquisition”
means any transaction, or any series of related transactions, by which any Person directly or indirectly, by means of a take-over
bid, tender offer, amalgamation, merger, purchase of assets, or similar transaction having the same effect as any of the foregoing,
(a) acquires any business or all or substantially all of the assets of any Person engaged in any business, (b) acquires control
of securities of a Person engaged in a business representing more than 50% of the ordinary voting power for the election of directors
or other governing body if the business affairs of such Person are managed by a board of directors or other governing body, or
(c) acquires control of more than 50% of the ownership interest in any Person engaged in any business that is not managed by a
board of directors or other governing body.

 

“Affected Lender”
has the meaning set forth in Section 2.07(a).

 

“Affiliate” means,
with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries, Controls or
is Controlled by or is under common Control with the Person specified.

 

“Agreement” has
the meaning set forth in the introduction hereto.

 

“Asset Sale” is
defined in Section 9.09.

 

“Asset Sale Net Proceeds”
means the aggregate amount of the cash proceeds received from any Asset Sale, net of any bona fide costs incurred in connection
with such Asset Sale, plus, with respect to any non-cash proceeds of an Asset Sale, the fair market value of such non cash proceeds
as determined by the Majority Lenders, acting reasonably.

 

“Assignment and Assumption”
means an assignment and assumption entered into by a Lender and an assignee of such Lender.

 

    	[*] – indicates deleted language
 	1	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Bankruptcy Code”
means Title II of the United States Code entitled “Bankruptcy.”

 

“Benefit Plan”
means any employee benefit plan as defined in Section 3(3) of ERISA (whether governed by the laws of the United States or otherwise)
to which any Obligor or Subsidiary thereof incurs or otherwise has any obligation or liability, contingent or otherwise.

 

“Borrower” has
the meaning set forth in the introduction hereto.

 

“Borrower Facility”
means the premises located at 5600 Blazer Parkway, Suite 200, Dublin, Ohio, 43017, which are leased by Borrower pursuant to the
Borrower Lease.

 

“Borrower Landlord”
means BRE/COH OH LLC, a Delaware limited liability company.

 

“Borrower Lease”
means the Office Lease, dated August 29, 2013, by and between Borrower and Borrower Landlord.

 

“Borrower Party”
has the meaning set forth in Section 12.03(b).

 

“Borrowing” means
a borrowing consisting of Loans made on the same day by the Lenders according to their respective Commitments (including without
limitation a borrowing of a PIK Loan).

 

“Borrowing Date”
means the date of a Borrowing.

 

“Borrowing Notice Date”
means, (i) in the case of the first Borrowing, a date that is at least twelve Business Days prior to the Borrowing Date of such
Borrowing and, (ii) in the case of a subsequent Borrowing, a date that is at least twenty Business Days prior to the Borrowing
Date of such Borrowing.

 

“Business Day”
means a day (other than a Saturday or Sunday) on which commercial banks are not authorized or required to close in New York City.

 

“Capital Lease Obligations”
means, as to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or other agreement conveying
the right to use) real and/or personal Property which obligations are required to be classified and accounted for as a capital
lease on a balance sheet of such Person under GAAP and, for purposes of this Agreement, the amount of such obligations shall be
the capitalized amount thereof, determined in accordance with GAAP.

 

“Change of Control”
means (a) the acquisition of ownership, directly or indirectly, beneficially or of record, by any Person or group of Persons acting
jointly or otherwise in concert of capital stock representing more than 30% of the aggregate ordinary voting power represented
by the issued and outstanding capital stock of Borrower, (b) during any period of twelve (12) consecutive calendar months, the
occupation of a majority of the seats (other than vacant seats) on the board of directors of Borrower by Persons who were neither
(i) nominated by the board of directors of Borrower, nor (ii) appointed by directors so nominated, or (c) the acquisition of direct
or indirect Control of Borrower by any Person or group of Persons acting jointly or otherwise in concert; in each case whether
as a result of a tender or exchange offer, open market purchases, privately negotiated purchases or otherwise.

 

    	[*] – indicates deleted language
 	2	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Claims” includes
claims, demands, complaints, grievances, actions, applications, suits, causes of action, orders, charges, indictments, prosecutions,
informations (brought by a public prosecutor without grand jury indictment) or other similar processes, assessments or reassessments.

 

“Closing Date”
means the first Borrowing Date.

 

“Code” means the
Internal Revenue Code of 1986, as amended from time to time, and the rules and regulations promulgated thereunder from time to
time.

 

“Collateral” means
any Property in which a Lien is purported to be granted under any of the Security Documents (or all such Property, as the context
may require).

 

“Commitment” means,
with respect to each Lender, the obligation of such Lender to make Loans to Borrower in accordance with the terms and conditions
of this Agreement, which commitment is in the amount set forth opposite such Lender’s name on Schedule 1 under the
caption “Commitment”, as such Schedule may be amended from time to time. The aggregate Commitments on the date hereof
equal $60,000,000. For purposes of clarification, the amount of any PIK Loans shall not reduce the amount of the available Commitment.

 

“Commitment Period”
means the period from and including the first date on which all of the conditions precedent set forth in Section 6.01 have
been satisfied (or waived by the Lenders) and through and including February 15, 2017.

 

“Commodity Account”
is defined in the Security Agreement.

 

“Compliance Certificate”
has the meaning given to such term in Section 8.01(d).

 

“Contracts” means
contracts, licenses, leases, agreements, obligations, promises, undertakings, understandings, arrangements, documents, commitments,
entitlements or engagements under which a Person has, or will have, any liability or contingent liability (in each case, whether
written or oral, express or implied).

 

“Control” means,
in respect of a particular Person, the possession, directly or indirectly, of the power to direct or cause the direction of the
management or policies of such Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling”
and “Controlled” have meanings correlative thereto.

 

“Control Agent”
means the Lender acting as “Control Agent” under the Security Agreement.

 

“Copyright” is
defined in the Security Agreement.

 

“CRPPF” means
Capital Royalty Partners II – Parallel Fund “A” L.P.

 

“Cure Account”
has the meaning set forth in Section 10.03(a).

 

    	[*] – indicates deleted language
 	3	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Cure Amount”
has the meaning set forth in Section 10.03(a).

 

“Cure Right” has
the meaning set forth in Section 10.03(a).

 

“Default” means
any Event of Default and any event that, upon the giving of notice, the lapse of time or both, would constitute an Event of Default.

 

“Defaulting Lender”
means, subject to Section 2.06, any Lender that (a) has failed to perform any of its funding obligations hereunder,
including in respect of its Loans, within three (3) Business Days of the date required to be funded by it hereunder, (b) has
notified Borrower or any Lender that it does not intend to comply with its funding obligations or has made a public statement to
that effect with respect to its funding obligations hereunder or under other agreements in which it commits to extend credit, or
(c) has, or has a direct or indirect parent company that has, (i) become the subject of an Insolvency Proceeding, (ii) had
a receiver, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization
or liquidation of its business or a custodian appointed for it, or (iii) taken any action in furtherance of, or indicated
its consent to, approval of or acquiescence in any such proceeding or appointment; provided that a Lender shall not be a Defaulting
Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent
company thereof by a Governmental Authority.

 

“Default Rate”
has the meaning set forth in Section 3.02(b).

 

“Deposit Account”
is defined in the Security Agreement.

 

“Disclosure Letter”
means that certain Disclosure Letter of even date herewith to which each of the Schedules referenced herein is attached. Each reference
in this Agreement to a Schedule shall refer to the applicable Schedule attached to the Disclosure Letter.

 

“Dollars” and
“$” means lawful money of the United States of America.

 

“Domestic Subsidiary”
means any Subsidiary that is a corporation, limited liability company, partnership or similar business entity incorporated, formed
or organized under the laws of the United States, any State of the United States or the District of Columbia.

 

“EBITDA” means,
with respect to Borrower and its Subsidiaries for any period, the total of the following, all of which shall be determined by the
Majority Lenders in their reasonable credit judgment and shall be determined in accordance with GAAP: (a) the consolidated net
income (loss) of Borrower and its consolidated Subsidiaries for such period, plus (b) without duplication, to the extent included
in the calculation of consolidated net income of Borrower and its consolidated Subsidiaries for such period, the sum of the following
amounts of Borrower and its consolidated Subsidiaries for such period, (i) income taxes paid or accrued (excluding any amounts
Borrower or any of its Subsidiaries includes in its sales, general and administrative expenses), (ii) interest expense (net of
interest income), paid or accrued, (iii) amortization and depreciation expense, (iv) compensation paid in stock, and (v) other
non-cash charges as approved by the Majority Lenders in their sole discretion. EBITDA shall be measured on an accrual accounting
basis.

 

    	[*] – indicates deleted language
 	4	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Eligible Transferee”
means and includes a commercial bank, an insurance company, a finance company, a financial institution, any investment fund that
invests in loans or any other “accredited investor” (as defined in Regulation D of the Securities Act) that is principally
in the business of managing investments or holding assets for investment purposes and not an entity principally engaged in the
business of developing, commercializing, marketing, licensing or selling pharmaceutical products.

 

“Environmental Law”
means any federal, state, provincial or local governmental law, rule, regulation, order, writ, judgment, injunction or decree relating
to pollution or protection of the environment or the treatment, storage, disposal, release, threatened release or handling of hazardous
materials, and all local laws and regulations related to environmental matters and any specific agreements entered into with any
competent authorities which include commitments related to environmental matters.

 

“Equity Cure Right”
has the meaning set forth in Section 10.03(a).

 

“Equity Interest”
shall mean, with respect to any Person, any and all shares, interests, participations or other equivalents, including membership
interests (however designated, whether voting or nonvoting), of equity of such Person, including, if such Person is a partnership,
partnership interests (whether general or limited) and any other interest or participation that confers on a Person the right to
receive a share of the profits and losses of, or distributions of property of, such partnership, but excluding debt securities
convertible or exchangeable into such equity.

 

“Equivalent Amount”
means, with respect to an amount denominated in one currency, the amount in another currency that could be purchased by the amount
in the first currency determined by reference to the Exchange Rate at the time of determination.

 

“ERISA” means
the United States Employee Retirement Income Security Act of 1974, as amended.

 

“ERISA Affiliate”
means, collectively, any Obligor, Subsidiary thereof, and any Person under common control, or treated as a single employer, with
any Obligor or Subsidiary thereof, within the meaning of Section 414(b), (c), (m) or (o) of the Code.

 

    	[*] – indicates deleted language
 	5	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“ERISA Event”
means (i) a reportable event as defined in Section 4043 of ERISA with respect to a Title IV Plan, excluding, however, such events
as to which the PBGC by regulation has waived the requirement of Section 4043(a) of ERISA that it be notified within 30 days of
the occurrence of such event; (ii) the applicability of the requirements of Section 4043(b) of ERISA with respect to a contributing
sponsor, as defined in Section 4001(a)(13) of ERISA, to any Title IV Plan where an event described in paragraph (9), (10), (11),
(12) or (13) of Section 4043(c) of ERISA is reasonably expected to occur with respect to such plan within the following 30 days;
(iii) a withdrawal by any Obligor or any ERISA Affiliate thereof from a Title IV Plan or the termination of any Title IV Plan resulting
in liability under Sections 4063 or 4064 of ERISA; (iv) the withdrawal of any Obligor or any ERISA Affiliate thereof in a complete
or partial withdrawal (within the meaning of Section 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential
liability therefore, or the receipt by any Obligor or any ERISA Affiliate thereof of notice from any Multiemployer Plan that it
is in reorganization or insolvency pursuant to Section 4241 or 4245 of ERISA; (v) the filing of a notice of intent to terminate,
the treatment of a plan amendment as a termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by
the PBGC to terminate a Title IV Plan or Multiemployer Plan; (vi) the imposition of liability on any Obligor or any ERISA Affiliate
thereof pursuant to Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (vii) the failure
by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Plan, or the failure to meet the minimum funding
standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in accordance with Section 412(c)
of the Code) or the failure to make by its due date a required installment under Section 430 of the Code with respect to any Title
IV Plan or the failure to make any required contribution to a Multiemployer Plan; (viii) the determination that any Title IV Plan
is considered an at-risk plan or a plan in endangered to critical status within the meaning of Sections 430, 431 and 432 of the
Code or Sections 303, 304 and 305 of ERISA; (ix) an event or condition which might reasonably be expected to constitute grounds
under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Title IV Plan or Multiemployer
Plan; (x) the imposition of any liability under Title I or Title IV of ERISA, other than PBGC premiums due but not delinquent under
Section 4007 of ERISA, upon any Obligor or any ERISA Affiliate thereof; (xi) an application for a funding waiver under Section
303 of ERISA or an extension of any amortization period pursuant to Section 412 of the Code with respect to any Title IV Plan;
(xii) the occurrence of a non-exempt prohibited transaction under Sections 406 or 407 of ERISA for which any Obligor or any Subsidiary
thereof may be directly or indirectly liable; (xiii) a violation of the applicable requirements of Section 404 or 405 of ERISA
or the exclusive benefit rule under Section 401(a) of the Code by any fiduciary or disqualified person for which any Obligor or
any ERISA Affiliate thereof may be directly or indirectly liable; (xiv) the occurrence of an act or omission which could give rise
to the imposition on any Obligor or any ERISA Affiliate thereof of fines, penalties, taxes or related charges under Chapter 43
of the Code or under Sections 409, 502(c), (i) or (1) or 4071 of ERISA; (xv) the assertion of a material claim (other than routine
claims for benefits) against any Plan or the assets thereof, or against any Obligor or any Subsidiary thereof in connection with
any such plan; (xvi) receipt from the IRS of notice of the failure of any Qualified Plan to qualify under Section 401(a) of the
Code, or the failure of any trust forming part of any Qualified Plan to fail to qualify for exemption from taxation under Section
501(a) of the Code; (xvii) the imposition of any lien (or the fulfillment of the conditions for the imposition of any lien) on
any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, in either case pursuant to Title I or IV,
including Section 302(f) or 303(k) of ERISA or to Section 401(a)(29) or 430(k) of the Code; or (xviii) the establishment or amendment
by any Obligor or any Subsidiary thereof of any “welfare plan”, as such term is defined in Section 3(1) of ERISA, that
provides post-employment welfare benefits in a manner that would increase the liability of any Obligor.

 

“ERISA Funding Rules”
means the rules regarding minimum required contributions (including any installment payment thereof) to Title IV Plans, as set
forth in Sections 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA.

 

“Event of Default”
has the meaning set forth in Section 11.01.

 

    	[*] – indicates deleted language
 	6	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Exchange Rate”
means the rate at which any currency (the “Pre-Exchange Currency”) may be exchanged into another currency
(the “Post-Exchange Currency”), as set forth on such date on the relevant Reuters screen at or about
11:00 a.m. (Central time) on such date. In the event that such rate does not appear on the Reuters screen, the “Exchange
Rate” with respect to exchanging such Pre-Exchange Currency into such Post-Exchange Currency shall be determined by reference
to such other publicly available service for displaying exchange rates as may be agreed upon by Borrower and the Majority Lenders
or, in the absence of such agreement, such Exchange Rate shall instead be determined by the Majority Lenders by any reasonable
method as they deem applicable to determine such rate, and such determination shall be conclusive absent manifest error.

 

“Excluded Taxes”
means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a payment
to a Recipient: (a) Taxes imposed on or measured by net income (however denominated), franchise Taxes and branch profits Taxes,
in each case imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the
case of any Lender, its applicable lending office located in, the jurisdiction imposing such Tax, (b) Other Connection Taxes, (c)
U.S. federal withholding Taxes that are imposed on amounts payable to a Lender to the extent that the obligation to withhold amounts
existed on the date that such Lender became a “Lender” under this Agreement, except in each case to the extent such
Lender is a direct or indirect assignee of any other Lender that was entitled, at the time the assignment of such other Lender
became effective, to receive additional amounts under Section 5.03, (d) any Taxes imposed in connection with FATCA, and
(e) Taxes attributable to such Recipient’s failure to comply with Section 5.03(e).

 

“Expense Cap”
has the meaning set forth in the Fee Letter.

 

“FATCA” means
Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively
comparable and not more onerous to comply with), any regulations or official interpretations thereof and any agreements entered
into pursuant to Section 1471(b)(1) of the Code.

 

“Fee Letter” means
that fee letter agreement dated as of the date hereof between Borrower and the Lenders party thereto.

 

“Foreign Lender”
means a Lender that is not a U.S. Person.

 

“Foreign Subsidiary”
means a Subsidiary of Borrower that is not a Domestic Subsidiary.

 

“GAAP” means generally
accepted accounting principles in the United States of America, as in effect from time to time, set forth in the opinions and pronouncements
of the Accounting Principles Board and the American Institute of Certified Public Accountants, in the statements and pronouncements
of the Financial Accounting Standards Board and in such other statements by such other entity as may be in general use by significant
segments of the accounting profession that are applicable to the circumstances as of the date of determination. Subject to Section
1.02, all references to “GAAP” shall be to GAAP applied consistently with the principles used in the preparation
of the financial statements described in Section 7.04(a).

 

    	[*] – indicates deleted language
 	7	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Governmental Approval”
means any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing
or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.

 

“Governmental Authority”
means any nation, government, branch of power (whether executive, legislative or judicial), state, province or municipality or
other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative
functions of or pertaining to government, including without limitation regulatory authorities, governmental departments, agencies,
commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other law-, rule-
or regulation-making organizations or entities of any State, territory, county, city or other political subdivision of the United
States.

 

“Guarantee” of
or by any Person (the “guarantor”) means any obligation, contingent or otherwise, of the guarantor guaranteeing
or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the “primary
obligor”) in any manner, whether directly or indirectly, and including any obligation of the guarantor, direct or
indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation
or to purchase (or to advance or supply funds for the purchase of) any security for the payment thereof, (b) to purchase or lease
property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment
thereof, (c) to maintain working capital, equity capital or any other financial statement condition or liquidity of the primary
obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (d) as an account party in respect
of any letter of credit or letter of guaranty issued to support such Indebtedness or obligation; provided, that the term Guarantee
shall not include endorsements for collection or deposit in the ordinary course of business.

 

“Guarantee Assumption Agreement”
means a Guarantee Assumption Agreement substantially in the form of Exhibit A by an entity that, pursuant to Section
8.12(a), is required to become a “Subsidiary Guarantor” hereunder in favor of the Lenders.

 

“Guaranteed Obligations”
has the meaning set forth in Section 13.01.

 

“Hazardous Material”
means any substance, element, chemical, compound, product, solid, gas, liquid, waste, by-product, pollutant, contaminant or material
which is hazardous or toxic, and includes, without limitation, (a) asbestos, polychlorinated biphenyls and petroleum (including
crude oil or any fraction thereof) and (b) any material classified or regulated as “hazardous” or “toxic”
or words of like import pursuant to an Environmental Law.

 

“Hedging Agreement”
means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement or other
interest or currency exchange rate or commodity price hedging arrangement.

 

    	[*] – indicates deleted language
 	8	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Indebtedness”
of any Person means, without duplication, (a) all obligations of such Person for borrowed money or obligations of such Person with
respect to deposits or advances of any kind by third parties, (b) all obligations of such Person evidenced by bonds, debentures,
notes or similar instruments, (c) all obligations of such Person upon which interest charges are customarily paid, (d) all obligations
of such Person under conditional sale or other title retention agreements relating to property acquired by such Person, (e) all
obligations of such Person in respect of the deferred purchase price of property or services (excluding current accounts payable
incurred in the ordinary course of business), (f) all Indebtedness of others secured by (or for which the holder of such Indebtedness
has an existing right, contingent or otherwise, to be secured by) any Lien on property owned or acquired by such Person, whether
or not the Indebtedness secured thereby has been assumed, (g) all Guarantees by such Person of Indebtedness of others, (h) all
Capital Lease Obligations of such Person, (i) all obligations, contingent or otherwise, of such Person as an account party in respect
of letters of credit and letters of guaranty (j) obligations under any Hedging Agreement currency swaps, forwards, futures or derivatives
transactions, and (k) all obligations, contingent or otherwise, of such Person in respect of bankers’ acceptances. The Indebtedness
of any Person shall include the Indebtedness of any other entity (including any partnership in which such Person is a general partner)
to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with
such entity, except to the extent the terms of such Indebtedness provide that such Person is not liable therefor.

 

“Indemnified Party”
has the meaning set forth in Section 12.03(b).

 

“Indemnified Taxes”
means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any Obligation and
(b) to the extent not otherwise described in clause (a), Other Taxes.

 

“Insolvency Proceeding”
means (i) any case, action or proceeding before any court or other Governmental Authority relating to bankruptcy, reorganization,
insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors, or (ii) any general assignment for the
benefit of creditors, composition, marshaling of assets for creditors, or other, similar arrangement in respect of any Person’s
creditors generally or any substantial portion of such Person’s creditors, in each case undertaken under U.S. Federal, state
or foreign law, including the Bankruptcy Code.

 

“Intellectual Property”
means all Patents, Trademarks, Copyright, and Technical Information, whether registered or not, domestic and foreign. Intellectual
Property shall include all:

 

(a)        applications
or registrations relating to such Intellectual Property;

 

(b)        rights
and privileges arising under applicable Laws with respect to such Intellectual Property;

 

(c)        rights
to sue for past, present or future infringements of such Intellectual Property; and

 

(d)        rights
of the same or similar effect or nature in any jurisdiction corresponding to such Intellectual Property throughout the world.

 

“Interest-Only Period”
means the period from and including the first Borrowing Date and through and including the sixteenth (16th) Payment
Date following the first Borrowing Date.

 

    	[*] – indicates deleted language
 	9	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Interest Period”
means, with respect to each Borrowing, (i) initially, the period commencing on and including the Borrowing Date thereof and ending
on and excluding the next Payment Date, and, (ii) thereafter, each period beginning on and including the last day of the immediately
preceding Interest Period and ending on and excluding the next succeeding Payment Date.

 

“Invention” means
any novel, inventive and useful art, apparatus, method, process, machine (including article or device), manufacture or composition
of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including article or device), manufacture
or composition of matter.

 

“Investment” means,
for any Person: (a) the acquisition (whether for cash, property, services or securities or otherwise) of capital stock, bonds,
notes, debentures, partnership or other ownership interests or other securities of any other Person or any agreement to make any
such acquisition (including any “short sale” or any sale of any securities at a time when such securities are not owned
by the Person entering into such sale); (b) the making of any deposit with, or advance, loan or other extension of credit to, any
other Person (including the purchase of property from another Person subject to an understanding or agreement, contingent or otherwise,
to resell such property to such Person), but excluding any such advance, loan or extension of credit having a term not exceeding
90 days arising in connection with the sale of inventory or supplies by such Person in the ordinary course of business; (c) the
entering into of any Guarantee of, or other contingent obligation with respect to, Indebtedness or other liability of any other
Person and (without duplication) any amount committed to be advanced, lent or extended to such Person; or (d) the entering into
of any Hedging Agreement.

 

“IRS” means the
U.S. Internal Revenue Service or any successor agency, and to the extent relevant, the U.S. Department of the Treasury.

 

“Knowledge” means
the actual knowledge of any Responsible Officer of any Person or, so long as he or she is employed by Borrower or its Subsidiaries,
the actual knowledge of Ricardo J. Gonzalez, Brent L. Larson, and Thomas J. Klima, so long as such Person is an officer of Borrower.

 

“Landlord Consent”
means a Landlord Consent substantially in the form of Exhibit G.

 

“Laws” means,
collectively, all international, foreign, federal, state, provincial, territorial, municipal and local statutes, treaties, rules,
guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation
or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof,
and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with,
any Governmental Authority, in each case whether or not having the force of law.

 

“Lenders” means
Capital Royalty Partners II L.P., CRPPF and PIOP, together with their successors and each assignee of a Lender pursuant to Section
12.05(b) and “Lender” means any one of them.

 

    	[*] – indicates deleted language
 	10	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Lien” means any
mortgage, lien, pledge, charge or other security interest, or any lease, title retention agreement, mortgage, restriction, easement,
right-of-way, option or adverse claim (of ownership or possession) or other encumbrance of any kind or character whatsoever or
any preferential arrangement that has the practical effect of creating a security interest.

 

“Liquidity” means
the balance of unencumbered cash and Permitted Cash Equivalent Investments (which for greater certainty shall not include any undrawn
credit lines), in each case, to the extent held in an account over which the Lenders have a first priority perfected security interest.

 

“Loan” means (i)
each loan advanced by a Lender pursuant to Section 2.01 and (ii) each PIK Loan deemed to have been advanced by a Lender
pursuant to Section 3.02(d). For purposes of clarification, any calculation of the aggregate outstanding principal amount
of Loans on any date of determination shall include both the aggregate principal amount of loans advanced pursuant to Section
2.01 and not yet repaid, and all PIK Loans deemed to have been advanced and not yet repaid, on or prior to such date of determination.

 

“Loan Documents”
means, collectively, this Agreement, the Fee Letter, the Notes, the Security Documents, any subordination agreement or any intercreditor
agreement entered into by Lenders with any other creditors of Obligors, and any other present or future document, instrument, agreement
or certificate executed by Obligors for the benefit of Lenders in connection with this Agreement or any of the other Loan Documents,
all as amended, restated, supplemented or otherwise modified.

 

“Loss” means judgments,
debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or unliquidated, matured or
unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, professional fees, including fees
and disbursements of legal counsel on a full indemnity basis, and all costs incurred in investigating or pursuing any Claim or
any proceeding relating to any Claim.

 

“Majority Lenders”
means, at any time, Lenders having at such time in excess of 50% of the aggregate Commitments (or, if such Commitments are terminated,
the outstanding principal amount of the Loans) then in effect, ignoring, in such calculation, the Commitments of and outstanding
Loans owing to any Defaulting Lender.

 

“Margin Stock”
means “margin stock” within the meaning of Regulations U and X.

 

“Material Adverse Change”
and “Material Adverse Effect” mean a material adverse change in or effect on (i) the business, condition
(financial or otherwise), operations, performance, Property or prospects of Borrower and its Subsidiaries taken as a whole, (ii)
the ability of any Obligor to perform its obligations under the Loan Documents, or (iii) the legality, validity, binding effect
or enforceability of the Loan Documents or the rights and remedies of the Lenders under any of the Loan Documents.

 

“Material Agreements”
means (A) the agreements which are listed in Schedule 7.14 (as updated by Borrower from time to time in accordance with
Section 7.21 to list all such agreements that meet the description set forth in clause (B) of this definition) and (B) all
other agreements held by the Obligors from time to time, the absence or termination of any of which would reasonably be expected
to result in a Material Adverse Effect; provided, however, that “Material Agreements” exclude all: (i) licenses
implied by the sale of a product; and (ii) paid-up licenses for commonly available software programs under which an Obligor is
the licensee. “Material Agreement” means any one such agreement.

 

    	[*] – indicates deleted language
 	11	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Material Indebtedness”
means, at any time, any Indebtedness of any Obligor, the outstanding principal amount of which, individually or in the aggregate,
exceeds $500,000 (or the Equivalent Amount in other currencies).

 

“Material Intellectual Property”
means, the Obligor Intellectual Property described in Schedule 7.05(c) and any other Obligor Intellectual Property after
the date hereof the loss of which could reasonably be expected to have a Material Adverse Effect.

 

“Maturity Date”
means the earlier to occur of (i) the twenty-fourth (24th) Payment Date following the first Borrowing Date, and (ii)
the date on which the Loans are accelerated pursuant to Section 11.02.

 

“Maximum Rate”
has the meaning set forth in Section 12.18.

 

“Minimum Required EBITDA”
has the meaning set forth in Section 10.02.

 

“Minimum Required Revenue”
has the meaning set forth in Section in 10.02.

 

“Monthly Cash Burn Amount”
means, with respect to the Borrower and its consolidated Subsidiaries, as of any date of determination, an amount equal to (a)
the sum of (i) EBITDA of Borrower and its consolidated Subsidiaries for the immediately preceding six (6) month period, less (ii)
(A) cash taxes, (b) non-financed capital expenditures, (C) cash interest payments, (D) dividends or distributions paid to the extent
permitted to be paid hereunder, and (E) to the extent such payments are not deducted in the calculation of EBITDA, license payments,
in each case paid by Borrower or any of its consolidated Subsidiaries during the immediately preceding six (6) month period, and
less (iii) the current portion of interest bearing liabilities due and payable in the immediately succeeding six month period,
divided by (b) six.

 

“Multiemployer Plan”
means any multiemployer plan, as defined in Section 400l(a)(3) of ERISA, to which any ERISA Affiliate incurs or otherwise has any
obligation or liability, contingent or otherwise.

 

“Non-Consenting Lender”
has the meaning set forth in Section 2.07(a).

 

“Non-Disclosure Agreement”
has the meaning set forth in Section 12.16.

 

“Note” means a
promissory note executed and delivered by Borrower to the Lenders in accordance with Section 2.04 or 3.02(d).

 

“Notice of Borrowing”
has the meaning set forth in Section 2.02.

 

    	[*] – indicates deleted language
 	12	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Obligations”
means, with respect to any Obligor, all amounts, obligations, liabilities, covenants and duties of every type and description owing
by such Obligor to any Lender, any other indemnitee hereunder or any participant, arising out of, under, or in connection with,
any Loan Document, whether direct or indirect (regardless of whether acquired by assignment), absolute or contingent, due or to
become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by
any instrument or for the payment of money, including, without duplication, (i) if such Obligor is Borrower, all Loans, (ii) all
interest, whether or not accruing after the filing of any petition in bankruptcy or after the commencement of any insolvency, reorganization
or similar proceeding, and whether or not a claim for post-filing or post-petition interest is allowed in any such proceeding,
and (iii) all other fees, expenses (including fees, charges and disbursement of counsel), interest, commissions, charges, costs,
disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to such Obligor under any Loan Document.

 

“Obligor Intellectual Property”
means Intellectual Property owned by or licensed to any of the Obligors.

 

“Obligors” means,
collectively, Borrower and the Subsidiary Guarantors and their respective successors and permitted assigns.

 

“Other Connection Taxes”
means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the
jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to,
performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other
transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).

 

“Other Taxes”
means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment
made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security
interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed
with respect to an assignment (other than an assignment made pursuant to Section 5.03(g)).

 

“Oxford Loan”
means borrowings of the Borrower pursuant to that certain Loan and Security Agreement dated March 4, 2014 by and between Borrower
and Oxford Finance, LLC, as amended.

 

“Participant”
has the meaning set forth in Section 12.05(e).

 

“Patents” is defined
in the Security Agreement.

 

“Payment Date”
means each March 31, June 30, September 30, December 31 and the Maturity Date, commencing on the first such date to occur following
the first Borrowing Date; provided that, if any such date shall occur on a day that is not a Business Day, the applicable
Payment Date shall be the next preceding Business Day.

 

“PBGC” means the
United States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing similar
functions.

 

    	[*] – indicates deleted language
 	13	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Permitted
Acquisition” means any acquisition by Borrower or any of its wholly-owned Subsidiaries, whether by purchase, merger
or otherwise, of all or substantially all of the assets of, all of the Equity Interests of, or a business line or unit or a division
of, any Person; provided that:

 

(a)        Borrower
shall have delivered to the Lenders at least twenty (20) days prior to the consummation thereof (or such shorter period as the
Lenders may accept): (i) (x) notice of such Acquisition setting forth in reasonable detail the terms and conditions of such Acquisition,
(y) pro forma financial statements of Borrower and its Subsidiaries after giving effect to the consummation of such Acquisition
and (z) to the extent available, a due diligence package, in each case prior to closing of such Acquisition; (ii) evidence satisfactory
to the Lenders that Borrower has, immediately before and immediately after giving effect to the consummation of such Acquisition,
unrestricted cash and Permitted Cash Equivalent Investments in one or more Deposit Accounts or Securities Accounts subject to control
agreement for the benefit of the Secured Parties in an aggregate amount equal to or greater than the positive value of the product
of (A) twelve (12) times (B) the Monthly Cash Burn Amount as determined as of the last day of the month immediately preceding the
Acquisition for which financial statements have been delivered to the Lenders in accordance with this Agreement and (iii) to the
extent available, such other information, agreements, instruments and other documents as any Lender that is Lender as of the Effective
Date shall reasonably request;

 

(b)        such
Person (in the case of an acquisition of Equity Interests) or assets (in the case of an acquisition of assets or a division) shall
be engaged in the business of pharmaceutical or medical device research, development, commercialization, licensing, distribution
or sales, and such business would not subject the Control Agent or any Lender to regulatory or third party approvals in connection
with the exercise of its rights and remedies under this Agreement or any other Loan Documents;

 

(c)        such
Acquisition shall not be hostile and shall have been approved by the board of directors or other similar body and or the stockholders
or other equity holders of such Person;

 

(d)        the
business and assets acquired in such Acquisition shall only involve assets located in the United States and be free and clear of
all Liens (other than Permitted Liens);

 

(e)        Borrower
shall have delivered to the Lenders (i) as soon as available, executed counterparts of the respective agreements, documents or
instruments pursuant to which such Acquisition is to be consummated, including any related management non-compete, employment option
or other material agreements, any schedules to such agreements, documents or instruments and all other material ancillary agreements,
instruments and documents to be executed or delivered in connection therewith, (ii) to the extent required under the related acquisition
agreement all consents and approvals from applicable Governmental Authorities and other Persons and (iii) if required by the Majority
Lenders, environmental assessments satisfactory to the Majority Lenders;

 

    	[*] – indicates deleted language
 	14	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(f)       at
or prior to the closing of such Acquisition, (i) the Control Agent will be granted first priority perfected Lien subject to Permitted
Liens for the ratable benefit of Control Agent and Lenders in all assets or stock acquired pursuant thereto and (ii) any new Subsidiary
created or acquired pursuant to such Acquisition shall have: (A) joined this Agreement as a Subsidiary Guarantor, (B) guaranteed
the Obligations and (C) granted to Control Agent for the benefit of the Lenders’ security interest in all of its Collateral
to secure such guaranty;

 

(g)        immediately
prior to, and after giving effect thereto, no Event of Default shall have occurred and be continuing or would result therefrom;

 

(h)      all
transactions in connection therewith shall be consummated, in all material respects, in accordance with all applicable Laws and
in conformity with all applicable Governmental Approvals;

 

(i)         in
the case of the acquisition of all of the Equity Interests of such Person, all of the Equity Interests (except for any such securities
in the nature of directors’ qualifying shares required pursuant to applicable Law) acquired, or otherwise issued by such
Person or any newly formed Subsidiary of Borrower in connection with such acquisition, shall be owned 100% by an Obligor or any
other Subsidiary, and Borrower shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of Borrower,
each of the actions set forth in Section 8.12, if applicable; and

 

(j)         Borrower
and its Subsidiaries are Solvent and shall be in compliance with the financial covenants set forth in Section 10.01 and
Section 10.02 on a pro forma basis after giving effect to such acquisition.

 

“Permitted Cash Equivalent Investments”
means (i) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof
having maturities of not more than two (2) years from the date of acquisition and (ii) commercial paper maturing no more than one
(1) year after its creation and having the highest rating from either Standard & Poor’s Ratings Group or Moody’s
Investors Service, Inc.

 

“Permitted Cure Debt”
means Indebtedness incurred in connection with the exercise of the Subordinated Debt Cure Right and (i) that is governed by documentation
containing representations, warranties, covenants and events of default no more burdensome or restrictive than those contained
in the Loan Documents, (ii) that has a maturity date later than the Maturity Date, (iii) in respect of which no cash payments of
principal or interest are required prior to the Maturity Date, (iv) in respect of which the holders have agreed in favor of Borrower
and Lenders (A) that prior to the date on which the Commitments have expired or been terminated and all Obligations have been paid
in full indefeasibly in cash, such holders will not exercise any remedies available to them in respect of such Indebtedness, and
(B) that such Indebtedness is unsecured, and (C) to terms of subordination in substantially the form attached hereto as Exhibit
H or otherwise satisfactory to the Majority Lenders and (v) is designated by Borrower at the time of incurrence as “Permitted
Cure Debt.”

 

    	[*] – indicates deleted language
 	15	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Permitted Indebtedness”
means any Indebtedness permitted under Section 9.01, and the Indebtedness under the Oxford Loan that is discharged prior
to or simultaneously with the first Borrowing.

 

“Permitted Liens”
means any Liens permitted under Section 9.02, and any Liens securing the Oxford Loan that are discharged or released prior
to or simultaneously with the first Borrowing.

 

“Permitted Priority Debt”
means Indebtedness of Borrower, in an amount not to exceed at any time 80% of the face amount at such time of Borrower’s
non delinquent accounts receivable; provided that (a) such Indebtedness, if secured, is secured solely by Borrower’s
cash (excluding all amounts in the Cure Account), accounts receivable, inventory and cash proceeds thereof held in a segregated
account but is otherwise unsecured, and (b) the holders or lenders thereof have executed and delivered to Lenders an intercreditor
agreement in form and substance reasonably satisfactory to the Majority Lenders.

 

“Permitted Priority Liens”
means (i) Liens permitted under Section 9.02(c), (d), (e), (f), (g), and (j), and (ii) Liens permitted under Section
9.02(b) provided that such Liens are also of the type described in Section 9.02(c), (d), (e), (f), (g), and (j).

 

“Permitted Refinancing”
means, with respect to any Indebtedness, any extensions, renewals and replacements of such Indebtedness; provided that such
extension, renewal or replacement (i) shall not increase the outstanding principal amount of such Indebtedness, (ii) contains terms
relating to outstanding principal amount, amortization, maturity, collateral (if any) and subordination (if any), and other material
terms taken as a whole no less favorable in any material respect to Borrower and its Subsidiaries or the Lenders than the terms
of any agreement or instrument governing such existing Indebtedness, (iii) shall have an applicable interest rate which does not
exceed the rate of interest of the Indebtedness being replaced, and (iv) shall not contain any new requirement to grant any lien
or security or to give any guarantee that was not an existing requirement of such Indebtedness.

 

“Permitted Subordinated Debt”
means Indebtedness (i) that is governed by documentation containing representations, warranties, covenants and events of default
no more burdensome or restrictive than those contained in the Loan Documents, (ii) that has a maturity date later than the Maturity
Date, (iii) in respect of which no cash payments of principal or interest are required prior to the Maturity Date, and (iv) in
respect of which the holders have agreed in favor of Borrower and Lenders (A) that prior to the date on which the Commitments have
expired or been terminated and all Obligations have been paid in full indefeasibly in cash, such holders will not exercise any
remedies available to them in respect of such Indebtedness, and (B) that such Indebtedness is unsecured, and (C) to terms of subordination
in substantially the form attached hereto as Exhibit H or otherwise satisfactory to the Majority Lenders.

 

“Person” means
any individual, corporation, company, voluntary association, partnership, limited liability company, joint venture, trust, unincorporated
organization or Governmental Authority or other entity of whatever nature.

 

“PIK Loan” has
the meaning set forth in Section 3.02(d).

 

    	[*] – indicates deleted language
 	16	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“PIK Period” means
the period beginning on the first Borrowing Date through and including the earlier to occur of (i) the sixteenth (16th)
Payment Date after the first Borrowing Date and (ii) the date on which any Default shall have occurred (provided that
if such Default shall have been cured or waived, the PIK Period shall resume until the earlier to occur of the next Default and
the sixteenth (16th) Payment Date after the first Borrowing Date).

 

“PIOP” means Parallel
Investment Opportunities Partners II L.P., a Delaware limited partnership.

 

“Plan” means any
employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of
the Code or Section 302 of ERISA, and in respect of which Borrower or any ERISA Affiliate is (or, if such plan were terminated,
would under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of ERISA.

 

“Platinum Loan Agreement”
means that certain Loan Agreement, dated as of July 25, 2012, by and between the Borrower and Platinum-Montaur Life Sciences,
LLC, as amended, restated, supplemented or otherwise modified from time to time.

 

“Platinum Lending Failure”
means that Platinum-Montaur Life Sciences, LLC (a) has failed to perform any of its funding obligations under the Platinum
Loan Agreement within three (3) Business Days of the date required to be funded by it thereunder, (b) has notified Borrower
or any Lender in writing that it does not intend to comply with its funding obligations under the Platinum Loan Agreement or has
made a public statement to that effect with respect to its funding obligations thereunder or under other agreements in which it
commits to extend credit, or (c) has, or has a direct or indirect parent company that has, (i) become the subject of
an Insolvency Proceeding, (ii) had a receiver, conservator, trustee, administrator, assignee for the benefit of creditors
or similar Person charged with reorganization or liquidation of its business or a custodian appointed for it, or (iii) taken
any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment.

 

“Prepayment Premium” has
the meaning set forth in Section 3.03(a).

 

“Product” means
Lymphoseek (technetium Tc 99m tilmanocept) injection, and its successors.

 

“Property” of
any Person means any property or assets, or interest therein, of such Person.

 

“Proportionate Share”
means, with respect to any Lender, the percentage obtained by dividing (a) the sum of the Commitment (or, if the Commitments are
terminated, the outstanding principal amount of the Loans) of such Lender then in effect by (b) the sum of the Commitments (or,
if the Commitments are terminated, the outstanding principal amount of the Loans) of all Lenders then in effect.

 

“Qualified Plan”
means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or was at any
time maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof
has ever made, or was ever obligated to make, contributions, and (ii) that is intended to be tax qualified under Section 401(a)
of the Code.

 

    	[*] – indicates deleted language
 	17	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Real Property Security Documents”
means the Landlord Consents, bailee waivers, collateral access agreements and any mortgage or deed of trust or any other real property
security document executed or required hereunder to be executed by any Obligor in favor of the Lenders.

 

“Recipient” means
any Lender or any other recipient of any payment to be made by or on account of any Obligation.

 

“Redemption Date”
has the meaning set forth in Section 3.03(a).

 

“Redemption Price”
has the meaning set forth in Section 3.03(a).

 

“Register” has
the meaning set forth in Section 12.05(d).

 

“Regulation T”
means Regulation T of the Board of Governors of the Federal Reserve System, as amended.

 

“Regulation U”
means Regulation U of the Board of Governors of the Federal Reserve System, as amended.

 

“Regulation X”
means Regulation X of the Board of Governors of the Federal Reserve System, as amended.

 

“Regulatory Approvals”
means any registrations, licenses, authorizations, permits or approvals issued by any Governmental Authority and applications or
submissions related to any of the foregoing.

 

“Requirement of Law”
means, as to any Person, any statute, law, treaty, rule or regulation or determination, order, injunction or judgment of an arbitrator
or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its Properties or
revenues.

 

“Responsible Officer”
of any Person means each of the chief executive officer, chief financial officer and chief commercial officer of such Person.

 

“Restricted Payment”
means any dividend or other distribution (whether in cash, securities or other property) with respect to any Equity Interest of
Borrower or any of its Subsidiaries, or any payment (whether in cash, securities or other property), including any sinking fund
or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such shares
of capital stock of Borrower or any of its Subsidiaries or any option, warrant or other right to acquire any such shares of capital
stock of Borrower or any of its Subsidiaries.

 

“Restrictive Agreement”
has the meaning set forth in Section 7.15.

 

“Revenue” of a
Person means all revenue properly recognized under GAAP, consistently applied, less all rebates, discounts and other price allowances.

 

    	[*] – indicates deleted language
 	18	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“SBA” means U.S.
Small Business Administration.

 

“SBIC” means Small
Business Investment Company.

 

“SBIC Act” means
Small Business Investment Act of 1958, as amended.

 

“Secured Parties”
is defined in the Security Agreement.

 

“Security Agreement”
means the Security Agreement, in the form of Exhibit I hereto, among the Obligors, the Lenders and the Control Agent, granting
a security interest in the Obligors’ personal Property in favor of the Lenders.

 

“Security Documents”
means, collectively, the Security Agreement, each Short-Form IP Security Agreement, each Real Property Security Document, and each
other security document, control agreement or financing statement required or recommended to perfect Liens in favor of the Lenders.

 

“Securities Account”
has the meaning set forth in the Security Agreement.

 

“Short-Form IP Security Agreements”
means short-form copyright, patent or trademark (as the case may be) security agreements, entered into by one or more Obligors
in favor of the Lenders, each in form and substance satisfactory to the Majority Lenders (and as amended, modified or replaced
from time to time).

 

“Solvent” means,
with respect to any Person at any time, that (a) the present fair saleable value of the Property of such Person is greater than
the total amount of liabilities (including contingent liabilities) of such Person, (b) the present fair saleable value of the Property
of such Person is not less than the amount that will be required to pay the probable liability of such Person on its debts as they
become absolute and matured, (c) such Person has not incurred and does not intend to, and does not believe that it will, incur
debts or liabilities beyond such Person’s ability to pay as such debts and liabilities mature and (d) such Person would not
be unable to obtain a letter from its auditors that did not contain a going concern qualification.

 

“Specified Financial Covenants”
has the meaning set forth in Section 10.03(a).

 

“Subordinated Debt Cure Right”
has the meaning set forth in Section 10.03(a).

 

“Subsidiary” means,
with respect to any Person (the “parent”) at any date, any corporation, limited liability company, partnership,
association or other entity the accounts of which would be consolidated with those of the parent in the parent’s consolidated
financial statements if such financial statements were prepared in accordance with GAAP as of such date, as well as any other corporation,
limited liability company, partnership, association or other entity (a) of which securities or other ownership interests representing
more than 50% of the equity or more than 50% of the ordinary voting power or, in the case of a partnership, more than 50% of the
general partnership interests are, as of such date, owned, controlled or held, or (b) that is, as of such date, otherwise Controlled,
by the parent or one or more subsidiaries of the parent or by the parent and one or more subsidiaries of the parent.

 

    	[*] – indicates deleted language
 	19	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

“Subsidiary Guarantors”
means each of the Subsidiaries of Borrower identified under the caption “SUBSIDIARY GUARANTORS” on the signature pages
hereto and each Subsidiary of Borrower that becomes, or is required to become, a “Subsidiary Guarantor” after the date
hereof pursuant to Section 8.12(a) or (b).

 

“Substitute Lender”
has the meaning set forth in Section 2.07(a).

 

“Taxes” means
all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees
or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

 

“Technical Information”
means all trade secrets and other proprietary or confidential information, including without limitation know-how, information of
a scientific, technical, or business nature in any form or medium, standards and specifications, conceptions, ideas, innovations,
discoveries, Invention disclosures, all documented research, developmental, demonstration or engineering work and all other information,
data, plans, specifications, reports, summaries, experimental data, manuals, models, samples, know-how, technical information,
systems, methodologies, computer programs, and information technology.

 

“Title IV Plan”
means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (i) that is or was at any
time maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof
has ever made, or was obligated to make, contributions, and (ii) that is or was subject to Section 412 of the Code, Section 302
of ERISA or Title IV of ERISA.

 

“Trademarks” is
defined in the Security Agreement.

 

“Transactions”
means the execution, delivery and performance by each Obligor of this Agreement and the other Loan Documents to which such Obligor
is intended to be a party and the Borrowings (and the use of the proceeds of the Loans).

 

“U.S. Person”
means a “United States Person” within the meaning of Section 7701(a)(30) of the Code.

 

“U.S. Tax Compliance Certificate”
has the meaning set forth in Section 5.03(e)(ii)(B)(3).

 

“Use of Proceeds Statement”
has the meaning set forth in Section 6.01(g)(xiv).

 

“Withdrawal Liability”
means, at any time, any liability incurred (whether or not assessed) by any ERISA Affiliate and not yet satisfied or paid in full
at such time with respect to any Multiemployer Plan pursuant to Section 4201 of ERISA.

 

1.02        Accounting
Terms and Principles. All accounting determinations required to be made pursuant hereto shall, unless expressly otherwise provided
herein, be made in accordance with GAAP. All components of financial calculations made to determine compliance with this Agreement,
including Section 10, shall be adjusted to include or exclude, as the case may be, without duplication, such components
of such calculations attributable to any Acquisition consummated after the first day of the applicable period of determination
and prior to the end of such period, as determined in good faith by Borrower based on assumptions expressed therein and that were
reasonable based on the information available to Borrower at the time of preparation of the Compliance Certificate setting forth
such calculations.

 

    	[*] – indicates deleted language
 	20	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

1.03       Interpretation.
For all purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires, (a)
the terms defined in this Agreement include the plural as well as the singular and vice versa; (b) words importing gender include
all genders; (c) any reference to a Section, Annex, Schedule or Exhibit refers to a Section of, or Annex, Schedule or Exhibit to,
this Agreement; (d) any reference to “this Agreement” refers to this Agreement, including all Annexes, Schedules and
Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its
Annexes, Schedules and Exhibits as a whole and not to any particular Section, Annex, Schedule, Exhibit or any other subdivision;
(e) references to days, months and years refer to calendar days, months and years, respectively; (f) all references herein to “include”
or “including” shall be deemed to be followed by the words “without limitation”; (g) the word “from”
when used in connection with a period of time means “from and including” and the word “until” means “to
but not including”; and (h) accounting terms not specifically defined herein shall be construed in accordance with GAAP (except
for the term “property” , which shall be interpreted as broadly as possible, including, in any case, cash, securities,
other assets, rights under contractual obligations and permits and any right or interest in any property, except where otherwise
noted). Unless otherwise expressly provided herein, references to organizational documents, agreements (including the Loan Documents)
and other contractual instruments shall be deemed to include all permitted subsequent amendments, restatements, extensions, supplements
and other modifications thereto.

 

1.04       Changes
to GAAP. If, after the date hereof, any change occurs in GAAP or in the application thereof and such change would cause any
amount required to be determined for the purposes of the covenants to be maintained or calculated pursuant to Section 8,
9 or 10 to be materially different than the amount that would be determined prior to such change, then:

 

(a)        Borrower
will provide a detailed notice of such change (an “Accounting Change Notice”) to the Lenders within 30
days of such change;

 

(b)        either
Borrower or the Majority Lenders may indicate within 90 days following the date of the Accounting Change Notice that they wish
to revise the method of calculating such financial covenants or amend any such amount, in which case the parties will in good faith
attempt to agree upon a revised method for calculating the financial covenants;

 

(c)        until
Borrower and the Majority Lenders have reached agreement on such revisions, (i) such financial covenants or amounts will be determined
without giving effect to such change and (ii) all financial statements, Compliance Certificates and similar documents provided
hereunder shall be provided together with a reconciliation between the calculations and amounts set forth therein before and after
giving effect to such change in GAAP;

 

    	[*] – indicates deleted language
 	21	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(d)        if
no party elects to revise the method of calculating the financial covenants or amounts, then the financial covenants or amounts
will not be revised and will be determined in accordance with GAAP without giving effect to such change; and

 

(e)        any
Event of Default arising as a result of such change which is cured by operation of this Section 1.04 shall be deemed to
be of no effect ab initio.

 

SECTION
2

THE COMMITMENT

 

2.01        Commitments.
Each Lender agrees severally, on and subject to the terms and conditions of this Agreement (including Section 6), to make
up to two term loans (provided that PIK Loans shall be deemed not to constitute “term loans” for purposes of this Section
2.01) to Borrower, each on a Business Day during the Commitment Period in Dollars in an aggregate principal amount for such
Lender not to exceed such Lender’s Commitment; provided, however, that at no time shall any Lender be obligated
to make a Loan in excess of such Lender’s Proportionate Share of the amount by which the then effective Commitments exceeds
the aggregate principal amount of Loans outstanding at such time. Amounts of Loans repaid may not be reborrowed.

 

2.02        Borrowing
Procedures. Subject to the terms and conditions of this Agreement (including Section 6), each Borrowing (other than
a Borrowing of PIK Loans) shall be made on written notice in the form of Exhibit B given by Borrower to the Lenders not
later than 11:00 a.m. (Central time) on the Borrowing Notice Date (a “Notice of Borrowing”).

 

2.03        Fees.
The Borrower shall pay to the Lenders such fees as described in the Fee Letter.

 

2.04        Notes.
If requested by any Lender, the Loans of such Lender shall be evidenced by one or more promissory notes (each a “Note”).
Borrower shall prepare, execute and deliver to the Lenders such promissory note(s) payable to the Lenders (or, if requested by
the Lenders, to the Lenders and their registered assigns) and in the form attached hereto as Exhibit C-1. Thereafter, the
Loans and interest thereon shall at all times (including after assignment pursuant to Section 12.05) be represented by one
or more promissory notes in such form payable to the payee named therein (or, if such promissory note is a registered note, to
such payee and its registered assigns).

 

2.05        Use
of Proceeds. Borrower shall use the proceeds of the Loans for general working capital purposes and corporate purposes and to
pay fees, costs and expenses incurred in connection with the Transactions; provided that the Lenders shall have no responsibility
as to the use of any proceeds of Loans in the amount made by PIOP. No portion of any proceeds of Loans in the amount made by PIOP
(i) will be used to acquire realty or to discharge an obligation relating to the prior acquisition of realty; (ii) will be used
outside of the United States (except to pay for services to be rendered outside the United States and to acquire from abroad inventory,
material and equipment or property rights for use or sale in the United States, unless prohibited by Part 107.720 of the United
States Code of Federal Regulations); or (iii) will be used for any purpose contrary to the public interest (including but not limited
to activities which are in violation of law) or inconsistent with free competitive enterprise, in each case, within the meaning
of Part 107.720 of Title 13 of the United States Code of Federal Regulations. Borrower will use the proceeds of the Loans in the
amount made by PIOP for only those purposes specified in the SBA Form 1031 provided to the Lenders, and Borrower shall not violate
any SBA regulations which may be applicable to it.

 

    	[*] – indicates deleted language
 	22	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

2.06        Defaulting
Lenders.

 

(a)        Adjustments.
Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such
time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable law:

 

(b)        Waivers
and Amendments. Such Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect
to this Agreement shall be restricted as set forth in Section 12.04.

 

(c)        Reallocation
of Payments. Any payment of principal, interest, fees or other amounts received by the Lenders for the account of such Defaulting
Lender (whether voluntary or mandatory, at maturity, pursuant to Section 11 or otherwise), shall be applied at such time
or times as follows: first, as Borrower may request (so long as no Default exists), to the funding of any Loan in respect of which
such Defaulting Lender has failed to fund its portion thereof as required by this Agreement; second, if so determined by the Majority
Lenders and Borrower, to be held in a non-interest bearing deposit account and released in order to satisfy obligations of such
Defaulting Lender to fund Loans under this Agreement; third, to the payment of any amounts owing to the Lenders as a result of
any judgment of a court of competent jurisdiction obtained by any Lender against such Defaulting Lender as a result of such Defaulting
Lender’s breach of its obligations under this Agreement; fourth, so long as no Default exists, to the payment of any amounts
owing to Borrower as a result of any judgment of a court of competent jurisdiction obtained by Borrower against such Defaulting
Lender as a result of such Defaulting Lender’s breach of its obligations under this Agreement; and fifth, to such Defaulting
Lender or as otherwise directed by a court of competent jurisdiction; provided that if (A) such payment is a payment of the principal
amount of any Loans in respect of which such Defaulting Lender has not fully funded its appropriate share and (B) such Loans were
made at a time when the conditions set forth in Section 6 were satisfied or waived, such payment shall be applied solely
to pay the Loans of all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of
such Defaulting Lender. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or
held) to pay amounts owed by a Defaulting Lender pursuant to this Section 2.06(c) shall be deemed paid to and redirected
by such Defaulting Lender, and each Lender irrevocably consents hereto.

 

(d)        Defaulting
Lender Cure. If Borrower and the Majority Lenders agree in writing in their sole discretion that a Defaulting Lender should
no longer be deemed to be a Defaulting Lender, that Lender will, to the extent applicable, purchase that portion of outstanding
Loans of the other Lenders or take such other actions as necessary to cause the Loans to be held on a pro rata basis by
the Lenders in accordance with their Proportionate Share, whereupon that Lender will cease to be a Defaulting Lender; provided
that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of Borrower while
that Lender was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected
parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder
arising from that Lender’s having been a Defaulting Lender.

 

    	[*] – indicates deleted language
 	23	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

2.07        Substitution
of Lenders. 

 

(a)        Substitution
Right. If any Lender (an “Affected Lender”), (i) becomes a Defaulting Lender or (ii) does
not consent to any amendment, waiver or consent to any Loan Document for which the consent of the Majority Lenders is obtained
but that requires the consent of other Lenders (a “Non-Consenting Lender”), then (x) Borrower may elect
to pay in full such Affected Lender with respect to all Obligations due to such Affected Lender or (y) either Borrower or the Majority
Lenders shall identify any willing Lender or Affiliate of any Lender or Eligible Transferee (in each case, a “Substitute
Lender”) to substitute for such Affected Lender; provided that any substitution of a Non-Consenting Lender
shall occur only with the consent of Majority Lenders.

 

(b)        Procedure.
To substitute such Affected Lender or pay in full all Obligations owed to such Affected Lender, Borrower shall deliver a notice
to such Affected Lender. The effectiveness of such payment or substitution shall be subject to the delivery by Borrower (or, as
may be applicable in the case of a substitution, by the Substitute Lender) of (i) payment for the account of such Affected
Lender, of, to the extent accrued through, and outstanding on, the effective date for such payment or substitution, all Obligations
owing to such Affected Lender (which for the avoidance of doubt, shall not include any Prepayment Premium) and (ii) in the
case of a substitution, an Assignment and Assumption executed by the Substitute Lender, which shall thereunder, among other things,
agree to be bound by the terms of the Loan Documents.

 

(c)        Effectiveness.
Upon satisfaction of the conditions set forth in Section 2.07(a) and (b), the Control Agent shall record such substitution
or payment in the Register, whereupon (i) in the case of any payment in full of an Affected Lender, such Affected Lender’s
Commitments shall be terminated and (ii) in the case of any substitution of an Affected Lender, (A) such Affected Lender
shall sell and be relieved of, and the Substitute Lender shall purchase and assume, all rights and claims of such Affected Lender
under the Loan Documents, except that the Affected Lender shall retain such rights under the Loan Documents that expressly provide
that they survive the repayment of the Obligations and the termination of the Commitments, (B) such Affected Lender shall
no longer constitute a “Lender” hereunder and such Substitute Lender shall become a “Lender” hereunder
and (C) such Affected Lender shall execute and deliver an Assignment and Assumption to evidence such substitution; provided,
however, that the failure of any Affected Lender to execute any such Assignment and Assumption shall not render such sale
and purchase (or the corresponding assignment) invalid.

 

SECTION
3

PAYMENTS OF PRINCIPAL AND INTEREST

 

3.01        Repayment.

 

(a)        Repayment.
During the Interest-Only Period, no payments of principal of the Loans shall be due. Borrower agrees to repay to the Lenders the
outstanding principal amount of the Loans, on each Payment Date occurring after the Interest-Only Period, in equal installments.
The amounts of such installments shall be calculated by dividing (i) the sum of the aggregate principal amount of the Loans outstanding
on the first day following the end of the Interest-Only Period, by (b) the number of Payment Dates remaining prior to and including
the Maturity Date.

 

    	[*] – indicates deleted language
 	24	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(b)        Application.
Any optional or mandatory prepayment of the Loans shall be applied to the installments thereof under Section 3.01(a) in
the inverse order of maturity. To the extent not previously paid, the principal amount of the Loans, together with all other outstanding
Obligations, shall be due and payable on the Maturity Date.

 

3.02        Interest.

 

(a)        Interest
Generally. Subject to Section 3.02(d), Borrower agrees to pay to the Lenders interest on the unpaid principal amount
of the Loans and the amount of all other outstanding Obligations, in the case of the Loans, for the period from the applicable
Borrowing Date, and in the case of any other Obligation, from the date such other Obligation is due and payable, in each case,
until paid in full, at a rate per annum equal to 14.00%.

 

(b)        Default
Interest. Notwithstanding the foregoing, upon the occurrence and during the continuance of any Event of Default, the interest
payable pursuant to Section 3.02(a) shall increase automatically by 4.00% per annum (such aggregate increased rate,
the “Default Rate”). Notwithstanding any other provision herein (including Section 3.02(d)), if
interest is required to be paid at the Default Rate, it shall be paid entirely in cash. If any Obligation is not paid when due
under the applicable Loan Document, the amount thereof shall accrue interest at a rate equal to 4.00% per annum (without
duplication of interest payable at the Default Rate).

 

(c)        Interest
Payment Dates. Subject to Section 3.02(d), accrued interest on the Loans shall be payable in arrears on each Payment
Date with respect to the most recently completed Interest Period in cash, and upon the payment or prepayment of the Loans (on the
principal amount being so paid or prepaid); provided that interest payable at the Default Rate shall be payable from time
to time on demand.

 

(d)        Paid
In-Kind Interest. Notwithstanding Section 3.01(a), at any time during the PIK Period, Borrower may elect to pay the
interest on the outstanding principal amount of the Loans payable pursuant to Section 3.01 as follows: (i) only 10.00% of
the 14.00% per annum interest in cash and (ii) 4.00% of the 14.00% per annum interest as compounded interest, added
to the aggregate principal amount of the Loans (the amount of any such compounded interest being a “PIK Loan”).
At the request of the Lenders, each PIK Loan may be evidenced by a Note in the form of Exhibit C-2. The principal amount
of each PIK Loan shall accrue interest in accordance with the provisions of this Agreement applicable to the Loans.

 

3.03        Prepayments.

 

(a)        Optional
Prepayments. Borrower shall have the right to optionally prepay in whole or in part the outstanding principal amount of the
Loans in whole or in part on any Payment Date (a “Redemption Date”) and fifteen (15) days prior written
notice to Lenders for an amount equal to the aggregate principal amount of the Loans being prepaid plus the Prepayment Premium
plus any accrued but unpaid interest and any fees then due and owing (such aggregate amount, the “Redemption Price”).
The applicable “Prepayment Premium” shall be an amount calculated pursuant to Section 3.03(a)(i).

 

    	[*] – indicates deleted language
 	25	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(i)           If
the Redemption Date occurs:

 

(A)        on
or prior to the fourth (4th) Payment Date, the Prepayment Premium shall be an amount equal to 5.00% of the aggregate
outstanding principal amount of the Loans being prepaid on such Redemption Date (prior to giving effect to such redemption);

 

(B)        after
the fourth (4th) Payment Date, and on or prior to the eighth (8th) Payment Date, the Prepayment Premium shall
be an amount equal to 4.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date (prior
to giving effect to such redemption);

 

(C)        after
the eighth (8th) Payment Date, and on or prior to the twelfth (12th) Payment Date, the Prepayment Premium
shall be an amount equal to 3.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date
(prior to giving effect to such redemption);

 

(D)        after
the twelfth (12th) Payment Date, and on or prior to the sixteenth (16th) Payment Date, the Prepayment Premium
shall be an amount equal to 2.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date
(prior to giving effect to such redemption);

 

(E)        after
the sixteenth (16th) Payment Date, and on or prior to the twentieth (20th) Payment Date, the Prepayment Premium
shall be an amount equal to 1.00% of the aggregate outstanding principal amount of the Loans being prepaid on such Redemption Date
(prior to giving effect to such redemption);

 

(F)        after
the twentieth (20th) Payment Date, the Prepayment Premium shall be an amount equal to 0.00% of the aggregate outstanding
principal amount of the Loans being prepaid on such Redemption Date (prior to giving effect to such redemption).

 

(ii)         To
determine the aggregate outstanding principal amount of the Loans, and how many Payment Dates have occurred, as of any Redemption
Date for purposes of Section 3.03(a):

 

(A)        if,
as of such Redemption Date, the Borrower shall have made only one Borrowing, the number of Payment Dates shall be deemed to be
the number of Payment Dates that shall have occurred following the first Borrowing Date;

 

(B)        if,
as of such Redemption Date, the Borrower shall have made more than one Borrowing, then the Redemption Price shall equal the sum
of multiple Redemption Prices calculated with respect to the Loans of each Borrowing, each of which Redemption Prices shall be
calculated based on solely the aggregate outstanding principal amount of the Loans borrowed in such Borrowing (and PIK Loans subsequently
borrowed in respect of interest payments thereon), as though the applicable number of Payment Dates equals the number of Payment
Dates that shall have occurred following the applicable Borrowing Date. In the case of any partial prepayment, the amount of such
prepayment shall be allocated to Loans made in the various Borrowings (and PIK Loans in respect thereof) in the order in which
such Borrowings were made;

 

    	[*] – indicates deleted language
 	26	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(iii)        No
partial prepayment shall be made under this Section 3.03(a) in connection with any event described in Section 3.03(b).

 

(iv)        On
or prior to any Redemption Date, the Lenders may notify Borrower of a reduction in the amounts due under Section 3.03(a)(i)
with respect to any portion of the Loans held by any entity licensed by the SBA as an SBIC.

 

Notwithstanding anything herein to the contrary,
there shall be no Prepayment Premium or other prepayment penalty charged on any application of cash constituting Cure Amounts (including
any accrued interest, distributions, dividends or capital gains thereon) to the extent the same shall have been applied at the
option of Majority Lenders to reduce the aggregate outstanding principal amount of the Loans.

 

(b)          Mandatory
Prepayments.

 

(i)          Asset
Sales. In the event of any contemplated Asset Sale or series of Asset Sales (other than any Asset Sale permitted under Section
9.09(a) or (b)) yielding Asset Sale Net Proceeds in excess of $2,000,000, Borrower shall provide 30 days’ prior written
notice of such Asset Sale to the Lenders and, if within such notice period Majority Lenders advise Borrower that a prepayment is
required pursuant to this Section 3.03(b)(i), Borrower shall: (x) if the assets sold represent substantially all of the
assets or revenues of Borrower, or represent any specific line of business which either on its own or together with other lines
of business sold over the term of this Agreement account for revenue generated by such lines of business exceeding 10.00% of the
revenue of Borrower in the immediately preceding year, prepay the aggregate outstanding principal amount of the Loans in an amount
equal to the Redemption Price applicable on the date of such Asset Sale in accordance with Section 3.03(a), and (y) in the
case of all other Asset Sales not described in the foregoing clause (x), prepay the Loans in an amount equal to the entire
amount of the Asset Sale Net Proceeds of such Asset Sale, plus any accrued but unpaid interest and any fees then due and owing,
credited in the following order:

 

(A)        first,
in reduction of Borrower’s obligation to pay any unpaid interest and any fees then due and owing;

 

(B)        second,
in reduction of Borrower’s obligation to pay any Claims or Losses referred to in Section 12.03 then due and owing;

 

(C)        third,
in reduction of Borrower’s obligation to pay any amounts due and owing on account of the unpaid principal amount of the Loans;

 

(D)        fourth,
in reduction of any other Obligation then due and owing; and

 

(E)        fifth,
to Borrower or such other Persons as may lawfully be entitled to or directed by Borrower to receive the remainder.

 

    	[*] – indicates deleted language
 	27	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(ii)        Change
of Control. In the event of a Change of Control, Borrower shall immediately provide notice of such Change of Control to the
Lenders and, if within 10 days of receipt of such notice Majority Lenders notify Borrower in writing that a prepayment is required
pursuant to this Section 3.03(b)(ii), Borrower shall prepay the aggregate outstanding principal amount of the Loans in an
amount equal to the Redemption Price applicable on the date of such Change of Control in accordance with Section 3.03(a).

 

SECTION
4

PAYMENTS, ETC.

 

4.01       Payments.

 

(a)          Payments
Generally. Each payment of principal, interest and other amounts to be made by the Obligors under this Agreement or any other
Loan Document shall be made in Dollars, in immediately available funds, without deduction, set off or counterclaim, to an account
to be designated by the Majority Lenders by notice to Borrower, not later than 4:00 p.m. (Central time) on the date on which such
payment shall become due (each such payment made after such time on such due date to be deemed to have been made on the next succeeding
Business Day).

 

(b)          Application
of Payments. Each Obligor shall, at the time of making each payment under this Agreement or any other Loan Document, specify
to the Lenders the amounts payable by such Obligor hereunder to which such payment is to be applied (and in the event that Obligors
fail to so specify, or if an Event of Default has occurred and is continuing, the Lenders may apply such payment in the manner
they determine to be appropriate).

 

(c)          Non-Business
Days. If the due date of any payment under this Agreement (other than of principal of or interest on the Loans) would otherwise
fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, and, in the case of
any payment accruing interest, interest thereon shall be payable for the period of such extension.

 

4.02       Computations.
All computations of interest and fees hereunder shall be computed on the basis of a year of 360 days and actual days elapsed during
the period for which payable.

 

4.03       Notices.
Each notice of optional prepayment shall be effective only if received by the Lenders not later than 4:00 p.m. (Central time) on
the date one Business Day prior to the date of prepayment. Each notice of optional prepayment shall specify the amount to be prepaid
and the date of prepayment.

 

4.04       Set-Off.

 

(a)          Set-Off
Generally. Upon the occurrence and during the continuance of any Event of Default, the Lenders and each of their Affiliates
are hereby authorized at any time and from time to time, to the fullest extent permitted by law, to set off and apply any and all
deposits (general or special, time or demand, provisional or final) at any time held and other indebtedness at any time owing by
the Lenders or such Affiliates to or for the credit or the account of Borrower against any and all of the Obligations, whether
or not the Lenders shall have made any demand and although such obligations may be unmatured. The Lenders agree promptly to notify
Borrower after any such set-off and application, provided that the failure to give such notice shall not affect the validity of
such set-off and application. The rights of the Lenders and their Affiliates under this Section 4.04 are in addition to
other rights and remedies (including other rights of set-off) that the Lenders and their Affiliates may have.

 

    	[*] – indicates deleted language
 	28	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(b)          Exercise
of Rights Not Required. Nothing contained herein shall require the Lenders to exercise any such right or shall affect the right
of the Lenders to exercise, and retain the benefits of exercising, any such right with respect to any other indebtedness or obligation
of Borrower.

 

SECTION
5

YIELD PROTECTION, ETC.

 

5.01       Additional
Costs.

 

(a)          Change
in Requirements of Law Generally. If, on or after the date hereof, the adoption of any Requirement of Law, or any change in
any Requirement of Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority
charged with the interpretation or administration thereof, or compliance by any of the Lenders (or its lending office) with any
request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem
applicable any reserve (including any such requirement imposed by the Board of Governors of the Federal Reserve System), special
deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the date hereof,
against assets of, deposits with or for the account of, or credit extended by, a Lender (or its lending office) or shall impose
on a Lender (or its lending office) any other condition affecting the Loans or the Commitment, and the result of any of the foregoing
is to increase the cost to such Lender of making or maintaining the Loans, or to reduce the amount of any sum received or receivable
by such Lender under this Agreement or any other Loan Document, by an amount deemed by such Lender to be material (other than (i)
Indemnified Taxes and (ii) Taxes described in clause (c) or (d) of the definition of “Excluded Taxes”),
then Borrower shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender for such increased
cost or reduction.

 

(b)          Change
in Capital Requirements. If a Lender shall have determined that, on or after the date hereof, the adoption of any Requirement
of Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any
Governmental Authority charged with the interpretation or administration thereof, or any request or directive regarding capital
adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after
the date hereof, has or would have the effect of reducing the rate of return on capital of a Lender (or its parent) as a consequence
of a Lender’s obligations hereunder or the Loans to a level below that which a Lender (or its parent) could have achieved
but for such adoption, change, request or directive by an amount reasonably deemed by it to be material, then Borrower shall pay
to such Lender on demand such additional amount or amounts as will compensate such Lender (or its parent) for such reduction.

 

    	[*] – indicates deleted language
 	29	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(c)        Notification
by Lender. The Lenders will promptly notify Borrower of any event of which it has knowledge, occurring after the date hereof,
which will entitle a Lender to compensation pursuant to this Section 5.01. Before giving any such notice pursuant to this
Section 5.01(c) such Lender shall designate a different lending office if such designation (x) will, in the reasonable judgment
of such Lender, avoid the need for, or reduce the amount of, such compensation and (y) will not, in the reasonable judgment of
such Lender, be materially disadvantageous to such Lender. A certificate of the Lender claiming compensation under this Section
5.01, setting forth the additional amount or amounts to be paid to it hereunder, shall be conclusive and binding on Borrower
in the absence of manifest error.

 

(d)        Notwithstanding
anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines
or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by
the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the
United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute
a change in Requirements of Law for all purposes of this Section 5.01, regardless of the date enacted, adopted or issued.

 

5.02       Illegality.
Notwithstanding any other provision of this Agreement, in the event that on or after the date hereof the adoption of or any change
in any Requirement of Law or in the interpretation or application thereof by any competent Governmental Authority shall make it
unlawful for a Lender or its lending office to make or maintain the Loans (and, in the opinion of such Lender, the designation
of a different lending office would either not avoid such unlawfulness or would be disadvantageous to such Lender), then such Lender
shall promptly notify Borrower thereof following which (a) the Lender’s Commitment shall be suspended until such time as
such Lender may again make and maintain the Loans hereunder and (b) if such Requirement of Law shall so mandate, the Loans shall
be prepaid by Borrower on or before such date as shall be mandated by such Requirement of Law in an amount equal to the Redemption
Price applicable on the date of such prepayment in accordance with Section 3.03(a).

 

5.03       Taxes.

 

(a)        Payments
Free of Taxes. Any and all payments by or on account of any Obligation shall be made without deduction or withholding for any
Taxes, except as required by applicable law. If any applicable law requires the deduction or withholding of any Tax from any such
payment by an Obligor, then such Obligor shall be entitled to make such deduction or withholding and shall timely pay the full
amount deducted or withheld to the relevant Governmental Authority in accordance with applicable law and, if such Tax is an Indemnified
Tax, then the sum payable by such Obligor shall be increased as necessary so that after such deduction or withholding has been
made (including such deductions and withholdings applicable to additional sums payable under this Section 5) the applicable
Recipient receives an amount equal to the sum it would have received had no such deduction or withholding been made.

 

(b)        Payment
of Other Taxes by Borrower. Borrower shall timely pay to the relevant Governmental Authority in accordance with applicable
law, or at the option of each Lender, timely reimburse it for, Other Taxes.

 

    	[*] – indicates deleted language
 	30	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(c)          Evidence
of Payments. As soon as practicable after any payment of Taxes by Borrower to a Governmental Authority pursuant to this Section
5, Borrower shall deliver to each Lender the original or a certified copy of a receipt issued by such Governmental Authority
evidencing such payment.

 

(d)          Indemnification.
Borrower shall reimburse and indemnify each Recipient, within 10 days after demand therefor, for the full amount of any Indemnified
Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 5) payable
or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient and any reasonable expenses arising
therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant
Governmental Authority. A certificate as to the amount of such payment or liability delivered to Borrower by a Lender shall be
conclusive absent manifest error.

 

(e)          Status
of Lenders.

 

(i)        Any
Lender that is entitled to an exemption from, or reduction of withholding Tax with respect to payments made under any Loan Document
shall timely deliver to Borrower such properly completed and executed documentation reasonably requested by Borrower as will permit
such payments to be made without withholding or at a reduced rate of withholding; provided that, other than in the case of U.S.
Federal withholding Taxes, such Lender has received written notice from Borrower advising it of the availability of such exemption
or reduction and containing all applicable documentation. In addition, any Lender shall deliver such other documentation prescribed
by applicable law as reasonably requested by Borrower as will enable Borrower to determine whether or not such Lender is subject
to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences,
the completion, execution and submission of such documentation (other than such documentation set forth in Section 5.03(e)(ii)(A),
(B), (C) or (D)) shall not be required if in the Lender’s reasonable judgment such completion, execution or
submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial
position of such Lender.

 

(ii)          Without
limiting the generality of the foregoing, in the event that Borrower is a U.S. Person:

 

(A)        any
Lender that is a U.S. Person shall deliver to Borrower on or prior to the date on which such Lender becomes a Lender under this
Agreement (and from time to time thereafter upon the reasonable request of Borrower), executed originals of IRS Form W-9 (or successor
form) certifying that such Lender is exempt from U.S. Federal backup withholding tax;

 

(B)        any
Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower (in such number of copies as shall be
requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from
time to time thereafter upon the reasonable request of Borrower), whichever of the following is applicable:

 

    	[*] – indicates deleted language
 	31	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(1)        in
the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x) with respect
to payments of interest under any Loan Document, executed originals of IRS Form W-8BEN (or successor form) establishing an exemption
from, or reduction of, U.S. Federal withholding Tax pursuant to the “interest” article of such tax treaty and (y) with
respect to any other applicable payments under any Loan Document, IRS Form W-8BEN (or successor form) establishing an exemption
from, or reduction of, U.S. Federal withholding Tax pursuant to the “business profits” or “other income”
article of such tax treaty;

 

(2)        executed
originals of IRS Form W-8ECI (or successor form);

 

(3)        in
the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x)
a certificate substantially in the form of Exhibit D to the effect that such Foreign Lender is not a “bank”
within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the applicable Borrower within
the meaning of Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C)
of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed originals of IRS Form W-8BEN (or successor
form); or

 

(4)        to
the extent a Foreign Lender is not the beneficial owner, executed originals of IRS Form W-8IMY (or successor form), accompanied
by IRS Form W-8ECI (or successor form), IRS Form W-8BEN (or successor form), a U.S. Tax Compliance Certificate, IRS Form W-9 (or
successor form), and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender
is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption,
such Foreign Lender may provide a U.S. Tax Compliance Certificate on behalf of each such direct and indirect partner.

 

(C)         any
Foreign Lender shall, to the extent it is legally entitled to do so, deliver to Borrower (in such number of copies as shall be
requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from
time to time thereafter upon the reasonable request of Borrower), executed originals of any other form prescribed by applicable
law as a basis for claiming exemption from or a reduction in U.S. Federal withholding Tax, duly completed, together with such supplementary
documentation as may be prescribed by applicable law to permit Borrower to determine the withholding or deduction required to be
made; and

 

(D)         any
Foreign Lender shall deliver to Borrower any forms and information necessary to establish that such Foreign Lender is not subject
to withholding tax under FATCA.

 

Each Lender agrees that if any form or certification it previously
delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify
Borrower in writing of its legal inability to do so.

 

    	[*] – indicates deleted language
 	32	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(f)        Treatment
of Certain Refunds. If any party determines, in its sole discretion exercised in good faith, that it has received a refund
of any Taxes as to which it has been indemnified pursuant to this Section 5 (including by the payment of additional amounts
pursuant to this Section 5), it shall pay to the indemnifying party an amount equal to such refund (but only to the extent
of indemnity payments made under this Section 5 with respect to the Taxes giving rise to such refund), net of all out-of-pocket
expenses (including Taxes) of such indemnified party and without interest (other than any interest paid by the relevant Governmental
Authority with respect to such refund). Such indemnifying party, upon the request of such indemnified party, shall repay to such
indemnified party the amount paid over pursuant to this paragraph (plus any penalties, interest or other charges imposed by the
relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental
Authority. Notwithstanding anything to the contrary in this Section 5.03(f), in no event will the indemnified party be required
to pay any amount to an indemnifying party pursuant to this Section 5.03(f) the payment of which would place the indemnified
party in a less favorable net after-Tax position than the indemnified party would have been in if the indemnification payments
or additional amounts giving rise to such refund had never been paid. This Section 5.03(f) shall not be construed to require
any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems confidential)
to the indemnifying party or any other Person.

 

(g)        Mitigation
Obligations. If Borrower is required to pay any Indemnified Taxes or additional amounts to any Lender or to any Governmental
Authority for the account of any Lender pursuant to Section 5.01 or this Section 5.03, then such Lender shall
(at the request of Borrower) use commercially reasonable efforts to designate a different lending office for funding or booking
its Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates
if, in the sole reasonable judgment of such Lender, such designation or assignment and delegation would (i) eliminate or reduce
amounts payable pursuant to Section 5.01 or this Section 5.03, as the case may be, in the future, (ii) not
subject such Lender to any unreimbursed cost or expense and (iii) not otherwise be disadvantageous to such Lender. Borrower hereby
agrees to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and
delegation.

 

SECTION
6

CONDITIONS PRECEDENT

 

6.01       Conditions
to the First Borrowing. The obligation of each Lender to make a Loan as part of the first Borrowing shall not become effective
until the following conditions precedent shall have been satisfied or waived in writing by the Majority Lenders:

 

(a)        Borrowing
Date. Such Borrowing shall be made within fifteen (15) Business Days after the date hereof.

 

(b)        Amount
of First Borrowing. The amount of such Borrowing shall equal $50,000,000.

 

(c)        Terms
of Material Agreements, Etc. Lenders shall be reasonably satisfied with the terms and conditions of all of the Obligors’
Material Agreements.

 

    	[*] – indicates deleted language
 	33	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(d)          No
Law Restraining Transactions. No applicable law or regulation shall restrain, prevent or, in the reasonable judgment of the
Lenders, impose materially adverse conditions upon the Transactions.

 

(e)          Payment
of Fees. Lenders shall be satisfied with the arrangements to deduct the fees set forth in the Fee Letter (including without
limitation the financing fee required pursuant to the Fee Letter) from the proceeds advanced.

 

(f)          Lien
Searches. Lenders shall be satisfied with Lien searches regarding Borrower and its Subsidiaries made within two Business Days
prior to such Borrowing.

 

(g)          Documentary
Deliveries. The Lenders shall have received the following documents, each of which shall be in form and substance satisfactory
to the Lenders:

 

(i)          Agreement.
This Agreement duly executed and delivered by Borrower and each of the other parties hereto.

 

(ii)         Security
Documents.

 

(A)        The
Security Agreement, duly executed and delivered by each of the Obligors;

 

(B)        Each
Real Property Security Document, duly executed and delivered by each of the Obligors party thereto;

 

(C)        (1)
Each of the Short-Form IP Security Agreements, duly executed and delivered by the applicable Obligor, and (2) such Intellectual
Property security agreements, duly executed and delivered by the applicable Obligor, as the Lenders may require with respect to
foreign Intellectual Property;

 

(D)        Charge
Over Shares with respect to the shares of Navidea Biopharmaceuticals Limited;

 

(E)        Original
share certificates or other documents or evidence of title with regard to all Equity Interests owned by the Obligors (to the extent
that such Equity Interests are certificated), together with share transfer documents, undated and executed in blank;

 

(F)        Duly
executed control agreements in favor of the Lenders for all Deposit Accounts, Securities Accounts and Commodity Accounts owned
by the Obligors in the United States;

 

(G)        Evidence
of filing of UCC-1 financing statements against each Obligor in its jurisdiction of formation or incorporation, as the case may
be;

 

(H)        Evidence
of filing of (1) each of the Short-Form IP Security Agreements in the United States Patent and Trademark Office or the United States
Copyright office, as applicable, and (2) such foreign filings as the Lenders may require with respect to foreign Intellectual
Property; and

 

    	[*] – indicates deleted language
 	34	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(I)        Without
limitation, all other documents and instruments reasonably required to perfect the Lenders’ Lien on, and security interest
in, the Collateral required to be delivered on or prior to such Borrowing Date shall have been duly executed and delivered and
be in proper form for filing, and shall create in favor of the Lenders, a perfected Lien on, and security interest in, the Collateral,
subject to no Liens other than Permitted Liens.

 

(iii)         Notes.
Any Notes requested in accordance with Section 2.04.

 

(iv)         Approvals.
Certified copies of all material licenses, consents, authorizations and approvals of, and notices to and filings and registrations
with, any Governmental Authority (including all foreign exchange approvals), and of all third-party consents and approvals, necessary
in connection with the making and performance by the Obligors of the Loan Documents and the Transactions.

 

(v)         Corporate
Documents. Certified copies of the constitutive documents of each Obligor (if publicly available in such Obligor’s jurisdiction
of formation) and of resolutions of the Board of Directors (or shareholders, if applicable) of each Obligor authorizing the making
and performance by it of the Loan Documents to which it is a party.

 

(vi)         Incumbency
Certificate. A certificate of each Obligor as to the authority, incumbency and specimen signatures of the persons who have
executed the Loan Documents and any other documents in connection herewith on behalf of the Obligors.

 

(vii)        Landlord
Consent. A Landlord Consent, in substantially the form attached hereto as Exhibit G, or such other form as reasonably
acceptable to Lenders, for the Borrower Facility.

 

(viii)       Officer’s
Certificate. A certificate, dated such Borrowing Date and signed by the President, a Vice President or a financial officer
of Borrower, confirming compliance with the conditions set forth in Section 6.03.

 

(ix)         Opinions
of Counsel. A favorable opinion, dated such Borrowing Date, of counsel to each Obligor in form acceptable to the Lenders and
their counsel, in the form set forth in Exhibit F with such changes as shall be reasonably acceptable to Lenders.

 

(x)          Insurance.
Certificates of insurance evidencing the existence of all insurance required to be maintained by Borrower pursuant to Section
8.05(b) and the designation of the Lenders as the loss payees or additional named insured, as the case may be, thereunder.

 

(xi)         Subordination
Agreements and Platinum Loan Agreement Amendment. Each of Platinum-Montaur Life Sciences LLC and R-NAV, LLC shall have executed
and delivered to the Lenders a subordination agreement, and Platinum-Montaur Life Sciences LLC and Borrower shall have executed
and delivered an amendment to the Platinum Loan Agreement, in each case in form and substance satisfactory to Lenders.

 

(xii)        Other
Liens. Duly executed and delivered copies of such acknowledgement letters as are reasonably requested by the Lenders with respect
to existing Liens.

 

    	[*] – indicates deleted language
 	35	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(xiii)       SBA
Forms. Completed SBA Forms 480, 652, and 1031 (Parts A and B), showing Borrower’s financial projections (including balance
sheets and income and cash flow statements) for the period described therein and a representation to PIOP of Borrower’s intended
use of proceeds of the Loans (the “Use of Proceeds Statement”).

 

6.02      
Conditions to the Second Borrowing. The obligation of each Lender to make a Loan as part of the second Borrowing is subject
to the following conditions precedent:

 

(a)          First
Borrowing. A first Borrowing of $50,000,000 shall have occurred.

 

(b)          Borrowing
Date. Such Borrowing shall occur on or prior to February 15, 2017.

 

(c)          Amount
of Borrowing. The amount of such Borrowing shall not exceed $10,000,000.

 

(d)          Borrowing
Milestone. Borrower shall have achieved, by a date not later than December 31, 2016, Revenue in the sale of the Product of
not less than $[*] (the “Borrowing Milestone”) during the twelve-month period immediately prior to such date.

 

(e)          Notice
of Milestone Achievement and Audit. Borrower shall have delivered to the Lenders a notice certifying satisfaction of the condition
set forth in Section 6.02(c) no later than thirty (30) days thereafter, and the Lenders shall have been reasonably satisfied
with the results of its audit of Borrower’s Revenue by examining Borrower’s books and records.

 

(f)           Notice
of Borrowing. A Notice of Borrowing shall have been received no later than 45 calendar days after satisfaction of the condition
set forth in Section 6.02(c).

 

(g)          Financing
Fee. Except in the case of any PIK Loan, each Lender shall have received its portion of the fees payable pursuant to the Fee
Letter.

 

6.03       Conditions
to Each Borrowing. The obligation of each Lender to make a Loan as part of any Borrowing (including the first Borrowing) is
also subject to satisfaction of the following further conditions precedent on the applicable Borrowing Date:

 

(a)          Commitment
Period. Except in the case of any PIK Loan, such Borrowing Date shall occur during the Commitment Period.

 

(b)          No
Default; Representations and Warranties. Both immediately prior to the making of such Loan and after giving effect thereto
and to the intended use thereof:

 

(i)          no
Default shall have occurred and be continuing; and

 

(ii)         the
representations and warranties made by Borrower in Section 7 shall be true on and as of the Borrowing Date, and immediately
after giving effect to the application of the proceeds of the Borrowing, with the same force and effect as if made on and as of
such date (except that the representation regarding representations and warranties that refer to a specific earlier date shall
be that they were true on such earlier date).

 

    	[*] – indicates deleted language
 	36	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(c)        Notice
of Borrowing. Except in the case of any PIK Loan, Capital Royalty Partners II L.P. shall have received a Notice of Borrowing
as and when required pursuant to Section 2.02.

 

Each Borrowing shall constitute a certification
by Borrower to the effect that the conditions set forth in this Section 6.03 have been fulfilled as of the applicable Borrowing
Date.

 

SECTION
7

REPRESENTATIONS AND WARRANTIES

 

Borrower represents and warrants to the
Lenders that:

 

7.01       Power
and Authority. Each of Borrower and its Subsidiaries (a) is a duly organized and validly existing under the laws of its jurisdiction
of organization, (b) has all requisite corporate or other power, and has all material governmental licenses, authorizations, consents
and approvals necessary to own its assets and carry on its business as now being or as proposed to be conducted except to the extent
that failure to have the same could not reasonably be expected to have a Material Adverse Effect, (c) is qualified to do business
and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such qualification necessary
and where failure so to qualify could (either individually or in the aggregate) reasonably be expected to have a Material Adverse
Effect, and (d) has full power, authority and legal right to make and perform each of the Loan Documents to which it is a party
and, in the case of Borrower, to borrow the Loans hereunder.

 

7.02       Authorization;
Enforceability. The Transactions are within each Obligor’s corporate powers and have been duly authorized by all necessary
corporate and, if required, by all necessary shareholder action. This Agreement has been duly executed and delivered by each Obligor
and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute,
a legal, valid and binding obligation of such Obligor, enforceable against each Obligor in accordance with its terms, except as
such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar laws of general applicability
affecting the enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether
such enforceability is considered in a proceeding in equity or at law).

 

7.03       Governmental
and Other Approvals; No Conflicts. The Transactions (a) do not require any consent or approval of, registration or filing with,
or any other action by, any Governmental Authority or any third party, except for (i) such as have been obtained or made and are
in full force and effect and (ii) filings and recordings in respect of the Liens created pursuant to the Security Documents, (b)
will not violate any applicable law or regulation or the charter, bylaws or other organizational documents of Borrower and its
Subsidiaries or any order of any Governmental Authority, other than any such violations that, individually or in the aggregate,
could not reasonably be expected to have a Material Adverse Effect, (c) will not violate or result in a default under any indenture,
agreement or other instrument binding upon Borrower and its Subsidiaries or assets, or give rise to a right thereunder to require
any payment to be made by any such Person, and (d) will not result in the creation or imposition of any Lien (other than Permitted
Liens) on any asset of Borrower and its Subsidiaries.

 

    	[*] – indicates deleted language
 	37	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

7.04       Financial
Statements; Material Adverse Change.

 

(a)          Financial
Statements. Borrower has heretofore furnished to the Lenders certain financial statements as provided for in Section 8.01.
Such financial statements present fairly, in all material respects, the financial position and results of operations and cash flows
of Borrower and its Subsidiaries as of such dates and for such periods in accordance with GAAP, subject to year-end audit adjustments
and the absence of footnotes in the case of the statements previously-delivered statements of the type described in Section
8.01(b). Neither Borrower nor any of its Subsidiaries has any material contingent liabilities or unusual forward or long-term
commitments not disclosed in the aforementioned financial statements.

 

(b)          No
Material Adverse Change. Since December 31, 2014, there has been no Material Adverse Change.

 

7.05       Properties.

 

(a)          Property
Generally. Each Obligor has good title to, or valid leasehold interests in, all its real and personal Property material to
its business, subject only to Permitted Liens and except for minor defects in title that do not interfere with its ability to conduct
its business as currently conducted or to utilize such properties for their intended purposes.

 

(b)          Intellectual
Property. The Obligors represent and warrant to the Lenders as of the date hereof as follows, and the Obligors acknowledge
that the Lenders are relying on such representations and warranties in entering into this Agreement:

 

(i)          Schedule
7.05(b) (as amended from time to time by Borrower in accordance with Section 7.21) contains:

 

(A)        a
complete and accurate list of all applied for or registered Patents, including the jurisdiction and patent number;

 

(B)        a
complete and accurate list of all applied for or registered Trademarks, including the jurisdiction, trademark application or registration
number and the application or registration date; and

 

(C)        a
complete and accurate list of all applied for or registered Copyrights;

 

(ii)          Each
Obligor is the absolute beneficial owner of all right, title and interest in and to Obligor Intellectual Property listed as owned
on Schedule 7.05(c) free and clear of any Liens or Claims of any kind whatsoever other than Permitted Liens, and has the
right to use the Obligor Intellectual Property listed as licensed on Schedule 7.05(c) as provided in the applicable license(s).
Without limiting the foregoing, and except as set forth in Schedule 7.05(b) (as amended from time to time by Borrower in
accordance with Section 7.21):

 

(A)        other
than with respect to the Material Agreements, or as permitted by Section 9.09, the Obligors have not transferred ownership
of Material Intellectual Property, in whole or in part, to any other Person who is not an Obligor;

 

    	[*] – indicates deleted language
 	38	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(B)        other
than (i) the Material Agreements, (ii) customary restrictions in in-bound licenses of Intellectual Property and non-disclosure
agreements, or (iii) as would have been or is permitted by Section 9.09, there are no judgments, covenants not to sue, permits,
grants, licenses, Liens (other than Permitted Liens), Claims, or other agreements or arrangements relating to Borrower’s
Material Intellectual Property, including any development, submission, services, research, license or support agreements, which
bind, obligate or otherwise restrict the Obligors;

 

(C)        the
use by Obligors of any of the Obligor Intellectual Property, to the best of Borrower’s Knowledge, does not breach, violate,
infringe or interfere with or constitute a misappropriation of any valid rights arising under any Intellectual Property of any
other Person;

 

(D)        there
are no pending or, to Borrower’s Knowledge, threatened Claims against the Obligors asserted by any other Person relating
to the Obligor Intellectual Property, including any Claims of adverse ownership, invalidity, infringement, misappropriation, violation
or other opposition to or conflict with such Intellectual Property; the Obligors have not received any written notice from any
Person that Borrower’s business, the use of the Obligor Intellectual Property, or the manufacture, use or sale of any product
or the performance of any service by Borrower infringes upon, violates or constitutes a misappropriation of, or may infringe upon,
violate or constitute a misappropriation of, or otherwise interfere with, any other Intellectual Property of any other Person;

 

(E)        the
Obligors have no Knowledge that the Obligor Intellectual Property is being infringed, violated, misappropriated or otherwise used
by any other Person without the express authorization of the Obligors. Without limiting the foregoing, the Obligors have not put
any other Person on notice of actual or potential infringement, violation or misappropriation of any of the Obligor Intellectual
Property; the Obligors have not initiated the enforcement of any Claim with respect to any of the Obligor Intellectual Property;

 

(F)        all
relevant current and former employees and contractors of Borrower have executed written confidentiality and invention assignment
Contracts with Borrower that irrevocably assign to Borrower or its designee all of their rights to any Inventions relating to Borrower’s
business;

 

(G)        to
the Knowledge of the Obligors, the Obligor Intellectual Property is all the Intellectual Property necessary for the operation of
Borrower’s business as it is currently conducted or as currently contemplated to be conducted;

 

(H)        the
Obligors have taken reasonable precautions to protect the secrecy, confidentiality and value of its Obligor Intellectual Property
consisting of trade secrets and confidential information.

 

(I)        each
Obligor has delivered to the Lenders accurate and complete copies of all Material Agreements relating to the Obligor Intellectual
Property;

 

    	[*] – indicates deleted language
 	39	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(J)        there
are no pending or, to the Knowledge of any of the Obligors, threatened in writing Claims against the Obligors asserted by any other
Person relating to the Material Agreements, including any Claims of breach or default under such Material Agreements;

 

(iii)        With
respect to the Obligor Intellectual Property consisting of Patents, except as set forth in Schedule 7.05(b) (as amended
from time to time by Borrower in accordance with Section 7.21), and without limiting the representations and warranties
in Section 7.05(b)(ii):

 

(A)        each
of the issued claims in such Patents, to Borrower’s Knowledge, is valid and enforceable;

 

(B)        the
inventors claimed in such Patents have executed written Contracts with Borrower or its predecessor-in-interest that properly and
irrevocably assigns to Borrower or predecessor-in-interest all of their rights to any of the Inventions claimed in such Patents
to the extent permitted by applicable law;

 

(C)        none
of the Patents, or the Inventions claimed in them, have been dedicated to the public except as a result of intentional decisions
made by the applicable Obligor;

 

(D)        to
Borrower’s Knowledge, all relevant prior art material to the issued claims in such Patents was adequately disclosed to or
considered by the respective patent offices during prosecution of such Patents to the extent required by applicable law or regulation;

 

(E)        subsequent
to the issuance of such Patents, neither any Obligor nor their predecessors in interest, have filed any disclaimer or filed any
other voluntary reduction in the scope of the Inventions claimed in such Patents;

 

(F)        no
allowable or allowed subject matter of such Patents, to Borrower’s Knowledge, is subject to any competing conception claims
of allowable or allowed subject matter of any patent applications or patents of any third party and have not been the subject of
any interference, re-examination or opposition proceedings, nor are the Obligors aware of any basis for any such interference,
re-examination or opposition proceedings;

 

(G)        none
of the issued claims in such Patents, to Borrower’s Knowledge, have ever been finally adjudicated to be invalid, unpatentable
or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding, and, with the exception of publicly
available documents in the applicable Patent Office recorded with respect to any Patents, the Obligors have not received any notice
asserting that such issued claims in such Patents are invalid, unpatentable or unenforceable; if any of such Patents is terminally
disclaimed to another patent or patent application, all patents and patent applications subject to such terminal disclaimer are
included in the Collateral;

 

(H)        the
Obligors have not received an opinion, whether preliminary in nature or qualified in any manner, which concludes that a challenge
to the validity or enforceability of any of the issued claims in such Patents is more likely than not to succeed;

 

    	[*] – indicates deleted language
 	40	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(I)        the
Obligors have no Knowledge that they or any prior owner of such Patents or their respective agents or representatives have engaged
in any conduct, or omitted to perform any necessary act, the result of which would invalidate or render unpatentable or unenforceable
any such Patents; and

 

(J)        all
maintenance fees, annuities, and the like due or payable on the Patents have been timely paid or the failure to so pay was the
result of an intentional decision by the applicable Obligor or would not reasonably be expected to result in a Material Adverse
Change.

 

(iv)        none
of the foregoing representations and statements of fact contains any untrue statement of material fact or omits to state any material
fact necessary to make any such statement or representation not misleading to a prospective Lender seeking full information as
to the Obligor Intellectual Property and the Borrower’s business.

 

(c)          Material
Intellectual Property. Schedule 7.05(c) (as amended from time to time by Borrower in accordance with Section 7.21)
contains an accurate list of the Obligor Intellectual Property that is material to Borrower’s business with an indication
as to whether the applicable Obligor owns or has an exclusive or non-exclusive license to such Obligor Intellectual Property.

 

7.06       No
Actions or Proceedings.

 

(a)          Litigation.
There is no litigation, investigation or proceeding pending or, to the best of Borrower’s Knowledge, threatened with respect
to Borrower and its Subsidiaries by or before any Governmental Authority or arbitrator (i) that involves more than $250,000, (ii)
that either individually or in the aggregate could reasonably be expected to have a Material Adverse Effect, except as specified
in Schedule 7.06 (as amended from time to time by Borrower in accordance with Section 7.21) or (iii) that involves
this Agreement or the Transactions.

 

(b)          Environmental
Matters. The operations and Property of Borrower and its Subsidiaries comply with all applicable Environmental Laws, except
to the extent the failure to so comply (either individually or in the aggregate) could not reasonably be expected to have a Material
Adverse Effect.

 

(c)          Labor
Matters. Borrower has not engaged in unfair labor practices and there are no material labor actions or disputes involving the
employees of Borrower.

 

7.07       Compliance
with Laws and Agreements. Each of the Obligors is in compliance with all laws, regulations and orders of any Governmental Authority
applicable to it or its property and all indentures, agreements and other instruments binding upon it or its property, except where
the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect.
No Default has occurred and is continuing.

 

7.08       Taxes.
Except as set forth on Schedule 7.08, each of the Obligors has timely filed or caused to be filed all tax returns and reports
required to have been filed and has paid or caused to be paid all taxes required to have been paid by it, except taxes that are
being contested in good faith by appropriate proceedings and for which such Obligor has set aside on its books adequate reserves
with respect thereto in accordance with GAAP.

 

    	[*] – indicates deleted language
 	41	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

7.09       Full
Disclosure. Borrower has disclosed to the Lenders all Material Agreements to which any Obligor is subject, the breach or termination
of which could, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and all other matters
to its Knowledge, that, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.
None of the reports, financial statements, certificates or other information furnished by or on behalf of the Obligors to the Lenders
in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder or thereunder (as modified
or supplemented by other information so furnished) contains any material misstatement of material fact or omits to state any material
fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided
that, with respect to projected financial information, Borrower represents only that such information was prepared in good
faith based upon assumptions believed to be reasonable at the time.

 

7.10       Regulation.

 

(a)          Investment
Company Act. Neither Borrower nor any of its Subsidiaries is an “investment company” as defined in, or subject
to regulation under, the Investment Company Act of 1940.

 

(b)         Margin
Stock. Neither Borrower nor any of its Subsidiaries is engaged principally, or as one of its important activities, in the business
of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock, and no part
of the proceeds of the Loans will be used to buy or carry any Margin Stock in violation of Regulation T, U or X.

 

7.11       Solvency.
Borrower is and, immediately after giving effect to the Borrowing and the use of proceeds thereof will be, Solvent.

 

7.12       Subsidiaries.
Set forth on Schedule 7.12 is a complete and correct list of all Subsidiaries as of the date hereof. Each such Subsidiary
is duly organized and validly existing under the jurisdiction of its organization shown in said Schedule 7.12, and the percentage
ownership by Borrower of each such Subsidiary is as shown in said Schedule 7.12.

 

7.13       Indebtedness
and Liens. Set forth on Schedule 7.13(a) is a complete and correct list of all Indebtedness of each Obligor outstanding
as of the date hereof. Schedule 7.13(b) is a complete and correct list of all Liens granted by Borrower and other Obligors
with respect to their respective Property and outstanding as of the date hereof.

 

7.14       Material
Agreements. Set forth on Schedule 7.14 (as amended from time to time by Borrower in accordance with Section 7.21)
is a complete and correct list of (i) each Material Agreement and (ii) each agreement creating or evidencing any Material Indebtedness.
Except as disclosed on Schedule 7.14, no Obligor is in material default under any such Material Agreement or agreement creating
or evidencing any Material Indebtedness. Except as otherwise disclosed on Schedule 7.14, all material vendor purchase agreements
and provider contracts of the Obligors are in full force and effect without material modification from the form in which the same
were disclosed to the Lenders.

 

    	[*] – indicates deleted language
 	42	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

7.15       Restrictive
Agreements. None of the Obligors is subject to any indenture, agreement, instrument or other arrangement that prohibits, restricts
or imposes any condition upon (a) the ability of Borrower or any Subsidiary to create, incur or permit to exist any Lien upon any
of its property or assets (other than (x) customary provisions in contracts (including without limitation leases and in-bound licenses
of Intellectual Property) restricting the assignment thereof and (y) restrictions or conditions imposed by any agreement governing
secured Permitted Indebtedness permitted under Section 9.01(h), to the extent that such restrictions or conditions apply
only to the property or assets securing such Indebtedness), or (b) the ability of any Subsidiary to pay dividends or other distributions
with respect to any shares of its capital stock or to make or repay loans or advances to Borrower or any other Subsidiary or to
Guarantee Indebtedness of Borrower or any other Subsidiary (each, a “Restrictive Agreement”), except
those listed on Schedule 7.15 or otherwise permitted under Section 9.11.

 

7.16       Real
Property.

 

(a)          Generally.
Neither Borrower nor any of its Subsidiaries owns or leases (as tenant thereof) any real property, except as described on Schedule
7.16 (as amended from time to time by Borrower in accordance with Section 7.21).

 

(b)          Borrower
Lease. (i) Borrower has delivered a true, accurate and complete copy of the Borrower Lease to Lenders.

 

(ii)        Borrower
Lease is in full force and effect and no default has occurred under the Borrower Lease and, to the Knowledge of Borrower, there
is no existing condition which, but for the passage of time or the giving of notice, could reasonably be expected to result in
a default under the terms of the Borrower Lease.

 

(iii)        Borrower
is the tenant under the Borrower Lease and has not transferred, sold, assigned, conveyed, disposed of, mortgaged, pledged, hypothecated,
or encumbered any of its interest in, the Borrower Lease.

 

7.17       Pension
Matters. Schedule 7.17 sets forth, as of the date hereof, a complete and correct list of, and that separately identifies,
(a) all Title IV Plans, (b) all Multiemployer Plans and (c) all material Benefit Plans. Each Benefit Plan, and each trust thereunder,
intended to qualify for tax exempt status under Section 401 or 501 of the Code or other Requirements of Law so qualifies. Except
for those that could not, in the aggregate, have a Material Adverse Effect, (x) each Benefit Plan is in compliance with applicable
provisions of ERISA, the Code and other Requirements of Law, (y) there are no existing or pending (or to the Knowledge of any Obligor
or Subsidiary thereof, threatened) claims (other than routine claims for benefits in the normal course), sanctions, actions, lawsuits
or other proceedings or investigation involving any Benefit Plan to which any Obligor or Subsidiary thereof incurs or otherwise
has or could have an obligation or any liability or Claim and (z) no ERISA Event is reasonably expected to occur. Borrower and
each of its ERISA Affiliates has met all applicable requirements under the ERISA Funding Rules with respect to each Title IV Plan,
and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained. As of the most recent
valuation date for any Title IV Plan, the funding target attainment percentage (as defined in Section 430(d)(2) of the Code) is
at least 60%, and neither Borrower nor any of its ERISA Affiliates knows of any facts or circumstances that could reasonably be
expected to cause the funding target attainment percentage to fall below 60% as of the most recent valuation date. As of the date
hereof, no ERISA Event has occurred in connection with which obligations and liabilities (contingent or otherwise) remain outstanding.
No ERISA Affiliate would have any Withdrawal Liability as a result of a complete withdrawal from any Multiemployer Plan on the
date this representation is made.

 

    	[*] – indicates deleted language
 	43	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

7.18       Collateral;
Security Interest. Each Security Document is effective to create in favor of the Lenders, upon the first Borrowing, a legal,
valid and enforceable security interest in the Collateral subject thereto and each such security interest is perfected to the extent
required by (and has the priority required by) the applicable Security Document. The Security Documents collectively are effective,
upon the first Borrowing, to create in favor of the Lenders a legal, valid and enforceable security interest in the Collateral,
which security interests are first-priority (subject only to Permitted Priority Liens).

 

7.19        Regulatory
Approvals. Borrower and its Subsidiaries hold, and will continue to hold, either directly or through licensees and agents,
all Regulatory Approvals, licenses, permits and similar governmental authorizations of a Governmental Authority necessary or required
for Borrower and its Subsidiaries to conduct their operations and business in the manner currently conducted.

 

7.20        Small
Business Concern. Borrower, together with its “affiliates” (as that term is defined in Title 13 of the United States
Code of Federal Regulations) is a “Small Business” within the meaning of the SBIC Act, and the regulations promulgated
thereunder (including part 107 and 121 of Title 13 of the United States Code of Federal Regulations). Borrower’s primary
business activity does not involve, directly or indirectly, providing funds to others (other than to its Subsidiaries), the purchase
or discounting of debt obligations, factoring or long term leasing of equipment with no provision for maintenance or repair, and
Borrower is not classified under Major Group 65 (Real Estate) or Industry No. 1531 (Operative Builders) of the SIC Manual. Borrower
acknowledges that it has been advised that PIOP is a Small Business Investment Company and licensee under the SBIC Act. The information
regarding Borrower and its affiliates set forth in the SBA Form 480, Form 652, and Form 1031 is accurate and complete. Borrower
acknowledges that the Lenders are relying on the representations and warranties made by Borrower to the SBA in the SBA Form 480
provided to the Lenders.

 

7.21        Update
of Schedules. Each of Schedules 7.05(b) (in respect of the lists of Patents, Trademarks, and Copyrights under
Section 7.05(b)(i)), 7.05(c), 7.06, 7.14 and 7.16 may be updated by Borrower from time to time
in order to insure the continued accuracy of such Schedule as of any upcoming date on which representations and warranties are
made incorporating the information contained on such Schedule. Such update may be accomplished by Borrower providing to the Lenders,
in writing (including by electronic means), a revised version of such Schedule in accordance with the provisions of Section 12.02.
Each such updated Schedule shall be effective immediately upon the receipt thereof by the Lenders.

 

    	[*] – indicates deleted language
 	44	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

SECTION
8

AFFIRMATIVE COVENANTS

 

Each Obligor covenants and agrees with the
Lenders that, until the Commitments have expired or been terminated and all Obligations have been paid in full indefeasibly in
cash:

 

8.01       Financial
Statements and Other Information. Borrower will furnish to the Lenders:

 

(a)        as
soon as available and in any event within five (5) days following date Borrower files Form 10-Q with the Securities and Exchange
Commission, the consolidated and consolidating balance sheets of the Obligors as of the end of such quarter, and the related consolidated
and consolidating statements of income, shareholders’ equity and cash flows of Borrower and its Subsidiaries for such quarter
and the portion of the fiscal year through the end of such quarter, prepared in accordance with GAAP consistently applied, all
in reasonable detail and setting forth in comparative form the figures for the corresponding period in the preceding fiscal year,
together with a certificate of a Responsible Officer of Borrower stating that such financial statements fairly present the financial
condition of Borrower and its Subsidiaries as at such date and the results of operations of Borrower and its Subsidiaries for the
period ended on such date and have been prepared in accordance with GAAP consistently applied, subject to changes resulting from
normal, year-end audit adjustments and except for the absence of notes;

 

(b)        as
soon as available and in any event within five (5) days following the date Borrower files Form 10-K with the Securities and Exchange
Commission, the consolidated and consolidating balance sheets of Borrower and its Subsidiaries as of the end of such fiscal year,
and the related consolidated and consolidating statements of income, shareholders’ equity and cash flows of Borrower and
its Subsidiaries for such fiscal year, prepared in accordance with GAAP consistently applied, all in reasonable detail and setting
forth in comparative form the figures for the previous fiscal year, accompanied by a report and opinion thereon of BDO USA, LLP
or another firm of independent certified public accountants of recognized national standing acceptable to the Lenders, which report
and opinion shall be prepared in accordance with generally accepted auditing standards and shall not be subject to any “going
concern” or like qualification or exception or any qualification or exception as to the scope of such audit, and in the case
of such consolidating financial statements, certified by a Responsible Officer of Borrower;

 

(c)        together
with the financial statements required pursuant to Sections 8.01(a) and (b), a compliance certificate of a Responsible
Officer as of the end of the applicable accounting period (which delivery may, unless a Lender requests executed originals, be
by electronic communication including fax or email and shall be deemed to be an original authentic counterpart thereof for all
purposes) in the form of Exhibit E (a “Compliance Certificate”) including details of any issues
that are material that are raised by auditors;

 

(d)        promptly
upon receipt thereof, copies of all letters of representation signed by an Obligor to its auditors and copies of all auditor reports
delivered for each fiscal quarter;

 

    	[*] – indicates deleted language
 	45	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(e)          as
soon as available, a consolidated financial forecast for Borrower and its Subsidiaries for the following two fiscal years, including
forecasted consolidated balance sheets, consolidated statements of income, shareholders’ equity and cash flows of Borrower
and its Subsidiaries, and a consolidated forecast of revenue for an additional three (3) years;

 

(f)           promptly
after the same are released, copies of all press releases;

 

(g)          promptly,
and in any event within five (5) Business Days after receipt thereof by an Obligor thereof, copies of each notice or other correspondence
received from any securities regulator or exchange to the authority of which Borrower may become subject from time to time concerning
any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of
such Obligor;

 

(h)          the
information regarding insurance maintained by Borrower and its Subsidiaries as required under Section 8.05;

 

(i)           prompt
notice of the Borrower’s achievement of the Borrowing Milestone;

 

(j)           within
five (5) days of filing, provide access (via posting and/or links on Borrower’s web site) to all reports on Form 10-K and
Form 10-Q filed with the SEC, any Governmental Authority succeeding to any or all of the functions of the SEC or with any national
securities exchange; and within five (5) days of filing, provide notice and access (via posting and/or links of Borrower’s
web site) to all reports on Form 8-K filed with the Securities and Exchange Commission, and copies of (or access to, via posting
and/or links on Borrower’s web site) all other reports, proxy statements and other materials filed by Borrower with the SEC,
any Governmental Authority succeeding to any of the functions of the SEC or with any national securities exchange;

 

(k)          promptly
following Lenders’ request at any time, proof of Borrower’s compliance with Section 10.01; and

 

(l)           within
five (5) days of delivery, copies of all statements, reports and notices (including board kits) made available to holders of Borrower’s
Equity Interests or holders of Permitted Subordinated Debt, provided that any such material may be redacted by Borrower
to exclude information relating to the Lenders (including Borrower’s strategy regarding the Loans).

 

8.02       Notices
of Material Events. Borrower will furnish to the Lenders written notice of the following promptly after a Responsible Officer
first learns of the existence of:

 

(a)          the
occurrence of any Default;

 

(b)          notice
of the occurrence of any event with respect to its property or assets resulting in a Loss aggregating $500,000 (or the Equivalent
Amount in other currencies) or more;

 

(c)          any
returns, recoveries, disputes and claims that involve more than $250,000 individually or in the aggregate in any calendar year;

 

    	[*] – indicates deleted language
 	46	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(d)        (A)
any proposed acquisition of stock, assets or property by any Obligor that would reasonably be expected to result in environmental
liability under Environmental Laws, and (B)(1) spillage, leakage, discharge, disposal, leaching, migration or release of any Hazardous
Material required to be reported to any Governmental Authority under applicable Environmental Laws, and (2) all actions, suits,
claims, notices of violation, hearings, investigations or proceedings pending, or to the best of Borrower’s Knowledge, threatened
against or affecting Borrower or any of its Subsidiaries or with respect to the ownership, use, maintenance and operation of their
respective businesses, operations or properties, relating to Environmental Laws or Hazardous Material;

 

(e)         the
assertion of any environmental matter by any Person against, or with respect to the activities of, Borrower or any of its Subsidiaries
and any alleged violation of or non-compliance with any Environmental Laws or any permits, licenses or authorizations which could
reasonably be expected to involve damages in excess of $100,000 other than any environmental matter or alleged violation that,
if adversely determined, could not (either individually or in the aggregate) have a Material Adverse Effect;

 

(f)         the
filing or commencement of any action, suit or proceeding by or before any arbitrator or Governmental Authority against or affecting
Borrower or any of its Affiliates that, if adversely determined, could reasonably be expected to result in a Material Adverse Effect;

 

(g)        (i)
on or prior to any filing by any ERISA Affiliate of any notice of intent to terminate any Title IV Plan, a copy of such notice
and (ii) promptly, and in any event within ten days, after any Responsible Officer of any ERISA Affiliate knows or has reason to
know that a request for a minimum funding waiver under Section 412 of the Code has been filed with respect to any Title IV Plan
or Multiemployer Plan, a notice (which may be made by telephone if promptly confirmed in writing) describing such waiver request
and any action that any ERISA Affiliate proposes to take with respect thereto, together with a copy of any notice filed with the
PBGC or the IRS pertaining thereto;

 

(h)        (i)
the termination of any Material Agreement; (ii) the receipt by Borrower or any of its Subsidiaries of any material notice under
any Material Agreement; (iii) the entering into of any new Material Agreement by an Obligor; or (iv) any material amendment to
a Material Agreement;

 

(i)          the
reports and notices as required by the Security Documents;

 

(j)          within
30 days of the date thereof, or, if earlier, on the date of delivery of any financial statements pursuant to Section 8.01,
notice of any material change in accounting policies or financial reporting practices by the Obligors;

 

(k)         promptly
after the occurrence thereof, notice of any labor controversy resulting in or threatening to result in any strike, work stoppage,
boycott, shutdown or other material labor disruption against or involving an Obligor;

 

(l)          a
licensing agreement or arrangement entered into by Borrower or any Subsidiary in connection with any infringement or alleged infringement
of the Intellectual Property of another Person;

 

    	[*] – indicates deleted language
 	47	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(m)          any
event that could reasonably be expected to materially and adversely affect the value of any Obligor’s Intellectual Property;

 

(n)          concurrently
with the delivery of financial statements under Section 8.01(b), the creation or other acquisition of any Intellectual Property
by Borrower or any Subsidiary after the date hereof and during such prior fiscal year which is registered or becomes registered
or the subject of an application for registration with the U.S. Copyright Office or the U.S. Patent and Trademark Office, as applicable,
or with any other equivalent foreign Governmental Authority;

 

(o)          any
change to any Obligor’s ownership of Deposit Accounts, Securities Accounts and Commodity Accounts, by delivering to Lenders
an updated Annex 7 to the Security Agreement setting forth a complete and correct list of all such accounts as of the date of such
change;

 

(p)          any
other development that results in, or could reasonably be expected to result in, a Material Adverse Effect; or

 

(q)          such
other information respecting the operations, properties, business or condition (financial or otherwise) of the Obligors (including
with respect to the Collateral) as the Majority Lenders may from time to time reasonably request.

 

Each notice delivered under this Section
8.02 shall be accompanied by a statement of a financial officer or other executive officer of Borrower setting forth the details
of the event or development requiring such notice and any action taken or proposed to be taken with respect thereto.

 

8.03       Existence;
Conduct of Business. (a) Such Obligor will, and will cause each of its Subsidiaries to, do or cause to be done all things necessary
to preserve, renew and keep in full force and effect its legal existence and the rights, licenses, permits, privileges and franchises
material to the conduct of its business; provided that the foregoing shall not prohibit any merger, amalgamation, consolidation,
liquidation or dissolution permitted under Section 9.03.

 

(b)          Without
obtaining the prior written approval of PIOP, Borrower will not change within one (1) year after the date hereof, Borrower’s
business activity to a business activity to which a licensee under the SBIC Act is prohibited from providing funds by the SBIC
Act, as more specifically set forth under Part 107.720 of Title 13 of the United States Code of Federal Regulations. If Borrower’s
business activity changes to such a prohibited business activity or the proceeds are used for ineligible business activities, Borrower
will use all commercially reasonable efforts and cooperate in good faith to assist PIOP to sell or transfer its Proportionate Share
of the Loans in a commercially reasonable manner; provided that in no way shall this be considered PIOP’s sole remedy
if Borrower’s business activity changes to such a prohibited business activity.

 

8.04       Payment
of Obligations. Such Obligor will, and will cause each of its Subsidiaries to, pay and discharge its obligations, including
(i) all taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the
date on which penalties attach thereto, and all lawful claims for labor, materials and supplies which, if unpaid, might become
a Lien upon any properties or assets of Borrower or any Subsidiary, except to the extent such taxes, fees, assessments or governmental
charges or levies, or such claims are being contested in good faith by appropriate proceedings and are adequately reserved against
in accordance with GAAP and (ii) all lawful claims which, if unpaid, would by law become a Lien upon its property not constituting
a Permitted Lien.

 

    	[*] – indicates deleted language
 	48	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

8.05       Insurance.
Such Obligor will, and will cause each of its Subsidiaries to maintain, with financially sound and reputable insurance companies,
insurance in such amounts and against such risks as are customarily maintained by companies engaged in the same or similar businesses
operating in the same or similar locations. Upon the request of Majority Lenders, Borrower shall furnish the Lenders from time
to time with full information as to the insurance carried by it and, if so requested, copies of all such insurance policies. Borrower
also shall furnish to the Lenders from time to time upon the request of the Majority Lenders a certificate from Borrower’s
insurance broker or other insurance specialist stating that all premiums then due on the policies relating to insurance on the
Collateral have been paid, that such policies are in full force and effect. Borrower shall use commercially reasonable efforts
to ensure, or cause others to ensure, that all insurance policies required under this Section 8.05 shall provide that they
shall not be terminated or cancelled nor shall any such policy be materially changed in a manner adverse to Borrower without at
least 30 days’ prior written notice to Borrower and the Lenders. Receipt of notice of termination or cancellation of any
such insurance policies or reduction of coverages or amounts thereunder shall entitle the Lenders to renew any such policies, cause
the coverages and amounts thereof to be maintained at levels required pursuant to the first sentence of this Section 8.05
or otherwise to obtain similar insurance in place of such policies, in each case at the expense of Borrower. Proceeds payable under
any policy shall, at the Control Agent’s option, be payable to the Control Agent, for the ratable benefit of the Lenders,
on account of the Obligations. Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing,
Borrower shall have the option of applying the proceeds of any casualty policy up to $100,000 with respect to any loss, but not
exceeding $100,000 in the aggregate for all losses under all casualty policies in any one year, toward the replacement or repair
of destroyed or damaged property; provided that any such replaced or repaired property (i) shall be of equal or like value as the
replaced or repaired Collateral and (ii) shall be deemed Collateral in which the Control Agent has been granted a first priority
security interest, and (b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such
casualty policy shall, at the option of the Control Agent, be payable to the Control Agent, for the ratable benefit of the Lenders,
on account of the Obligations.

 

8.06       Books
and Records; Inspection Rights. Such Obligor will, and will cause each of its Subsidiaries to, keep proper books of record
and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities.
Subject to the terms of the Non-Disclosure Agreement, such Obligor will, and will cause each of its Subsidiaries to, permit any
representatives designated by the Lenders, upon reasonable prior notice, to visit and inspect its properties, to examine and make
extracts from its books and records, and to discuss its affairs, finances and condition with its officers and independent accountants,
all at such reasonable times (but not more often than once a year unless an Event of Default has occurred and is continuing).

 

    	[*] – indicates deleted language
 	49	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

8.07       Compliance
with Laws and Other Obligations. Such Obligor will, and will cause each of its Subsidiaries to, (i) comply in all material
respects with all laws, rules, regulations and orders of any Governmental Authority applicable to it or its property (including
Environmental Laws) and (ii) comply in all material respects with all terms of Indebtedness and all other Material Agreements,
except where the failure to do so, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse
Effect.

 

8.08       Maintenance
of Properties, Etc.

 

(a)          Such
Obligor shall, and shall cause each of its Subsidiaries to, maintain and preserve all of its properties necessary or useful in
the proper conduct of its business in good working order and condition in accordance with the general practice of other Persons
of similar character and size, ordinary wear and tear and damage from casualty or condemnation excepted.

 

(b)          Without
limiting the generality of Section 8.08(a), each Obligor shall comply with each of the following covenants with respect
to the Borrower Lease:

 

(i)        Borrower
shall diligently perform and timely observe all of the terms, covenants and conditions of the Borrower Lease on the part of Borrower
to be performed and observed prior to the expiration of any applicable grace period therein provided and do everything necessary
to preserve and to keep unimpaired and in full force and effect the Borrower Lease.

 

(ii)        Borrower
shall promptly notify Lenders of the giving of any written notice by Borrower Landlord to Borrower of any default by Borrower thereunder,
and promptly deliver to Lenders a true copy of each such notice. If Borrower shall be in default under the Borrower Lease, Lenders
shall have the right (but not the obligation) to cause the default or defaults under the Borrower Lease to be remedied and otherwise
exercise any and all rights of Borrower under the Borrower Lease, as may be necessary to prevent or cure any default and Lenders
shall have the right to enter all or any portion of the Property, at such times and in such manner as Lenders reasonably deem necessary,
to prevent or to cure any such default. Without limiting the foregoing, upon any such default, Borrower shall promptly execute,
acknowledge and deliver to Lenders such instruments as may reasonably be required of Borrower to permit Lenders to cure any default
under the Borrower Lease or permit Lenders to take such other action required to enable Lenders to cure or remedy the matter in
default and preserve the security interest of Lenders under the Loan Documents with respect to the Borrower Facility.

 

(iii)        Borrower
shall use commercially reasonable efforts to enforce, in a commercially reasonable manner, each covenant or obligation of the Borrower
Landlord in the Borrower Lease in accordance with its terms. Subject to the terms and requirements of the Borrower Lease, within
ten (10) days after receipt of written request by Lenders, Borrower shall use reasonable efforts to obtain from the Borrower Landlord
under the Borrower Lease and furnish to Lenders an estoppel certificate from Borrower Landlord stating the date through which rent
has been paid and whether or not, to Borrower Landlord’s knowledge, there are any defaults thereunder and specifying the
nature of such claimed defaults, if any, and such other matters as Lenders may reasonably request or in the form required pursuant
to the terms of the Borrower Lease. Borrower shall furnish to Lenders all information that Lenders may reasonably request from
time to time in the possession of Borrower (or reasonably available to Borrower) concerning the Borrower Lease and Borrower’s
compliance with the Borrower Lease.

 

    	[*] – indicates deleted language
 	50	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(iv)        Borrower,
promptly upon learning that Borrower Landlord has failed to perform the material terms and provisions under the Borrower Lease
and immediately upon learning of a rejection or disaffirmance or purported rejection or disaffirmance of the Borrower Lease pursuant
to any state or federal bankruptcy law, shall notify Lenders thereof. Borrower shall promptly notify Lenders of any request that
any party to the Borrower Lease makes for arbitration or other dispute resolution procedure pursuant to the Borrower Lease and
of the institution of any such arbitration or dispute resolution. Borrower hereby authorizes Lenders to attend any such arbitration
or dispute, and upon the occurrence and during the continuance of an Event of Default participate in any such arbitration or dispute
resolution but such participation shall not be to the exclusion of Borrower; provided, however, that, in any case, Borrower
shall consult with Lenders with respect to the matters related thereto. Borrower shall promptly deliver to Lenders a copy of the
determination of each such arbitration or dispute resolution mechanism.

 

(v)        If
Lenders or their designee shall acquire or obtain a new Borrower Lease following a termination of the Borrower Lease, then Borrower
shall have no right, title or interest whatsoever in or to such new Borrower Lease, or any proceeds or income arising from the
estate arising under any such new Borrower Lease, including from any sale or other disposition thereof. Lenders or their designee
shall hold such new Borrower Lease free and clear of any right or claim of Borrower.

 

(vi)        Borrower
shall promptly, after obtaining knowledge of such filing notify Lenders orally of any filing by or against Borrower Landlord under
the Borrower Lease of a petition under the Bankruptcy Code or other applicable law. Borrower shall thereafter promptly give written
notice of such filing to Lenders, setting forth any information available to Borrower as to the date of such filing, the court
in which such petition was filed, and the relief sought in such filing. Borrower shall promptly deliver to Lenders any and all
notices, summonses, pleadings, applications and other documents received by Borrower in connection with any such petition and any
proceedings relating to such petition.

 

8.09       Licenses.
Such Obligor shall, and shall cause each of its Subsidiaries to, obtain and maintain all licenses, authorizations, consents, filings,
exemptions, registrations and other Governmental Approvals necessary in connection with the execution, delivery and performance
of the Loan Documents, the consummation of the Transactions or the operation and conduct of its business and ownership of its properties,
except where failure to do so could not reasonably be expected to have a Material Adverse Effect.

 

8.10       Action
under Environmental Laws. Such Obligor shall, and shall cause each of its Subsidiaries to, upon becoming aware of the presence
of any Hazardous Materials or the existence of any environmental liability under applicable Environmental Laws with respect to
their respective businesses, operations or properties, take all actions, at their cost and expense, as shall be necessary or advisable
to investigate and clean up the condition of their respective businesses, operations or properties, including all required removal,
containment and remedial actions, and restore their respective businesses, operations or properties to a condition in compliance
with applicable Environmental Laws.

 

    	[*] – indicates deleted language
 	51	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

8.11       Use
of Proceeds. The proceeds of the Loans will be used only as provided in Section 2.05. No part of the proceeds of the
Loans will be used, whether directly or indirectly, for any purpose that entails a violation of any of the Regulations of the Board
of Governors of the Federal Reserve System, including Regulations T, U and X. Neither Borrower nor any of its affiliates (as that
term is defined in Section 121.103 of Title 13 of the United States Code of Federal Regulation) will engage in any activities or
use directly or indirectly the proceeds from the Loans for any purpose for which an SBIC is prohibited from providing funds by
the SBIC Act as set forth in Section 107.720 of Title 13 of the United States Code of Federal Regulation.

 

8.12       Certain
Obligations Respecting Subsidiaries; Further Assurances. 

 

(a)          Subsidiary
Guarantors. Such Obligor will take such action, and will cause each of its Subsidiaries to take such action, from time to time
as shall be necessary to ensure that all Subsidiaries that are Domestic Subsidiaries, and such Foreign Subsidiaries as are required
under Section 8.12(b), are “Subsidiary Guarantors” hereunder. Without limiting the generality of the foregoing,
in the event that Borrower or any of its Subsidiaries shall form or acquire any new Subsidiary that is a Domestic Subsidiary or
a Foreign Subsidiary meeting the requirements of Section 8.12(b), such Obligor and its Subsidiaries concurrently will:

 

(i)        cause
such new Subsidiary to become a “Subsidiary Guarantor” hereunder, and a “Grantor” under the Security Agreement,
pursuant to a Guarantee Assumption Agreement;

 

(ii)        take
such action or cause such Subsidiary to take such action (including delivering such shares of stock together with undated transfer
powers executed in blank) as shall be necessary to create and perfect valid and enforceable first priority (subject to Permitted
Priority Liens) Liens on substantially all of the personal property of such new Subsidiary as collateral security for the obligations
of such new Subsidiary hereunder;

 

(iii)        to
the extent that the parent of such Subsidiary is not a party to the Security Agreement or has not otherwise pledged Equity Interests
in its Subsidiaries in accordance with the terms of the Security Agreement and this Agreement, cause the parent of such Subsidiary
to execute and deliver a pledge agreement in favor of the Lenders in respect of all outstanding issued shares of such Subsidiary;
and

 

(iv)        deliver
such proof of corporate action, incumbency of officers, opinions of counsel and other documents as is consistent with those delivered
by each Obligor pursuant to Section 6.01 or as the Majority Lenders shall have requested.

 

(b)          Foreign
Subsidiaries. In the event that, at any time, Foreign Subsidiaries have, in the aggregate, (i) total revenues constituting
5% or more of the total revenues of Borrower and its Subsidiaries on a consolidated basis, or (ii) total assets constituting 5%
or more of the total assets of Borrower and its Subsidiaries on a consolidated basis, promptly (and, in any event, within 30 days
after such time) Obligors shall cause one or more of such Foreign Subsidiaries to become Subsidiary Guarantors in the manner set
forth in Section 8.12(a), such that, after such Subsidiaries become Subsidiary Guarantors, the non-guarantor Foreign Subsidiaries
in the aggregate shall cease to have revenues or assets, as applicable, that meet the thresholds set forth in clauses (i)
and (ii) above; provided that no Foreign Subsidiary shall be required to become a Subsidiary Guarantor if doing so
would result in material adverse tax consequences for Borrower and its Subsidiaries, taken as a whole.

 

    	[*] – indicates deleted language
 	52	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(c)          Further
Assurances. Such Obligor will, and will cause each of its Subsidiaries to, take such action from time to time as shall reasonably
be requested by the Majority Lenders to effectuate the purposes and objectives of this Agreement.

 

Without limiting the generality of the foregoing, each Obligor
will, and will cause each Person that is required to be a Subsidiary Guarantor to, take such action from time to time (including
executing and delivering such assignments, security agreements, control agreements and other instruments) as shall be reasonably
requested by the Majority Lenders to create, in favor of the Lenders, perfected security interests and Liens in substantially all
of the personal property of such Obligor as collateral security for the Obligations; provided that any such security interest
or Lien shall be subject to the relevant requirements of the Security Documents.

 

8.13       Termination
of Non-Permitted Liens. In the event that Borrower or any of its Subsidiaries shall become aware or be notified by the Lenders
of the existence of any outstanding Lien against any Property of Borrower or any of its Subsidiaries, which Lien is not a Permitted
Lien, Borrower shall use its best efforts to promptly terminate or cause the termination of such Lien.

 

8.14       Intellectual
Property. In the event that the Obligors acquire Obligor Intellectual Property during the term of this Agreement, then the
provisions of this Agreement shall automatically apply thereto and any such Obligor Intellectual Property shall automatically constitute
part of the Collateral under the Security Documents, without further action by any party, in each case from and after the date
of such acquisition (except that any representations or warranties of any Obligor shall apply to any such Obligor Intellectual
Property only from and after the date, if any, subsequent to such acquisition that such representations and warranties are brought
down or made anew as provided herein).

 

8.15       Small
Business Documentation. Borrower shall accurately complete, execute, and deliver to PIOP prior to the first Borrowing Date,
SBA Forms 480, 652, and 1031 (Parts A and B).

 

8.16       Post-Closing.

 

(a)        Borrower
shall use best efforts to cause the Borrower Landlord to execute and deliver to the Lenders, not later than thirty (30) days after
the Closing Date or such later date as Majority Lenders may agree, bailee waivers or other agreements from the lessor of each leased
property, the mortgagee of owned property or bailee or consignee as required under the Security Agreement in form and substance
satisfactory to Majority Lenders.

 

(b)        Borrower
shall deliver to the Lenders, not later than thirty (30) days after the Closing Date or such later date as Majority Lenders may
agree, documentation acceptable to Lenders as to the pledge of Borrower’s equity interests in Navidea Biopharmaceuticals
Limited.

 

    	[*] – indicates deleted language
 	53	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

SECTION
9

NEGATIVE COVENANTS

 

Each Obligor covenants and agrees with the
Lenders that, until the Commitments have expired or been terminated and all Obligations have been paid in full indefeasibly in
cash:

 

9.01       Indebtedness.
Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness,
whether directly or indirectly, except:

 

(a)         the
Obligations;

 

(b)         Indebtedness
existing on the date hereof and set forth in Part II of Schedule 7.13(a) and Permitted Refinancings thereof; provided
that, in each case, such Indebtedness is subordinated to the Obligations on terms satisfactory to the Majority Lenders;

 

(c)         Permitted
Priority Debt; so long as the Company has achieved revenue of at least $8.0 million during the immediately prior consecutive three
month period;

 

(d)         accounts
payable to trade creditors for goods and services and current operating liabilities (not the result of the borrowing of money)
incurred in the ordinary course of Borrower’s or such Subsidiary’s business in accordance with customary terms and
paid within the specified time, unless contested in good faith by appropriate proceedings and reserved for in accordance with GAAP;

 

(e)         Indebtedness
consisting of guarantees resulting from endorsement of negotiable instruments for collection by any Obligor in the ordinary course
of business;

 

(f)          Indebtedness
of any Obligor to any other Obligor;

 

(g)         Guarantees
by any Obligor of Indebtedness of any other Obligor; provided that the aggregate outstanding principal amount of such Indebtedness,
when added to the aggregate principal amount of the outstanding Indebtedness permitted in reliance on Section 9.01(h), does
not exceed $250,000 (or the Equivalent Amount in other currencies) at any time;

 

(h)         normal
course of business equipment financing; provided that (i) if secured, the collateral therefor consists solely of the assets
being financed, the products and proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding principal
amount of such Indebtedness, when added to the aggregate principal amount of the outstanding Indebtedness permitted in reliance
on Section 9.01(g), does not exceed $250,000 (or the Equivalent Amount in other currencies) at any time;

 

(i)          capitalized
lease obligations incurred by an Obligor to finance the acquisition, repair, repair, improvement or construction of fixed or capital
assets of such Person and Permitted Refinancings thereof, provided that (i) the aggregate outstanding principal amount of all such
Indebtedness does not exceed $250,000 at any time and (ii) the principal amount of such Indebtedness doesn’t exceed the lower
of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed with such Indebtedness
(each measured at the time of such acquisition, repair, improvement or construction is made);

 

    	[*] – indicates deleted language
 	54	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(j)           Permitted
Cure Debt not in excess of the Cure Amount;

 

(k)          Indebtedness
with respect of financing of insurance premiums not to exceed $300,000 in any fiscal year;

 

(l)           unsecured
Indebtedness owing by any Obligor to any Person that is not a holder of any Equity Interests in an Obligor on the date such Indebtedness
is incurred, which Indebtedness (i) does not exceed $750,000 in the aggregate at any time outstanding and (ii) is subordinated
to the Obligations pursuant to a subordination agreement in substantially the form attached hereto as Exhibit H or
such other agreement as is satisfactory to the Majority Lenders in their sole discretion; and

 

(m)         Indebtedness
approved in advance in writing by the Majority Lenders.

 

9.02       Liens.
Such Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on any
property or asset now owned by it, or assign or sell any income or revenues (including accounts receivable) or rights in respect
of any thereof, except:

 

(a)          Liens
securing the Obligations;

 

(b)          any
Lien on any property or asset of Borrower or any of its Subsidiaries existing on the date hereof and set forth in Part II of
Schedule 7.13(b); provided that (i) no such Lien shall extend to any other property or asset of Borrower or any of
its Subsidiaries and (ii) any such Lien shall secure only those obligations which it secures on the date hereof and extensions,
renewals and replacements thereof that do not increase the outstanding principal amount thereof;

 

(c)          Liens
described in the definition of “Permitted Priority Debt”;

 

(d)          Liens
securing Indebtedness permitted under Section 9.01(h); provided that such Liens are restricted solely to the collateral
described in Section 9.01(h);

 

(e)          Liens
imposed by law which were incurred in the ordinary course of business, including (but not limited to) carriers’, warehousemen’s
and mechanics’ liens and other similar liens arising in the ordinary course of business and which (x) do not in the aggregate
materially detract from the value of the Property subject thereto or materially impair the use thereof in the operations of the
business of such Person or (y) are being contested in good faith by appropriate proceedings, which proceedings have the effect
of preventing the forfeiture or sale of the Property subject to such liens and for which adequate reserves have been made if required
in accordance with GAAP;

 

(f)           pledges
or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance or other
similar social security legislation;

 

(g)          Liens
securing taxes, assessments and other governmental charges, the payment of which is not yet due or is being contested in good faith
by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate provisions,
if any, as shall be required by GAAP shall have been made;

 

    	[*] – indicates deleted language
 	55	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(h)          servitudes,
easements, rights of way, restrictions and other similar encumbrances on real Property imposed by applicable Laws and encumbrances
consisting of zoning or building restrictions, easements, licenses, restrictions on the use of property or minor imperfections
in title thereto which, in the aggregate, are not material, and which do not in any case materially detract from the value of the
property subject thereto or interfere with the ordinary conduct of the business of any of the Obligors;

 

(i)           with
respect to any real Property, (A) such defects or encroachments as might be revealed by an up-to-date survey of such real Property;
(B) the reservations, limitations, provisos and conditions expressed in the original grant, deed or patent of such property by
the original owner of such real Property pursuant to applicable Laws; and (C) rights of expropriation, access or user or any similar
right conferred or reserved by or in applicable Laws, which, in the aggregate for (A), (B) and (C), are not material, and which
do not in any case materially detract from the value of the property subject thereto or interfere with the ordinary conduct of
the business of any of the Obligors; and

 

(j)           Bankers
liens, rights of setoff and similar Liens incurred on deposits made in the ordinary course of business;

 

provided that no Lien otherwise
permitted under any of the foregoing Sections 9.02(b) through (i) shall apply to any Material Intellectual Property.

 

9.03       Fundamental
Changes and Acquisitions. Such Obligor will not, and will not permit any of its Subsidiaries to, (i) enter into any transaction
of merger, amalgamation or consolidation (ii) liquidate, wind up or dissolve itself (or suffer any liquidation or dissolution),
or (iii) make any Acquisition or otherwise acquire any business or substantially all the property from, or capital stock of, or
be a party to any acquisition of, any Person, except:

 

(a)          Investments
permitted under Section 9.05(e);

 

(b)          the
merger, amalgamation or consolidation of any Subsidiary Guarantor with or into any other Obligor;

 

(c)          the
sale, lease, transfer or other disposition by any Subsidiary Guarantor of any or all of its property (upon voluntary liquidation
or otherwise) to any other Obligor; and

 

(d)          the
sale, transfer or other disposition of the capital stock of any Subsidiary Guarantor to any other Obligor; and

 

(e)          Permitted
Acquisitions in an amount not exceeding $5,000,000 in the aggregate.

 

9.04       Lines
of Business. Such Obligor will not, and will not permit any of its Subsidiaries to, engage to any material extent in any business
other than the business engaged in on the date hereof by Borrower or any Subsidiary or a business reasonably related thereto.

 

9.05       Investments.
Such Obligor will not, and will not permit any of its Subsidiaries to, make, directly or indirectly, or permit to remain outstanding
any Investments except:

 

    	[*] – indicates deleted language
 	56	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(a)        Investments
outstanding on the date hereof and identified in Schedule 9.05;

 

(b)        operating
deposit accounts with banks;

 

(c)        extensions
of credit in the nature of accounts receivable or notes receivable arising from the sales of goods or services in the ordinary
course of business;

 

(d)        Permitted
Cash Equivalent Investments;

 

(e)        (i)
Investments by any Obligor in Borrower’s wholly-owned Subsidiary Guarantors, (ii) so long as it is not a wholly-owned Subsidiary
Guarantor, Investments by Obligors in Macrophage Therapeutics, Inc. in an amount that would cause the aggregate investment of the
Obligors therein to exceed $1,000,000, (iii) Investments by Obligors in R-NAV, LLC in an amount not exceeding the Obligors’
Investments therein on the Closing Date, it being understood that payment of principal and interest thereon of the notes by Borrower
in favor of R-NAV, LLC outstanding on the date hereof shall not be considered an additional Investment, and (iv) Investments by
Obligors in foreign Subsidiaries of Borrower in an aggregate amount not to exceed $50,000 in any fiscal year and $300,000 in the
aggregate;

 

(f)         Hedging
Agreements entered into in the ordinary course of Borrower’s financial planning solely to hedge currency risks (and not for
speculative purposes) and in an aggregate notional amount for all such Hedging Agreements not in excess of $100,000 (or the Equivalent
Amount in other currencies);

 

(g)        Investments
consisting of deposits with vendors, utilities and other like Persons made in the ordinary course of business;

 

(h)        employee
loans, travel advances and guarantees in accordance with Borrower’s usual and customary practices with respect thereto (if
permitted by applicable law) which in the aggregate shall not exceed $250,000 outstanding at any time (or the Equivalent Amount
in other currencies);

 

(i)         Investments
consisting of non-cash loans made by Borrower to officers, directors and employees of Borrower which are used by such Persons to
purchase simultaneously the stock of Borrower;

 

(j)         Investments
received in connection with any Insolvency Proceedings in respect of any customers, suppliers or clients and in settlement of delinquent
obligations of, and other disputes with, customers, suppliers or clients; and

 

(k)        Investments
permitted under Section 9.03.

 

9.06       Restricted
Payments. Such Obligor will not, and will not permit any of its Subsidiaries, Macrophage Therapeutics, Inc. or R-NAV, LLC to,
declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment, except:

 

(a)        Borrower
may declare and pay dividends with respect to its capital stock payable solely in additional shares of its common stock;

 

    	[*] – indicates deleted language
 	57	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(b)        Borrower
may purchase, redeem, retire, or otherwise acquire shares of its capital stock or other Equity Interests with the proceeds received
from a substantially concurrent issue of new shares of its capital stock or other Equity Interests;

 

(c)        for
the payment of dividends by any Subsidiary Guarantor to any other Obligor;

 

(d)        so
long as no Event of Default is continuing or would result therefrom, Borrower may satisfy tax obligations upon vesting of restricted
stock awards, collectively in an aggregate amount not to exceed $250,000 in any fiscal year; and

 

(e)        so
long as no Event of Default is continuing or would result therefrom, Borrower may repurchase Borrower’s stock from current
or former officers, employees or directors (or their permitted transferees or estates) upon their death, disability or termination
of employment.

 

9.07       Payments
of Indebtedness. Such Obligor will not, and will not permit any of its Subsidiaries to, make any payments in respect of any
Indebtedness other than (i) payments of the Obligations, (ii) scheduled payments of other Indebtedness and (iii) repayment of intercompany
Indebtedness permitted in reliance upon Section 9.01(f).

 

9.08       Change
in Fiscal Year. Such Obligor will not, and will not permit any of its Subsidiaries to, change the last day of its fiscal year
from that in effect on the date hereof, except to change the fiscal year of a Subsidiary acquired in connection with an Acquisition
to conform its fiscal year to that of Borrower.

 

9.09       Sales
of Assets, Etc. Unless the prepayment required under Section 3.03(b)(i) simultaneously is made, such Obligor will not,
and will not permit any of its Subsidiaries to, sell, lease, exclusively license (in terms of geography or field of use), transfer,
or otherwise dispose of any of its Property (including accounts receivable and capital stock of Subsidiaries) to any Person in
one transaction or series of transactions (any thereof, an “Asset Sale”), except:

 

(a)        transfers
of cash in the ordinary course of its business for equivalent value;

 

(b)        sales
of inventory in the ordinary course of its business on ordinary business terms;

 

(c)        development
and other collaborative arrangements where such arrangements provide for the licenses or disclosure of Patents, Trademarks, Copyrights
or other Intellectual Property rights in the ordinary course of business and consistent with general market practices where such
license requires periodic payments based on per unit sales of a product over a period of time and provided that such licenses must
be true licenses as opposed to licenses that are sales transactions in substance;

 

(d)        transfers
of Property by any Subsidiary Guarantor to any other Obligor;

 

(e)        dispositions
of any Property that is obsolete or worn out or no longer used or useful in the Business; and

 

(f)        any
transaction permitted under Section 9.03 or 9.05.

 

    	[*] – indicates deleted language
 	58	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

9.10       Transactions
with Affiliates. Such Obligor will not, and will not permit any of its Subsidiaries to, sell, lease, license or otherwise transfer
any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions
with, any of its Affiliates, except:

 

(a)        transactions
between or among Obligors;

 

(b)        any
transaction permitted under Section 9.01, 9.05, 9.06 or 9.09;

 

(c)        customary
compensation and indemnification of, and other employment arrangements with, directors, officers and employees of Borrower or any
Subsidiary in the ordinary course of business’

 

(d)        bona
fide consulting fees on arm’s-length paid to Affiliates for actual services rendered to Borrower in the ordinary course of
business in an aggregate amount not to exceed $125,000 in any fiscal year;

 

(e)        Borrower
may issue Equity Interests to Affiliates in exchange for cash, provided that the terms thereof are no less favorable (including
the amount of cash received by Borrower) to Borrower than those that would be obtained in a comparable arm’s-length transaction
with a Person not an Affiliate of Borrower; and

 

(f)        the
transactions set forth on Schedule 9.10.

 

9.11       Restrictive
Agreements. Such Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into, incur
or permit to exist any Restrictive Agreement other than (a) restrictions and conditions imposed by law or by this Agreement and
(b) Restrictive Agreements listed on Schedule 7.15.

 

9.12       Amendments
to Material Agreements. Such Obligor will not, and will not permit any of its Subsidiaries to, enter into any material amendment
to or modification of any Material Agreement or terminate any Material Agreement (unless replaced with another agreement that,
viewed as a whole, is on better terms for Borrower or such Subsidiary) without in each case the prior written consent of the Lender
(which consent shall not be unreasonably withheld or delayed). Without limiting the generality of the foregoing, such Obligor will
not enter into or materially amend any distribution or similar agreements with regard to the Product with Cardinal Health, and
will not enter into any material distribution or similar agreements with any other third parties or materially amend such agreements
without the written consent of the Majority Lenders (which consent shall not be unreasonably withheld or delayed).

 

9.13       Preservation
of Borrower Lease; Operating Leases.

 

(a)        Notwithstanding
any provision of this Agreement to the contrary, Borrower shall not:

 

    	[*] – indicates deleted language
 	59	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(i)          Surrender,
terminate, forfeit, or suffer or permit the surrender, termination or forfeiture of, or change, modify or amend, the Borrower Lease,
nor transfer, sell, assign, convey, dispose of, mortgage, pledge, hypothecate, assign or encumber any of its interest in, the Borrower
Lease;

 

(ii)         Consent
to, cause, agree to, or permit to occur any subordination, or consent to the subordination of, the Borrower Lease to any mortgage,
deed of trust or other lien encumbering (or that may in the future encumber) the interest of Borrower Landlord in the Borrower
Facility;

 

(iii)        Waive,
excuse, condone or in any way release or discharge Borrower Landlord of or from its material obligations, covenants and/or conditions
under the Borrower Lease; or

 

(iv)        Elect
to treat the Borrower Lease as terminated or rejected under subsection 365 of the Bankruptcy Code or other applicable Law. Any
such election made without Majority Lenders’ prior written consent shall be void. If, pursuant to subsection 365 of the Bankruptcy
Code or other applicable law, Borrower seeks to offset, against the rent reserved in the Borrower Lease, the amount of any damages
caused by the nonperformance by Borrower Landlord of any of its obligations thereunder after the rejection by Borrower Landlord
of the Borrower Lease under the Bankruptcy Code or other applicable Law, then Borrower shall not effect any offset of any amounts
objected to by Lenders.

 

(b)          Borrower
will not, and will not permit any of its Subsidiaries to, make any expenditures in respect of operating leases, except for:

 

(i)          real
estate operating leases;

 

(ii)         operating
leases between Borrower and any of its wholly-owned Subsidiaries or between any of Borrower’s wholly-owned Subsidiaries;
and

 

(iii)        operating
leases that would not cause Borrower and its Subsidiaries, on a consolidated basis, to make payments exceeding $250,000 (or the
Equivalent Amount in other currencies) in any fiscal year.

 

9.14       Sales
and Leasebacks. Except as disclosed on Schedule 9.14, such Obligor will not, and will not permit any of its Subsidiaries
to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation,
of any property (whether real, personal, or mixed), whether now owned or hereafter acquired, (i) which Borrower or such Subsidiary
has sold or transferred or is to sell or transfer to any other Person and (ii) which Borrower or such Subsidiary intends to use
for substantially the same purposes as property which has been or is to be sold or transferred.

 

9.15       Hazardous
Material. Such Obligor will not, and will not permit any of its Subsidiaries to, use, generate, manufacture, install, treat,
release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure
to comply could not reasonably be expected to result in a Material Adverse Change.

 

    	[*] – indicates deleted language
 	60	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

9.16       Accounting
Changes. Such Obligor will not, and will not permit any of its Subsidiaries to, make any significant change in accounting treatment
or reporting practices, except as required or permitted by GAAP.

 

9.17       Compliance
with ERISA. No ERISA Affiliate shall cause or suffer to exist (a) any event that could result in the imposition of a Lien with
respect to any Title IV Plan or Multiemployer Plan or (b) any other ERISA Event that would, in the aggregate, have a Material Adverse
Effect. No Obligor or Subsidiary thereof shall cause or suffer to exist any event that could result in the imposition of a Lien
with respect to any Benefit Plan.

 

SECTION
10

FINANCIAL COVENANTS

 

10.01     Minimum
Liquidity. Borrower shall maintain at all times Liquidity exclusive of any amounts in the Cure Account in an amount which shall
exceed the greater of (i) $5,000,000 and (ii) to the extent Borrower has incurred Permitted Priority Debt, the minimum
cash balance, if any, required of Borrower by Borrower’s Permitted Priority Debt creditors.

 

10.02     Minimum
EBITDA or Revenue. Borrower and its Subsidiaries shall have an annual EBITDA in each calendar year of no less than $5,000,000
(the “Minimum Required EBITDA”) or annual Revenue from sales of the Product (for each respective calendar
year, the “Minimum Required Revenue”):

 

(a)        during
the twelve month period beginning on January 1, 2015, of at least $11,000,000;

 

(b)        during
the twelve month period beginning on January 1, 2016, of at least $[*];

 

(c)        during
the twelve month period beginning on January 1, 2017, of at least $[*];

 

(d)        during
the twelve month period beginning on January 1, 2018, of at least $[*];

 

(e)        during
the twelve month period beginning on January 1, 2019, of at least $[*];

 

(f)         during
the twelve month period beginning on January 1, 2020, of at least $[*]; and

 

(g)        during
the twelve month period beginning on January 1, 2021 and each calendar year thereafter, of at least $45,000,000.

 

10.03    Cure
Right.

 

(a)        Notwithstanding
anything to the contrary contained in Section 11, in the event that the Borrower fails to comply with the covenants contained
in Section 10.02(a) through (g) (such covenants for such applicable periods being the “Specified Financial
Covenants”), Borrower shall have the right, within the period beginning ninety (90) days prior to and ending sixty
(60) days after, the end of the respective calendar year:

 

    	[*] – indicates deleted language
 	61	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(i)         to
issue additional shares of Equity Interests in exchange for cash (the “Equity Cure Right”),
or

 

(ii)        to
borrow Permitted Cure Debt (the “Subordinated Debt Cure Right” and, collectively with the Equity Cure
Right, the “Cure Right”),

 

in an amount equal to (x) two and one half (2.5) multiplied
by (y), at the election of Borrower as to the applicable calendar year, such election to be made within sixty (60) days after the
end of the applicable calendar year by written notice to the Lenders, (1) the Minimum Required Revenue less Borrower’s actual
Revenue for such period or (2) the Minimum Required EBITDA less Borrower’s actual EBITDA for such period (in each case, as
applicable to such calendar year) (the “Cure Amount”). The cash therefrom immediately shall be contributed
as equity or subordinated debt (only as permitted pursuant to Section 9.01), as applicable, to Borrower, and within sixty
(60) days of the end of the respective calendar year, pursuant to the exercise of such Cure Right, such cash in the amount of the
Cure Amount shall be deposited in a segregated, blocked account (the “Cure Account”) and, once so deposited,
shall be deemed to constitute Revenue or EBITDA of Borrower per Borrower’s election for such calendar year for purposes of
the Specified Financial Covenants and the Specified Financial Covenants shall be recalculated for all purposes under the Loan Documents.
If, after giving effect to the foregoing recalculation, Borrower shall then be in compliance with the requirements of the Specified
Financial Covenants, Borrower shall be deemed to have satisfied the requirements of the Specified Financial Covenants as of the
relevant date of determination with the same effect as though there had been no failure to comply therewith at such date, and the
applicable breach of the Specified Financial Covenants that had occurred, the related Default and Event of Default, shall be deemed
cured without any further action of Borrower or Lenders for all purposes under the Loan Documents. The Cure Account shall contain
only cash and Permitted Cash Equivalent Investments and be subject to a control agreement in favor of the Control Agent. Earnings
on investments in the Cure Account will remain in the Cure Account until released on approval as pursuant to Sections 10.03(b)
and (c) below.

 

(b)          The
amounts in the Cure Account will be released to the Borrower only if the Specified Financial Covenants for the subsequent calendar
year are satisfied without giving effect to this Section 10.03. If the Specified Financial Covenants for the subsequent
calendar year are not satisfied, an additional Cure Amount (as calculated based on the Specified Financial Covenants for such year)
shall be placed in the Cure Account by the Company.

 

(c)          If
the amounts in the Cure Account have not been released to the Company by the Maturity Date, or an Event of Default (other than
the failure to comply with Section 10.02) shall occur, all amounts in the Cure Account (including any accrued interest, distributions,
dividends or capital gains) shall, at the option of the Majority Lenders, be released from the Cure Account and delivered to the
Lenders to reduce the aggregate outstanding principal amount of the Loans. Notwithstanding anything herein to the contrary, there
shall be no Prepayment Premium or other prepayment penalty charged on any prepayment of the Loans using cash constituting Cure
Amounts or any related accrued interest, distributions, dividends or capital gains.

 

    	[*] – indicates deleted language
 	62	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

SECTION
11

EVENTS OF DEFAULT

 

11.01     Events
of Default. Each of the following events shall constitute an “Event of Default”:

 

(a)          Borrower
shall fail to pay any principal of any Loan when and as the same shall become due and payable, whether at the due date thereof
or at a date fixed for prepayment thereof or otherwise;

 

(b)         any
Obligor shall fail to pay any Obligation (other than an amount referred to in Section 11.01(a)) when and as the same shall
become due and payable, and such failure shall continue unremedied for a period of three (3) Business Days;

 

(c)         any
representation or warranty made or deemed made by or on behalf of Borrower or any of its Subsidiaries in or in connection with
this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial
statement or other document furnished pursuant to or in connection with this Agreement or any other Loan Document or any amendment
or modification hereof or thereof, shall: (i) prove to have been incorrect when made or deemed made to the extent that such representation
or warranty contains any materiality or Material Adverse Effect qualifier; or (ii) prove to have been incorrect in any material
respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality
or Material Adverse Effect qualifier;

 

(d)         any
Obligor shall fail to observe or perform any covenant, condition or agreement contained in Section 8.02, 8.03(a)
(with respect to Borrower’s existence), 8.11, 8.12, 8.14, 8.17(c), 9 or 10;

 

(e)         any
Obligor shall fail to observe or perform any covenant, condition or agreement contained in this Agreement (other than those specified
in Section 11.01(a), (b) or (d)) or any other Loan Document, and such failure shall continue unremedied for
a period of 20 or more days;

 

(f)          Borrower
or any of its Subsidiaries shall fail to make any payment (whether of principal or interest and regardless of amount) in respect
of any Material Indebtedness or Permitted Priority Debt, when and as the same shall become due and payable after giving effect
to any applicable grace or cure period as originally provided by the terms of such Indebtedness;

 

(g)         (i)
any material breach of, or “event of default” or similar event by any Obligor under, any Material Agreement, (ii) any
material breach of, or “event of default” or similar event under, the documentation governing any Material Indebtedness
shall occur, or (iii) any event or condition occurs (A) that results in any Material Indebtedness becoming due prior to its scheduled
maturity or (B) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders
of such Material Indebtedness or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due,
or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that
this Section 11.01(g) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer
of the property or assets securing such Material Indebtedness.

 

    	[*] – indicates deleted language
 	63	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(h)         any
Obligor (other than Macrophage Therapeutics, Inc. prior to the date the capital invested in such entity exceeds $1,000,000 in the
aggregate):

 

(i)          becomes
insolvent, or generally does not or becomes unable to pay its debts or meet its liabilities as the same become due, or admits in
writing its inability to pay its debts generally, or declares any general moratorium on its indebtedness, or proposes a compromise
or arrangement or deed of company arrangement between it and any class of its creditors;

 

(ii)         commits
an act of bankruptcy or makes an assignment of its property for the general benefit of its creditors or makes a proposal (or files
a notice of its intention to do so);

 

(iii)        institutes
any proceeding seeking to adjudicate it an insolvent, or seeking liquidation, dissolution, winding-up, reorganization, compromise,
arrangement, adjustment, protection, moratorium, relief, stay of proceedings of creditors generally (or any class of creditors),
or composition of it or its debts or any other relief, under any federal, provincial or foreign Law now or hereafter in effect
relating to bankruptcy, winding-up, insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors
or at common law or in equity, or files an answer admitting the material allegations of a petition filed against it in any such
proceeding;

 

(iv)        applies
for the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager, sequestrator, conservator,
custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other similar official for it or
any substantial part of its property; or

 

(v)        takes
any action, corporate or otherwise, to approve, effect, consent to or authorize any of the actions described in this Section
11.01(h) or (i), or otherwise acts in furtherance thereof or fails to act in a timely and appropriate manner in defense
thereof;

 

(i)           any
petition is filed, application made or other proceeding instituted against or in respect of Borrower or any Subsidiary:

 

(i)          seeking
to adjudicate it an insolvent;

 

(ii)         seeking
a receiving order against it;

 

(iii)        seeking
liquidation, dissolution, winding-up, reorganization, compromise, arrangement, adjustment, protection, moratorium, relief, stay
of proceedings of creditors generally (or any class of creditors), deed of company arrangement or composition of it or its debts
or any other relief under any federal, provincial or foreign law now or hereafter in effect relating to bankruptcy, winding-up,
insolvency, reorganization, receivership, plans of arrangement or relief or protection of debtors or at common law or in equity;
or

 

    	[*] – indicates deleted language
 	64	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(iv)        seeking
the entry of an order for relief or the appointment of, or the taking of possession by, a receiver, interim receiver, receiver/manager,
sequestrator, conservator, custodian, administrator, trustee, liquidator, voluntary administrator, receiver and manager or other
similar official for it or any substantial part of its property, and such petition, application or proceeding continues undismissed,
or unstayed and in effect, for a period of thirty (30) days after the institution thereof; provided that if an order, decree
or judgment is granted or entered (whether or not entered or subject to appeal) against Borrower or such Subsidiary thereunder
in the interim, such grace period will cease to apply; provided further that if Borrower or such Subsidiary files an answer
admitting the material allegations of a petition filed against it in any such proceeding, such grace period will cease to apply;

 

(j)          any
other event occurs which, under the laws of any applicable jurisdiction, has an effect equivalent to any of the events referred
to in either of Section 11.01(h) or (i);

 

(k)         one
or more judgments for the payment of money in an aggregate amount in excess of $250,000 (or the Equivalent Amount in other currencies)
shall be rendered against any Obligor or any combination thereof and the same shall remain undischarged for a period of 45 consecutive
days during which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach
or levy upon any assets of any Obligor to enforce any such judgment;

 

(l)          (i)
an ERISA Event shall have occurred that, in the opinion of the Lenders, when taken together with all other ERISA Events that have
occurred, could reasonably be expected to result in liability of Borrower and its Subsidiaries in an aggregate amount exceeding
(i) $250,000 in any year or (ii) $750,000 for all periods until repayment of all Obligations;

 

(m)        a
Change of Control shall have occurred;

 

(n)         a
Material Adverse Change shall have occurred;

 

(o)        
(i) any Lien created by any of the Security Documents shall at any time not constitute a valid and perfected Lien on the applicable
Collateral in favor of the Lenders, free and clear of all other Liens (other than Permitted Liens), (ii) except for expiration
in accordance with its terms, any of the Security Documents or any Guarantee of any of the Obligations (including that contained
in Section 13) shall for whatever reason cease to be in full force and effect, or (iii) any of the Security Documents or
any Guarantee of any of the Obligations (including that contained in Section 13), or the enforceability thereof, shall be
repudiated or contested by any Obligor;

 

(p)         there
is a default in any agreement to which any Obligor is a party with a third party or parties resulting in a right by such third
party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of $100,000;

 

(q)         a
Platinum Lending Failure occurs at any time as to which Borrower had negative EBITDA for the fiscal quarter most recently ended;

 

(r)         any
injunction, whether temporary or permanent, shall be rendered against any Obligor that prevents the Obligors from selling or manufacturing
the Product or its commercially available successors, or any of their other material and commercially available products in the
United States for more than 60 consecutive calendar days.

 

    	[*] – indicates deleted language
 	65	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

11.02     Remedies.
Upon the occurrence of any Event of Default, then, and in every such event (other than an Event of Default described in Section
11.01(h), (i) or (j)), and at any time thereafter during the continuance of such event, Majority Lenders may,
by notice to Borrower, take either or both of the following actions, at the same or different times: (i) terminate the Commitments,
and thereupon the Commitments shall terminate immediately, and (ii) declare the Loans then outstanding to be due and payable in
whole (or in part, in which case any principal not so declared to be due and payable may thereafter be declared to be due and payable),
and thereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and all fees
and other Obligations, shall become due and payable immediately (in the case of the Loans, at the Redemption Price therefor), without
presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor; and in case of an Event
of Default described in Section 11.01(h), (i) or (j), the Commitments shall automatically terminate and the
principal of the Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, shall automatically
become due and payable immediately (in the case of the Loans, at the Redemption Price therefor), without presentment, demand, protest
or other notice of any kind, all of which are hereby waived by each Obligor.

 

SECTION
12

MISCELLANEOUS

 

12.01     No
Waiver. No failure on the part of the Lenders to exercise and no delay in exercising, and no course of dealing with respect
to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single or partial exercise
of any right, power or privilege under any Loan Document preclude any other or further exercise thereof or the exercise of any
other right, power or privilege. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

 

12.02     Notices.
All notices, requests, instructions, directions and other communications provided for herein (including any modifications of, or
waivers, requests or consents under, this Agreement) shall be given or made in writing (including by telecopy) delivered, if to
Borrower, another Obligor or the Lenders, to its address specified on the signature pages hereto or its Guarantee Assumption Agreement,
as the case may be, or at such other address as shall be designated by such party in a notice to the other parties. Except as otherwise
provided in this Agreement, all such communications shall be deemed to have been duly given upon receipt of a legible copy thereof,
in each case given or addressed as aforesaid. All such communications provided for herein by telecopy shall be confirmed in writing
promptly after the delivery of such communication (it being understood that non-receipt of written confirmation of such communication
shall not invalidate such communication). Notwithstanding anything to the contrary in this Agreement, all notices, documents, certificates
and other deliverables to the Lenders by any Obligor may be made solely to the Control Agent and the Control Agent shall promptly
deliver such notices, documents, certificates and other deliverables to the other Lenders hereunder.

 

    	[*] – indicates deleted language
 	66	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

12.03     Expenses,
Indemnification, Etc.

 

(a)        Expenses.
Borrower agrees to pay or reimburse (i) the Lenders for all of their reasonable out of pocket costs and expenses (including the
reasonable fees and expenses of Cooley LLP, special counsel to the Lenders, and any sales, goods and services or other similar
taxes applicable thereto, and printing, reproduction, document delivery, communication and travel costs) in connection with (x)
the negotiation, preparation, execution and delivery of this Agreement and the other Loan Documents and the making of the Loans
(exclusive of post-closing costs), (y) post-closing costs and (z) the negotiation or preparation of any modification, supplement
or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not consummated) and (ii) the Lenders
for all of their reasonable out of pocket costs and expenses (including the reasonable fees and expenses of legal counsel) in connection
with any enforcement or collection proceedings resulting from the occurrence of an Event of Default; provided, however, that
Borrower shall not be required to pay or reimburse any amounts pursuant to Section 12.03(a)(i)(x) in excess of the Expense
Cap; provided further that, so long as the first Borrowing is made, then such fees shall be credited from the fees paid
by the Borrower pursuant to the Fee Letter.

 

(b)        Indemnification.
Borrower hereby indemnifies the Lenders, their Affiliates, and their respective directors, officers, employees, attorneys, agents,
advisors and controlling parties (each, an “Indemnified Party”) from and against, and agrees to hold
them harmless against, any and all Claims and Losses of any kind (including reasonable fees and disbursements of counsel), joint
or several, that may be incurred by or asserted or awarded against any Indemnified Party, in each case arising out of or in connection
with or relating to any investigation, litigation or proceeding or the preparation of any defense with respect thereto arising
out of or in connection with or relating to this Agreement or any of the other Loan Documents or the transactions contemplated
hereby or thereby or any use made or proposed to be made with the proceeds of the Loans, whether or not such investigation, litigation
or proceeding is brought by Borrower, any of its shareholders or creditors, an Indemnified Party or any other Person, or an Indemnified
Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in Section 6 are satisfied
or the other transactions contemplated by this Agreement are consummated, except to the extent such Claim or Loss is found in a
final, non-appealable judgment by a court of competent jurisdiction to have resulted from such Indemnified Party’s gross
negligence or willful misconduct. No Obligor shall assert any claim against any Indemnified Party, on any theory of liability,
for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other
Loan Documents or any of the transactions contemplated hereby or thereby or the actual or proposed use of the proceeds of the Loans.
Borrower, its Subsidiaries and Affiliates and their respective directors, officers, employees, attorneys, agents, advisors and
controlling parties are each sometimes referred to in this Agreement as a “Borrower Party.” No Lender
shall assert any claim against any Borrower Party, on any theory of liability, for consequential, indirect, special or punitive
damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the transactions contemplated
hereby or thereby or the actual or proposed use of the proceeds of the Loans.

 

12.04     Amendments,
Etc. Except as otherwise expressly provided in this Agreement, any provision of this Agreement may be modified or supplemented
only by an instrument in writing signed by Borrower and the Lenders. Any consent, approval, (including without limitation any approval
of or authorization for any amendment to any of the Loan Documents), instruction or other expression of the Lenders under any of
the Loan Documents may be obtained by an instrument in writing signed in one or more counterparts by Majority Lenders; provided
however, that the consent of all of the Lenders shall be required to:

 

    	[*] – indicates deleted language
 	67	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(i)          amend,
modify, discharge, terminate or waive any of the terms of this Agreement if such amendment, modification, discharge, termination
or waiver would increase the amount of the Loans, reduce the fees payable hereunder, reduce interest rates or other amounts payable
with respect to the Loans, extend any date fixed for payment of principal, interest or other amounts payable relating to the Loans
or extend the repayment dates of the Loans;

 

(ii)         amend
the provisions of Section 6;

 

(iii)        amend,
modify, discharge, terminate or waive any Security Document if the effect is to release a material part of the Collateral subject
thereto otherwise than pursuant to the terms hereof or thereof; or

 

(iv)        amend
this Section 12.04.

 

Notwithstanding anything to the contrary herein, a Defaulting
Lender shall not have any right to approve or disapprove any amendment, waiver or consent hereunder (and any amendment, waiver
or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the
applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of any Defaulting Lender may not be increased
or extended without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders
or each affected Lender that by its terms affects any Defaulting Lender more adversely than other affected Lenders shall require
the consent of such Defaulting Lender.

 

12.05     Successors
and Assigns.

 

(a)        General.
The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors
and assigns permitted hereby, except that Borrower may not assign or otherwise transfer any of its rights or obligations hereunder
without the prior written consent of the Lenders. Any of the Lenders may assign or otherwise transfer any of their rights or obligations
hereunder to an assignee in accordance with the provisions of Section 12.05(b), (ii) by way of participation in accordance
with the provisions of Section 12.05(e) or (iii) by way of pledge or assignment of a security interest subject to the restrictions
of Section 12.05(f). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other
than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in Section
12.05(d) and, to the extent expressly contemplated hereby, the Indemnified Parties) any legal or equitable right, remedy or
claim under or by reason of this Agreement.

 

    	[*] – indicates deleted language
 	68	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(b)        Assignments
by Lenders. Any of the Lenders may at any time assign to one or more Eligible Transferees (or, if an Event of Default has occurred
and is continuing, to any Person) all or a portion of their rights and obligations under this Agreement (including all or a portion
of the Commitment and the Loans at the time owing to it); provided, however, that no such assignment shall be made to Borrower,
an Affiliate of Borrower, or any employees or directors of Borrower at any time. Subject to the recording thereof by the Lenders
pursuant to Section 12.05(c), from and after the effective date specified in each Assignment and Assumption, the assignee
thereunder shall be a party to this Agreement and, to the extent of the interest assigned by such Assignment and Assumption, have
the rights and obligations of the Lenders under this Agreement, and correspondingly the assigning Lender shall, to the extent of
the interest assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case
of an Assignment and Assumption covering all of a Lender’s rights and obligations under this Agreement, such Lender shall
cease to be a party hereto) but shall continue to be entitled to the benefits of Section 5 and Section 12.03. Any
assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this Section 12.05(b)
shall be treated for purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance
with Section 12.05(e).

 

(c)        Amendments
to Loan Documents. Each of the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such
additional Security Documents and other instruments and agreements, in each case in form and substance reasonably acceptable to
the Lenders and the Obligors, as shall reasonably be necessary to implement and give effect to any assignment made under this Section
12.05.

 

(d)        Register.
Each Lender, acting solely for this purpose as an agent of Borrower, shall maintain at one of its offices (which shall be the office
of the Control Agent) a register for the recordation of the name and address of any assignee of the Lenders and the Commitment
and outstanding principal amount of the Loans owing thereto (the “Register”). The entries in the Register
shall be conclusive, absent manifest error, and Borrower shall treat each Person whose name is recorded in the Register pursuant
to the terms hereof as the “Lender” hereunder for all purposes of this Agreement, notwithstanding notice to the contrary.
The Register shall be available for inspection by Borrower, at any reasonable time and from time to time upon reasonable prior
notice.

 

(e)        Participations.
Any of the Lenders may at any time, without the consent of, or notice to, Borrower, sell participations to any Person (other than
a natural person or Borrower or any of Borrower’s Affiliates or Subsidiaries) (each, a “Participant”)
in all or a portion of such Lender’s rights and/or obligations under this Agreement (including all or a portion of the Commitment
and/or the Loans owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged,
(ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii)
Borrower shall continue to deal solely and directly with the Lenders in connection therewith.

 

Any agreement or instrument pursuant to which a Lender sells
such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment,
modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such
Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i) increase
or extend the term of such Lender’s Commitment, (ii) extend the date fixed for the payment of principal of or interest on
the Loans or any portion of any fee hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal,
or (iv) reduce the rate at which interest is payable thereon to a level below the rate at which the Participant is entitled to
receive such interest. Subject to Section 12.05(e), Borrower agrees that each Participant shall be entitled to the benefits
of Section 5 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section
12.05(b). To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 4.04(a)
as though it were the Lender.

 

    	[*] – indicates deleted language
 	69	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(f)        Limitations
on Rights of Participants. A Participant shall not be entitled to receive any greater payment under Section 5.01 or
5.03 than a Lender would have been entitled to receive with respect to the participation sold to such Participant, unless
the sale of the participation to such Participant is made with Borrower’s prior written consent.

 

(g)        Certain
Pledges. The Lenders may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement
and any other Loan Document to secure obligations of the Lenders, including any pledge or assignment to secure obligations to a
Federal Reserve Bank; provided that no such pledge or assignment shall release the Lenders from any of their obligations
hereunder or substitute any such pledgee or assignee for the Lenders as a party hereto.

 

12.06     Survival.
The obligations of Borrower under Sections 5.01, 5.02, 5.03, 12.03, 12.05, 12.09, 12.10,
12.11, 12.12, 12.13, 12.14 and Section 13 (solely to the extent guaranteeing any of the obligations
under the foregoing Sections) shall survive the repayment of the Loans and the termination of the Commitment and, in the case of
the Lenders’ assignment of any interest in the Commitment or the Loans hereunder, shall survive, in the case of any event
or circumstance that occurred prior to the effective date of such assignment, the making of such assignment, notwithstanding that
the Lenders may cease to be “Lenders” hereunder. In addition, each representation and warranty made, or deemed to be
made by a notice of the Loans, herein or pursuant hereto shall survive the making of such representation and warranty.

 

12.07     Captions.
The table of contents and captions and section headings appearing herein are included solely for convenience of reference and are
not intended to affect the interpretation of any provision of this Agreement.

 

12.08     Counterparts.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument
and any of the parties hereto may execute this Agreement by signing any such counterpart.

 

12.09     Governing
Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by, and construed in accordance
with, the law of the State of New York, without regard to principles of conflicts of laws that would result in the application
of the laws of any other jurisdiction; provided that Section 5-1401 of the New York General Obligations Law shall apply.

 

12.10     Jurisdiction,
Service of Process and Venue. 

 

(a)        Submission
to Jurisdiction. Each Obligor agrees that any suit, action or proceeding with respect to this Agreement or any other Loan Document
to which it is a party or any judgment entered by any court in respect thereof may be brought initially in the federal or state
courts in Houston, Texas or in the courts of its own corporate domicile and irrevocably submits to the non-exclusive jurisdiction
of each such court for the purpose of any such suit, action, proceeding or judgment. This Section 12.10(a) is for the benefit
of the Lenders only and, as a result, no Lender shall be prevented from taking proceedings in any other courts with jurisdiction.
To the extent allowed by applicable Laws, the Lenders may take concurrent proceedings in any number of jurisdictions.

 

    	[*] – indicates deleted language
 	70	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(b)        Alternative
Process. Nothing herein shall in any way be deemed to limit the ability of the Lenders to serve any such process or summonses
in any other manner permitted by applicable law.

 

(c)        Waiver
of Venue, Etc. Each Obligor irrevocably waives to the fullest extent permitted by law any objection that it may now or hereafter
have to the laying of the venue of any suit, action or proceeding arising out of or relating to this Agreement or any other Loan
Document and hereby further irrevocably waives to the fullest extent permitted by law any claim that any such suit, action or proceeding
brought in any such court has been brought in an inconvenient forum. A final judgment (in respect of which time for all appeals
has elapsed) in any such suit, action or proceeding shall be conclusive and may be enforced in any court to the jurisdiction of
which such Obligor is or may be subject, by suit upon judgment.

 

12.11     Waiver
of Jury Trial. EACH OBLIGOR AND EACH LENDER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY
AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE OTHER LOAN DOCUMENTS
OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.

 

12.12     Waiver
of Immunity. To the extent that any Obligor may be or become entitled to claim for itself or its Property or revenues any immunity
on the ground of sovereignty or the like from suit, court jurisdiction, attachment prior to judgment, attachment in aid of execution
of a judgment or execution of a judgment, and to the extent that in any such jurisdiction there may be attributed such an immunity
(whether or not claimed), such Obligor hereby irrevocably agrees not to claim and hereby irrevocably waives such immunity with
respect to its obligations under this Agreement and the other Loan Documents.

 

12.13     Entire
Agreement. This Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the
subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to
the subject matter hereof. EACH OBLIGOR ACKNOWLEDGES, REPRESENTS AND WARRANTS THAT IN DECIDING TO ENTER INTO THIS AGREEMENT AND
THE OTHER LOAN DOCUMENTS OR IN TAKING OR NOT TAKING ANY ACTION HEREUNDER OR THEREUNDER, IT HAS NOT RELIED, AND WILL NOT RELY, ON
ANY STATEMENT, REPRESENTATION, WARRANTY, COVENANT, AGREEMENT OR UNDERSTANDING, WHETHER WRITTEN OR ORAL, OF OR WITH THE LENDERS
OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS.

 

12.14     Severability.
If any provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by applicable law the
parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision hereof.

 

    	[*] – indicates deleted language
 	71	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

12.15     No
Fiduciary Relationship. Borrower acknowledges that the Lenders have no fiduciary relationship with, or fiduciary duty to, Borrower
arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between the Lenders and Borrower
is solely that of creditor and debtor. This Agreement and the other Loan Documents do not create a joint venture among the parties.

 

12.16     Confidentiality.
The Lenders agree to maintain the confidentiality of the Confidential Information (as defined in the Non-Disclosure Agreement (defined
below)) in accordance with the terms of that certain non-disclosure agreement dated March 8, 2013 between Borrower and Capital
Royalty L.P (the “Non-Disclosure Agreement”). Any new Lender that becomes party to this Agreement hereby
agrees to be bound by the terms of the Non-Disclosure Agreement. The parties to this Agreement shall prepare a mutually agreeable
press release announcing the completion of this transaction on the first Borrowing Date.

 

12.17     USA
PATRIOT Act. The Lenders hereby notify Borrower that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub.
L. 107-56 (signed into law October 26, 2001)) (the “Act”), they are required to obtain, verify and record
information that identifies Borrower, which information includes the name and address of Borrower and other information that will
allow such Lender to identify Borrower in accordance with the Act.

 

12.18     Maximum
Rate of Interest. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be
paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (in each case,
the “Maximum Rate”). If the Lenders shall receive interest in an amount that exceeds the Maximum Rate,
the excess interest shall be applied to the principal of the Loans, and not to the payment of interest, or, if the excessive interest
exceeds such unpaid principal, the amount exceeding the unpaid balance shall be refunded to the applicable Obligor. In determining
whether the interest contracted for, charged, or received by the Lenders exceeds the Maximum Rate, the Lenders may, to the extent
permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest,
(b) exclude voluntary prepayments and the effects thereof, (c) amortize, prorate, allocate, and spread in equal or unequal parts
the total amount of interest throughout the contemplated term of the Indebtedness and other obligations of any Obligor hereunder,
or (d) allocate interest between portions of such Indebtedness and other obligations under the Loan Documents to the end that no
such portion shall bear interest at a rate greater than that permitted by applicable Law.

 

12.19     Certain
Waivers.

 

(a)          Real
Property Security Waivers.

 

(i)        Each
Obligor acknowledges that all or any portion of the Obligations may now or hereafter be secured by a Lien or Liens upon real property
evidenced by certain documents including, without limitation, deeds of trust and assignments of rents. Lenders may, pursuant to
the terms of said real property security documents and applicable law, foreclose under all or any portion of one or more of said
Liens by means of judicial or nonjudicial sale or sales. Each Obligor agrees that Lenders may exercise whatever rights and remedies
they may have with respect to said real property security, all without affecting the liability of any Obligor under the Loan Documents,
except to the extent Lenders realize payment by such action or proceeding. No election to proceed in one form of action or against
any party, or on any obligation shall constitute a waiver of Lenders' rights to proceed in any other form of action or against
any Obligor or any other Person, or diminish the liability of any Obligor, or affect the right of Lenders to proceed against any
Obligor for any deficiency, except to the extent Lenders realize payment by such action, notwithstanding the effect of such action
upon any Obligor’s rights of subrogation, reimbursement or indemnity, if any, against Obligor or any other Person.

 

    	[*] – indicates deleted language
 	72	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

(ii)         To
the extent permitted under applicable law, each Obligor hereby waives any rights and defenses that are or may become available
to such Obligor by reason of Sections 2787 to 2855, inclusive, of the California Civil Code.

 

(iii)        To
the extent permitted under applicable law, each Obligor hereby waives all rights and defenses that such Obligor may have because
the Obligations are or may be secured by real property. This means, among other things:

 

(A)         Lenders
may collect from any Obligor without first foreclosing on any real or personal property collateral pledged by any other Obligor;

 

(B)         If
Lenders foreclose on any real property collateral pledged by any Obligor:

 

(1)        The
amount of the Loans may be reduced only by the price for which that collateral is sold at the foreclosure sale, even if the collateral
is worth more than the sale price; and

 

(2)        Lenders
may collect from each Obligor even if Lenders, by foreclosing on the real property collateral, have destroyed any right that such
Obligor may have to collect from any other Obligor.

 

(3)        To
the extent permitted under applicable law, this is an unconditional and irrevocable waiver of any rights and defenses each Obligor
may have because the Obligations are or may be secured by real property. These rights and defenses include, but are not limited
to, any rights or defenses based upon Section 580a, 580b, 580d or 726 of the California Code of Civil Procedure.

 

(iv)        To
the extent permitted under applicable law, each Obligor waives all rights and defenses arising out of an election of remedies by
Lenders, even though that election of remedies, such as a nonjudicial foreclosure with respect to security for a guaranteed obligation,
has destroyed such Obligor’s rights of subrogation and reimbursement against the principal by the operation of Section 580d
of the California Code of Civil Procedure or otherwise.

 

(b)         Waiver
of Marshaling. Without limiting the foregoing in any way, each Obligor hereby irrevocably
waives and releases, to the extent permitted by Law, any and all rights it may have at any time (whether arising directly or indirectly,
by operation of law, contract or otherwise) to require the marshaling of any assets of any Obligor, which right of marshaling might
otherwise arise from any payments made or obligations performed.

 

    	[*] – indicates deleted language
 	73	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

SECTION
13

GUARANTEE

 

13.01     The
Guarantee. The Subsidiary Guarantors hereby jointly and severally guarantee to the Lenders and their successors and assigns
the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of the principal of and interest
on the Loans and all fees and other amounts from time to time owing to the Lenders by Borrower under this Agreement or under any
other Loan Document and by any other Obligor under any of the Loan Documents, in each case strictly in accordance with the terms
thereof (such obligations being herein collectively called the “Guaranteed Obligations”). The Subsidiary
Guarantors hereby further jointly and severally agree that if Borrower shall fail to pay in full when due (whether at stated maturity,
by acceleration or otherwise) any of the Guaranteed Obligations, the Subsidiary Guarantors will promptly pay the same, without
any demand or notice whatsoever, and that in the case of any extension of time of payment or renewal of any of the Guaranteed Obligations,
the same will be promptly paid in full when due (whether at extended maturity, by acceleration or otherwise) in accordance with
the terms of such extension or renewal.

 

13.02     Obligations
Unconditional. The obligations of the Subsidiary Guarantors under Section 13.01 are absolute and unconditional, joint
and several, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of Borrower under
this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee
of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by applicable law, irrespective of any
other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or guarantor,
it being the intent of this Section 13.02 that the obligations of the Subsidiary Guarantors hereunder shall be absolute
and unconditional, joint and several, under any and all circumstances. Without limiting the generality of the foregoing, it is
agreed that the occurrence of any one or more of the following shall not alter or impair the liability of the Subsidiary Guarantors
hereunder, which shall remain absolute and unconditional as described above:

 

(a)        at
any time or from time to time, without notice to the Subsidiary Guarantors, the time for any performance of or compliance with
any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived;

 

(b)        any
of the acts mentioned in any of the provisions of this Agreement or any other agreement or instrument referred to herein shall
be done or omitted;

 

(c)        the
maturity of any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed Obligations shall be modified, supplemented
or amended in any respect, or any right under this Agreement or any other agreement or instrument referred to herein shall be waived
or any other guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or
in part or otherwise dealt with; or

 

(d)        any
lien or security interest granted to, or in favor of, the Lenders as security for any of the Guaranteed Obligations shall fail
to be perfected.

 

    	[*] – indicates deleted language
 	74	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

 

The Subsidiary Guarantors hereby expressly waive
diligence, presentment, demand of payment, protest and all notices whatsoever, and any requirement that the Lenders exhaust any
right, power or remedy or proceed against Borrower under this Agreement or any other agreement or instrument referred to herein,
or against any other Person under any other guarantee of, or security for, any of the Guaranteed Obligations.

 

13.03Reinstatement. The obligations
of the Subsidiary Guarantors under this Section 13 shall be automatically reinstated if and to the extent that for any reason
any payment by or on behalf of Borrower in respect of the Guaranteed Obligations is rescinded or must be otherwise restored by
any holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise,
and the Subsidiary Guarantors jointly and severally agree that they will indemnify the Lenders on demand for all reasonable costs
and expenses (including fees of counsel) incurred by the Lenders in connection with such rescission or restoration, including any
such costs and expenses incurred in defending against any claim alleging that such payment constituted a preference, fraudulent
transfer or similar payment under any bankruptcy, insolvency or similar law.

 

13.04Subrogation. The Subsidiary Guarantors
hereby jointly and severally agree that until the payment and satisfaction in full of all Guaranteed Obligations and the expiration
and termination of the Commitment of the Lenders under this Agreement they shall not exercise any right or remedy arising by reason
of any performance by them of their guarantee in Section 13.01, whether by subrogation or otherwise, against Borrower or
any other guarantor of any of the Guaranteed Obligations or any security for any of the Guaranteed Obligations.

 

13.05Remedies. The Subsidiary Guarantors
jointly and severally agree that, as between the Subsidiary Guarantors and the Lenders, the obligations of Borrower under this
Agreement and under the other Loan Documents may be declared to be forthwith due and payable as provided in Section 11 (and
shall be deemed to have become automatically due and payable in the circumstances provided in Section 11) for purposes of
Section 13.01 notwithstanding any stay, injunction or other prohibition preventing such declaration (or such obligations
from becoming automatically due and payable) as against Borrower and that, in the event of such declaration (or such obligations
being deemed to have become automatically due and payable), such obligations (whether or not due and payable by Borrower) shall
forthwith become due and payable by the Subsidiary Guarantors for purposes of Section 13.01.

 

13.06Instrument for the Payment of Money.
Each Subsidiary Guarantor hereby acknowledges that the guarantee in this Section 13 constitutes an instrument for the payment
of money, and consents and agrees that the Lenders, at their sole option, in the event of a dispute by such Subsidiary Guarantor
in the payment of any moneys due hereunder, shall have the right to proceed by motion for summary judgment in lieu of complaint
pursuant to N.Y. Civ. Prac. L&R § 3213.

 

13.07Continuing Guarantee. The guarantee
in this Section 13 is a continuing guarantee, and shall apply to all Guaranteed Obligations whenever arising.

  

    	[*] – indicates deleted language
 	75	 

    	CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO RULE 24B-2

    

  

13.08Rights of Contribution. The Subsidiary
Guarantors hereby agree, as between themselves, that if any Subsidiary Guarantor shall become an Excess Funding Guarantor (as defined
below) by reason of the payment by such Subsidiary Guarantor of any Guaranteed Obligations, each other Subsidiary Guarantor shall,
on demand of such Excess Funding Guarantor (but subject to the next sentence), pay to such Excess Funding Guarantor an amount equal
to such Subsidiary Guarantor’s Pro rata Share (as defined below and determined, for this purpose, without reference
to the properties, debts and liabilities of such Excess Funding Guarantor) of the Excess Payment (as defined below) in respect
of such Guaranteed Obligations. The payment obligation of a Subsidiary Guarantor to any Excess Funding Guarantor under this Section
13.08 shall be subordinate and subject in right of payment to the prior payment in full of the obligations of such Subsidiary
Guarantor under the other provisions of this Section 13 and such Excess Funding Guarantor shall not exercise any right or
remedy with respect to such excess until payment and satisfaction in full of all of such obligations.

 

For purposes of this Section 13.08, (i)
“Excess Funding Guarantor” means, in respect of any Guaranteed Obligations, a Subsidiary Guarantor that
has paid an amount in excess of its Pro rata Share of such Guaranteed Obligations, (ii) “Excess Payment”
means, in respect of any Guaranteed Obligations, the amount paid by an Excess Funding Guarantor in excess of its Pro rata
Share of such Guaranteed Obligations and (iii) “Pro Rata Share” means, for any Subsidiary Guarantor,
the ratio (expressed as a percentage) of (x) the amount by which the aggregate present fair saleable value of all properties of
such Subsidiary Guarantor (excluding any shares of stock of any other Subsidiary Guarantor) exceeds the amount of all the debts
and liabilities of such Subsidiary Guarantor (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding
the obligations of such Subsidiary Guarantor hereunder and any obligations of any other Subsidiary Guarantor that have been Guaranteed
by such Subsidiary Guarantor) to (y) the amount by which the aggregate fair saleable value of all properties of all of the Subsidiary
Guarantors exceeds the amount of all the debts and liabilities (including contingent, subordinated, unmatured and unliquidated
liabilities, but excluding the obligations of Borrower and the Subsidiary Guarantors hereunder and under the other Loan Documents)
of all of the Subsidiary Guarantors, determined (A) with respect to any Subsidiary Guarantor that is a party hereto on the first
Borrowing Date, as of such Borrowing Date, and (B) with respect to any other Subsidiary Guarantor, as of the date such Subsidiary
Guarantor becomes a Subsidiary Guarantor hereunder.

 

13.09General Limitation on Guarantee Obligations.
In any action or proceeding involving any provincial, territorial or state corporate law, or any state or federal bankruptcy, insolvency,
reorganization or other law affecting the rights of creditors generally, if the obligations of any Subsidiary Guarantor under Section
13.01 would otherwise, taking into account the provisions of Section 13.08, be held or determined to be void, invalid
or unenforceable, or subordinated to the claims of any other creditors, on account of the amount of its liability under Section
13.01, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further
action by such Subsidiary Guarantor, the Lenders or any other Person, be automatically limited and reduced to the highest amount
that is valid and enforceable and not subordinated to the claims of other creditors as determined in such action or proceeding.

 

[Signature Pages Follow]

 

    	[*] – indicates deleted language
 	76	 

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have
caused this Agreement to be duly executed and delivered as of the day and year first above written.

 

	 	BORROWER:
	 	 
	 	NAVIDEA BIOPHARMACEUTICALS, INC.
	 	 
	 	By	/s/ Brent L. Larson
	 	 	Name: Brent Larson
	 	 	Title: Chief Financial Officer
	 	 
	 	Address for Notices:
	 	5600 Blazer Parkway, Suite 200
	 	Dublin, OH 43017-1367
	 	 
	 	Attn:  CFO
	 	Tel.:    614-973-7474
	 	Fax:     614-793-7522
	 	Email: blarson@navidea.com
	 	E-mail in care of:  bjonhson@navidea.com

 

    	 	S-1	 

    	 

    

 

	 	SUBSIDIARY GUARANTOR:
	 	 
	 	MACROPHAGE THERAPEUTICS, INC.
	 	 
	 	By	/s/ Brent L. Larson
	 	 	Name: Brent Larson
	 	 	Title: Secretary
	 	 
	 	Address for Notices:
	 	5600 Blazer Parkway, Suite 200
	 	Dublin, OH 43017-1367
	 	 
	 	Attn:  Secretary
	 	Tel.:    614-973-7474
	 	Fax:    614-793-7522
	 	Email: blarson@navidea.com
	 	E-mail in care of:  bjonhson@navidea.com

 

    	 	S-2	 

    	 

    

 

	LENDERS:	 
	 	 
	CAPITAL ROYALTY PARTNERS II L.P.	 
	By CAPITAL ROYALTY PARTNERS II GP L.P., its General Partner	 
	By CAPITAL ROYALTY PARTNERS II GP LLC, its General Partner	 
	 	 
	 	By	/s/ Charles W. Tate	 
	 	 	Name:  Charles Tate	 
	 	 	Title:    Sole Member	 
	 	 
	Address for Notices:	 
	 	 
	1000 Main Street, Suite 2500	 
	Houston, TX 77002	 
	Attn:  General Counsel	 
	Tel.:   713.209.7350	 
	Fax:   713.209.7351	 
	Email:  adorenbaum@crglp.com	 
	 	 
	CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” L.P.	 
	By CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” GP L.P., its General Partner	 
	By CAPITAL ROYALTY PARTNERS II – PARALLEL FUND “A” GP LLC, its General Partner	 
	 	 
	 	By	/s/ Charles W. Tate	 
	 	 	Name:  Charles Tate	 
	 	 	Title:    Sole Member	 
	 	 
	Address for Notices:	 
	 	 
	1000 Main Street, Suite 2500	 
	Houston, TX 77002	 
	Attn:  General Counsel	 
	Tel.:    713.209.7350	 
	Fax:    713.209.7351	 
	Email: adorenbaum@crglp.com	 

 

    	 	S-3	 

    	 

    

 

	PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.	 
	 	 
	By PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II GP L.P., its General Partner	 
	 	 
	By PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II GP LLC, its General Partner	 
	 	 
	 	By	/s/ Charles W. Tate	 
	 	 	Name: Charles Tate	 
	 	 	Title:   Sole Member	 
	 	 
	Address for Notices:	 
	 	 
	1000 Main Street, Suite 2500	 
	Houston, TX 77002	 
	Attn:   General Counsel	 
	Tel.:    713.209.7350	 
	Fax:    713.209.7351	 
	Email: adorenbaum@crglp.com	 

 

    	 	S-4	 

    	 

    

 

Schedule 1

to Term Loan Agreement

 

Commitments

 

	Lender	 	Commitment	 	 	Proportionate Share	 
	Capital Royalty Partners II L.P.	 	$	21,000,000	 	 	 	35	%
	Capital Royalty Partners II – Parallel Fund “A” L.P.	 	$	21,000,000	 	 	 	35	%
	Parallel Investment Opportunities Partners II L.P.	 	$	18,000,000	 	 	 	30	%
	TOTAL	 	$	60,000,000	 	 	 	100	%

 

    	 

    	 

    

 

Schedule 7.05(b)

to Term Loan Agreement

 

Certain
Intellectual Property

 

Patents

 

	Owner	 	Patent Description/Title	 	Jurisdiction	 	Patent Number (if

issued)/Application 

Number (if applied 

for only)	 	Issuance Date 

(if 

issued)/Filing

Date (if applied

for only)
	Navidea	 	
        “Macromolecular Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	US	 	6,409,990	 	6/25/2002
	Navidea	 	
        “Macromolecular Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	
        Europe [France, Germany, Netherlands, Italy, Spain Sweden,
GB-UK] 
	 	EP1178838B1	 	9/29/04
	Navidea	 	
        “Macromolecular Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	JP	 	4056701	 	3/5/2008
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	US	 	
        8,545,808

         
	 	10/1/2013
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	US	 	
        14/039,648 (Pending)

         
	 	9/27/2013
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	EP	 	EP10736135.4 (Pending)	 	1/28/2010
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	AU	 	2010208624 (Pending)	 	1/28/2010
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	CA	 	
        2,750,230 (Pending)

         
	 	1/28/2010

 

    	 

    	 

    

 

	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	JP	 	
        2011-547973 (Pending)

         
	 	1/28/2010
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	KR	 	2011-7020202 (Pending)	 	1/28/2010
	Navidea/OSU	 	
        "Compositions, Methods and Kits for Diagnosing and Treating
        CD206 Expressing Cell-Related Disorders"

        (Lymphoseek – New Field/Composition)
	 	US	 	14/338,332	 	7/22/2014
	Navidea/OSU	 	
        "Compositions, Methods and Kits for Diagnosing and Treating
        CD206 Expressing Cell-Related Disorders"

        (Lymphoseek – New Field/Composition)
	 	PCT	 	PCT/US14/47708	 	7/22/2014
	Navidea	 	
        "Compositions and Methods for Diagnosing and Treating Macrophage
        Related Disorders Using Carbohydrate Based Macromolecular Carrier"

        (Lymphoseek – New Field/Composition)
	 	US	 	62/031,348	 	7/31/2014
	Navidea/OSU	 	
        "Compounds and Compositions for Targeting Macrophages and Other
        CD206 High Expressing Cells and Methods of Treating and Diagnosing Using Same"

        (Lymphoseek – New Field/Composition)
	 	US	 	62/106,194	 	1/21/2015
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	US	 	7,772,256	 	8/10/2010
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	EP	 	08724190.7 (pending)	 	3/5/2008
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	AR	 	080100905 (pending)	 	3/5/2008

 

    	 	S-ii	 

    	 

    

 

	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	AU	 	2008221668	 	7/28/2011
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	BR	 	PI0808503-0 (pending)	 	3/5/2008
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	JP	 	552641/2009 (pending)	 	3/5/2008
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	CA	 	
        2680157

        (pending)
	 	3/5/2008
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	CN	 	201210093347.6 (pending)	 	3/31/2012
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	CN	 	200880014994.5	 	6/13/2012
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	IN	 	5412/DELNP/200 (pending)	 	3/5/2008
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	KR	 	2009/7018603 (pending)	 	3/5/2008
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	MX	 	299829	 	6/4/2012

 

    	 	S-iii	 

    	 

    

 

	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	RU	 	2472789	 	N/A
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	US	 	8,193,363	 	6/5/2012
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	US	 	8,653,274	 	2/18/2014
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	US	 	
        14/149,563

        (pending)
	 	1/7/2014
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	EP	 	
        09810319.5

        (pending)
	 	8/28/2009
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	EA	 	EA19093	 	1/30/2014
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	AR	 	
        090103323

        (pending)
	 	8/28/2009
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	AU	 	2009286176	 	8/23/2012
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	BR	 	
        PI0917147-9

        (pending)
	 	8/28/2009

 

    	 	S-iv	 

    	 

    

 

	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits”(NAV4694 – Precursor Substance)
	 	JP	 	
        5613669

        (pending)
	 	10/29/2014
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	CA	 	
        2735497

        (pending)
	 	8/28/2009
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	CN	 	102197036	 	12/10/2014
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	CN	 	
        201410653507.7

        (pending)
	 	N/A
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	CN	 	
        201410655681.5

        (pending)
	 	N/A
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	IN	 	
        1428/DELNP/2011

        (pending)
	 	8/28/2009
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	KR	 	
        2011/7004579

        (pending)
	 	8/28/2009
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	MX	 	303024	 	9/4/2012

 

    	 	S-v	 

    	 

    

 

	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	US	 	8,163,928	 	4/24/2012
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	US	 	8,957,215	 	2/17/2015
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	EP	 	
        7709290.6

        (pending)
	 	1/25/2007
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	AR	 	
        70100305

        (pending)
	 	1/24/2007
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	AU	 	
        2007207904

         
	 	1/25/2007
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	BR	 	
        PI0707283

        (pending)
	 	1/25/2007
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	JP	 	5289061	 	1/25/2007
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	CN	 	101410393	 	1/25/2012
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	IN	 	
        6133/DELNP/2008

        (pending)
	 	1/25/2007
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	KR	 	10-1406248	 	6/19/2014
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	RU	 	2008130695	 	1/25/2007
	Navidea	 	
        “Heteroaryl Substituted Benzothiazoles”

        (AZD2184)
	 	MX	 	2008/009396	 	1/25/2007
	Navidea	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	US	 	7,670,591	 	3/2/2010
	Navidea	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	EP	 	
        7748254.5

        (pending)
	 	6/18/2007
	Navidea	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	CN	 	200780030807.8	 	6/18/2007
	Navidea	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	IN	 	
        10035/DELNP/2008

        (pending)
	 	6/18/2007
	Navidea	 	
        “Heteroaryl substituted benzoxazoles”

        (AZD2995)
	 	JP	 	5548842	 	6/18/2007

 

    	 	S-vi	 

    	 

    

Trademarks

 

	Owner	 	Trademark	 	Jurisdiction	 	Registration

Number (if 

registered)/Serial 

Number (if 

applied for only)	 	Registration 

Date (if 

registered)/Filing

Date (if applied

for only)
	Navidea	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	US	 	3,163,525	 	10/24/2006
	Navidea	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	CA	 	1647184	 	10/9/2013
	Navidea	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	EP	 	12,204,202	 	3/5/2014
	Navidea	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	JP	 	5,649,575	 	2/14/2014
	Navidea	 	
        “LYMPHOSEEK"

        (Standard Characters)
	 	CN	 	13988394	 	1/27/2014
	Navidea	 	
        "LYMPHOSEEK"

        (Logo)
	 	US	 	86/055,675	 	9/4/2013
	Navidea	 	
        "NAVIDEA"

        (Standard Characters)
	 	US	 	4,514,173	 	4/15/2014
	Navidea	 	
        "NAVIDEA"

        (Standard Characters)
	 	CA	 	1647179	 	10/9/2013
	Navidea	 	
        "NAVIDEA"

        (Standard Characters)
	 	EP	 	122,041,786	 	3/6/2014
	Navidea	 	
        "NAVIDEA"

        (Standard Characters)
	 	JP	 	5,652,414	 	2/28/2014
	Navidea	 	
        "NAVIDEA"

        (Standard Characters)
	 	CN	 	14109341	 	3/4/2013
	Navidea	 	
        "NAVIDEA BIOPHARMACEUTICALS"

        (Logo)
	 	US	 	4,207,633	 	9/11/2012
	Navidea	 	
        "MANOCEPT"

        (Standard Characters – Class 5)
	 	US	 	86/287,230	 	5/21/2014
	Navidea	 	
        "MANOCEPT"

        (Standard Characters – Class 42)
	 	US	 	86/287231	 	5/21/2014

 

 

    	 	S-vii	 

    	 

    

 

Copyrights

 

	Owner	 	Identifier	 	Registration 

Number	 	Registration

Date
	Navidea	 	“Neoprobe Corporation OneMedPlace Finance Forum San Francisco, CA January 2010.”	 	
        TX0007391587

         
	 	7/1/2011
	Navidea	 	“Neoprobe Corporation Product Pipeline — Oncology Diagnostic Drugs."	 	TX0007400138	 	7/5/2011

 

 

    	 	S-viii	 

    	 

    

 

Schedule 7.05(c) 

to Term Loan Agreement

 

Material
Intellectual Property

 

Patents

 

	Owner	 	Patent Description/Title	 	Jurisdiction	 	Patent Number (if

issued)/

Application

Number (if applied

for only)	 	Issuance

Date (if

issued)/

Filing Date

(if applied

for only)
	Navidea	 	
        “Macromolecular Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	US	 	6,409,990	 	6/25/2002
	Navidea	 	
        “Macromolecular Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	
        Europe

         
	 	EP1178838B1	 	9/29/04
	Navidea	 	
        “Macromolecular Carrier for Drug and Diagnostic Agent Delivery”

        (Lymphoseek - Composition)
	 	JP	 	4056701	 	3/5/2008
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	US	 	
        8,545,808

         
	 	10/1/2013
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	US	 	
        14/039,648 (Pending)

         
	 	9/27/2013
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	EP	 	EP10736135.4 (Pending)	 	1/28/2010
	Navidea	 	
        “Compositions for radiolabeling DTPA dextran”

        (Lymphoseek - Formulation)
	 	JP	 	
        2011-547973 (Pending)

         
	 	1/28/2010
	Navidea/OSU	 	
        "Compositions, Methods and Kits for Diagnosing and Treating
        CD206 Expressing Cell-Related Disorders"

        (Lymphoseek – New Field/Composition)
	 	US	 	14/338,332	 	7/22/2014
	Navidea/OSU	 	
        "Compositions, Methods and Kits for Diagnosing and Treating
        CD206 Expressing Cell-Related Disorders"

        (Lymphoseek – New Field/Composition)
	 	PCT	 	PCT/US14/47708	 	7/22/2014

 

    	 	S-ix	 

    	 

    

 

	Navidea	 	
        "Compositions and Methods for Diagnosing and Treating Macrophage
        Related Disorders Using Carbohydrate Based Macromolecular Carrier"

        (Lymphoseek – New Field/Composition)
	 	US	 	62/031,348	 	7/31/2014
	Navidea/OSU	 	
        "Compounds and Compositions for Targeting Macrophages and Other
        CD206 High Expressing Cells and Methods of Treating and Diagnosing Using Same"

        (Lymphoseek – New Field/Composition)
	 	US	 	62/106,194	 	1/21/2015
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	US	 	7,772,256	 	8/10/2010
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	EP	 	08724190.7 (pending)	 	3/5/2008
	Navidea	 	
        “2-Heteroaryl Substituted Benzothiophenes and Benzofuranes”

        (NAV4694 – Drug Substance)
	 	JP	 	552641/2009 (pending)	 	3/5/2008
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	US	 	8,193,363	 	6/5/2012
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	US	 	8,653,274	 	2/18/2014
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	US	 	
        14/149,563

        (pending)
	 	1/7/2014

 

    	 	S-x	 

    	 

    

 

	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	EP	 	
        09810319.5

        (pending)
	 	8/28/2009
	Navidea	 	
        “Compounds Suitable as Precursors to Compounds that
are Useful for Imaging Amyloid Deposits” (NAV4694 – Precursor Substance)
	 	JP	 	
        5613669

        (pending)
	 	10/29/2014

 

    	 	S-xi	 

    	 

    

 

Trademarks

 

	Owner	 	Trademark	 	Jurisdiction	 	Registration 

Number (if 

registered)/ Serial

Number (if applied

for only)	 	Registration Date 

(if registered)/ 

Filing Date (if 

applied for only)
	Navidea	 	
        “LYMPHOSEEK" (Standard Characters)

         
	 	US	 	3,163,525	 	10/24/2006
	Navidea	 	“LYMPHOSEEK" (Standard Characters)	 	EP	 	12,204,202	 	3/5/2014
	Navidea	 	“LYMPHOSEEK" (Standard Characters)	 	JP	 	5,649,575	 	2/14/2014

 

 

 

    	 	S-xii	 

    	 

    

 

 

 

Schedule 7.06

to Term Loan Agreement

 

Certain
Litigation

 

None.

 

    	 	S-xiii	 

    	 

    

 

Schedule 7.08

to Term Loan Agreement

 

TAXES

 

None, except immaterial amounts for state payroll taxes related
to new employees, which amounts will be paid in the ordinary course of business.

 

    	 

    	 

    

 

Schedule 7.12

to Term Loan Agreement

 

Information
Regarding Subsidiaries

 

	 
Subsidiary
	 	Jurisdiction of
 Organization	 	Direct Equity
 Holder	 	Percentage of
 Subsidiary held
 by Direct
 Equity Holder	 
	Cardiosonix Ltd.	 	Israel	 	Navidea Biopharmaceuticals, Inc.	 	 	100	%
	Navidea Biopharmaceuticals Limited	 	United Kingdom	 	Navidea Biopharmaceuticals, Inc.	 	 	100	%
	Macrophage Therapeutics, Inc.	 	Delaware, USA	 	Navidea Biopharmaceuticals, Inc.	 	 	99	%

 

    	 

    	 

    

 

Schedule 7.13(a)

to Term Loan Agreement

 

Existing
Indebtedness of Borrower and its Subsidiaries

 

Part I

 

		9.01(d):	Accounts payable to trade creditors for goods and services and current operating liabilities (not the result of the borrowing
of money) incurred in the ordinary course of Borrower’s or a Subsidiary’s business in accordance with customary terms,
all of which will be paid within the specified time, unless contested in good faith by appropriate proceedings and reserved for
in accordance with GAAP.

 

		9.01(f)	Indebtedness of any Obligor to any other Obligor.

 

		9.01(h)	Normal course of business equipment financing; provided that (i) if secured, the collateral therefor consists solely of the
assets being financed, the products and proceeds thereof and books and records related thereto, and (ii) the aggregate outstanding
principal amount of such Indebtedness, when added to the aggregate principal amount of the outstanding Indebtedness permitted in
reliance on Section 9.01(g), does not exceed $250,000 (or the Equivalent Amount in other currencies) at any time.

 

		9.01(i)	Capitalized lease obligations incurred by an Obligor to finance the acquisition, repair, improvement or construction of fixed
or capital assets of such Person and Permitted Refinancings thereof, provided that (i) the aggregate outstanding principal amount
of all such Indebtedness does not exceed $250,000 at any time and (ii) the principal amount of such Indebtedness doesn’t
exceed the lower of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed
with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made).

 

		9.01(k)	Indebtedness with respect of financing of insurance premiums not to exceed $300,000 in any fiscal year.

 

		9.01(l)	Unsecured Indebtedness owing by any Obligor to any Person that is not a holder of any Equity Interests in an Obligor on the
date such Indebtedness is incurred, which Indebtedness (i) does not exceed $750,000 in the aggregate at any time outstanding and
(ii) is subordinated to the Obligations pursuant to a subordination agreement in substantially the form attached hereto as Exhibit
H or such other agreement as is satisfactory to the Majority Lenders in their sole discretion.

 

    	 

    	 

    

 

Part II

 

 

	Name of Lender	 	Original Principal Amount/
 Principal Outstanding	 	 	Maturity Date
	 	 	 	 	 	 	 
	Oxford Finance LLC	 	$	28,942,369.24	 	 	April 2015 – March 2019
	 	 	 	 	 	 	 
	Platinum-Montaur Life Sciences, LLC	 	$	3,218,666.82	 	 	Subject to terms of Subordination Agreement with Oxford Finance LLC dated March 4, 2014

 

    	 

    	 

    

 

Schedule 7.13(b)

to Term Loan Agreement

 

Liens
Granted by the Obligors

 

Part I

 

		9.02(d)	Liens securing Indebtedness permitted under Section 9.01(h); provided that such Liens are restricted solely to the collateral
described in Section 9.01(h).

 

		9.02(e)	Liens imposed by law which were incurred in the ordinary course of business, including (but not limited to) carriers’,
warehousemen’s and mechanics’ liens and other similar liens arising in the ordinary course of business and which (x)
do not in the aggregate materially detract from the value of the Property subject thereto or materially impair the use thereof
in the operations of the business of such Person or (y) are being contested in good faith by appropriate proceedings, which proceedings
have the effect of preventing the forfeiture or sale of the Property subject to such liens and for which adequate reserves have
been made if required in accordance with GAAP.

 

		9.02(f)	Pledges or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance
or other similar social security legislation.

 

		9.02(g)	Liens securing taxes, assessments and other governmental charges, the payment of which is not yet due or is being contested
in good faith by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate
provisions, if any, as shall be required by GAAP shall have been made.

 

		9.02(j)	Bankers liens, rights of setoff and similar Liens incurred on deposits made in the ordinary course of business.

 

    	 

    	 

    

Part II

  

	Name
    of Holder of Lien/Encumbrance	 	Description
    of Property Encumbered
	 	 	 
	 Oxford Finance LLC	 	Substantially all assets of Borrower
	 	 	 
	
        U.S. Bank letter of credit in favor of landlord for 5600 Blazer
        Parkway (BRE/COH OH LLC)

        
	 	~ $265,000 of Borrower’s cash balance related to leasehold improvements at new Dublin offices

  

    	 

    	 

    

 

Schedule 7.14

to Term Loan Agreement

 

Material
Agreements of OBLIGORS

  

Supply
and Distribution Agreement, dated November 15, 2007, between Borrower and Cardinal Health 414, LLC (portions of this Exhibit have
been omitted pursuant to a request for confidential treatment and have been filed separately with the Commission) (incorporated
by reference to Exhibit 10.1 to Borrower's Current Report on Form 8-K filed November 21, 2007).

 

Manufacture
and Supply Agreement, dated November 30, 2009, between Borrower and Reliable Biopharmaceutical Corporation (portions of this Exhibit
have been omitted pursuant to a request for confidential treatment and have been filed separately with the Commission) (incorporated
by reference to Exhibit 10.1 to Borrower's June 30, 2010 Form 10-Q).

 

Loan
Agreement, dated July 25, 2012, between Borrower and Platinum-Montaur Life Sciences LLC (incorporated by reference to Exhibit 10.1
to Borrower's Current Report on Form 8-K filed July 31, 2012).

 

Amendment
to Loan Agreement, dated June 25, 2013, between Navidea Biopharmaceuticals, Inc. and Platinum-Montaur Life Sciences LLC (incorporated
by reference to Exhibit 10.4 to Borrower's Current Report on Form 8-K filed June 28, 2013).

 

License
Agreement, dated December 9, 2011, between AstraZeneca AB and Borrower (portions of this Exhibit have been omitted pursuant to
a request for confidential treatment and have been filed separately with the United States Securities and Exchange Commission)
(incorporated by reference to Exhibit 10.1 to Borrower's Current Report on Form 8-K/A filed April 11, 2012).

 

Manufacturing
Services Agreement, dated September 9, 2013, by and between Navidea Biopharmaceuticals, Inc. and OSO BioPharmaceuticals Manufacturing,
LLC (portions of this Exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately
with the United States Securities and Exchange Commission) (incorporated by reference to Exhibit 10.1 to Borrower's Current Report
on Form 8-K filed September 12, 2013).

 

Office
Lease, dated August 29, 2013, by and between Navidea Biopharmaceuticals, Inc. and BRE/COH OH LLC (portions of this Exhibit have
been omitted pursuant to a request for confidential treatment and have been filed separately with the United States Securities
and Exchange Commission) (incorporated by reference to Exhibit 10.1 to Borrower's Current Report on Form 8-K filed September 5,
2013)

 

Manufacturing
Services Agreement, dated August 16, 2013, by and between Navidea Biopharmaceuticals, Inc. and PETNET Solutions, Inc. (portions
of this Exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the United
States Securities and Exchange Commission) (incorporated by reference to Exhibit 10.1 to Borrower's Current Report on Form 8-K
filed August 22, 2013).

 

    	 

    	 

    

 

Loan
and Security Agreement, dated March 4, 2014, among Oxford Finance LLC, as collateral agent, the Lenders listed on Schedule 1.1
thereof or otherwise a party thereto from time to time including Oxford in its capacity as a Lender, and Navidea Biopharmaceuticals,
Inc. (incorporated by reference to Exhibit 10.1 to Borrower's Current Report on Form 8-K filed March 7, 2014).

 

Subordination
Agreement, dated March 4, 2014, by and among Platinum-Montaur Life Sciences LLC and Oxford Finance LLC, and consented to and acknowledged
by Navidea Biopharmaceuticals, Inc. (incorporated by reference to Exhibit 10.2 to Borrower's Current Report on Form 8-K filed March
7, 2014).

 

Second
Amendment to Loan Agreement, dated March 4, 2014, between Navidea Biopharmaceuticals, Inc. and Platinum-Montaur Life Sciences LLC
(incorporated by reference to Exhibit 10.3 to Borrower's Current Report on Form 8-K filed March 7, 2014).

 

Second
Amended and Restated Promissory Note, dated March 4, 2014, made by Navidea Biopharmaceuticals, Inc. in favor of Platinum-Montaur
Life Sciences LLC (incorporated by reference to Exhibit 10.4 to Borrower's Current Report on Form 8-K filed March 7, 2014).

 

Series
A Preferred Unit Purchase Agreement, dated July 15, 2014, among Borrower, R-NAV, LLC, and the other Purchasers named therein (incorporated
by reference to Exhibit 10.1 to Borrower's Current Report on Form 8-K filed July 16, 2014).

 

Promissory
Note, dated July 15, 2014, between Borrower as Maker and R-NAV, LLC (incorporated by reference to Exhibit 10.2 to Borrower's Current
Report on Form 8-K filed July 16, 2014).

 

Amended
and Restated License Agreement, dated July 14, 2014, between Borrower and the Regents of the University of California (portions
of this Exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the United
States Securities and Exchange Commission) (incorporated by reference to Exhibit 10.1 to Borrower's Quarterly Report on Form 10-Q
filed August 11, 2014).

 

Termination
of License Agreement, dated July 14, 2014, between Borrower and the Regents of the University of California (incorporated by reference
to Exhibit 10.2 to Borrower's Quarterly Report on Form 10-Q filed August 11, 2014).

 

License
Agreement, dated July 14, 2014, between Borrower and the Regents of the University of California (portions of this Exhibit have
been omitted pursuant to a request for confidential treatment and have been filed separately with the United States Securities
and Exchange Commission) (incorporated by reference to Exhibit 10.3 to Borrower's Quarterly Report on Form 10-Q filed August 11,
2014).

 

Employment
Agreement, dated October 13, 2014, between Navidea Biopharmaceuticals, Inc. and Ricardo J. Gonzalez (incorporated by reference
to Exhibit 10.1 to Borrower's Current Report on Form 8-K filed October 15, 2014). 

 

    	 

    	 

    

 

Termination
Agreement, dated April 21, 2015, by and between Navidea Biopharmaceuticals, Inc. and Alseres Pharmaceuticals, Inc. (portions of
this Exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the United
States Securities and Exchange Commission).

 

Termination
Agreement, dated April 21, 2015, by and between Navidea Biopharmaceuticals, Inc. and Alseres Pharmaceuticals, Inc. (portions of
this Exhibit have been omitted pursuant to a request for confidential treatment and have been filed separately with the United
States Securities and Exchange Commission).

 

Exclusive
License Agreement, dated March 5, 2015 between Borrower and SpePharm AG (portions of this Exhibit have been omitted pursuant to
a request for confidential treatment and have been filed separately with the United States Securities and Exchange Commission).

 

Exclusive
License Agreement, dated March 5, 2015 between Borrower and SpePharm AG (portions of this Exhibit have been omitted pursuant to
a request for confidential treatment and have been filed separately with the United States Securities and Exchange Commission).

 

Exclusive
License Agreement, dated March 5, 2015 between Borrower and SpePharm AG.

 

Securities
Purchase Agreement between Macrophage Therapeutics, Dr. Michael Goldberg and Platinum, dated March 11, 2015.

 

Macrophage
Therapeutics Sublicense between Borrower and Macrophage Therapeutics dated March 11, 2015.

 

    	 

    	 

    

 

Schedule 7.15

to Term Loan Agreement

 

Restrictive
Agreements

 

See agreements with lenders listed on Schedule 7.13(a) Part
II.

 

    	 

    	 

    

 

Schedule 7.16

to Term Loan Agreement

 

Real
Property Owned or Leased by Borrower OR ANY SUBSIDARY

 

None.

 

    	 

    	 

    

 

Schedule 7.17

to Term Loan Agreement

 

PENSION
MATTERS

 

Navidea Biopharmaceuticals, Inc. 2014 Stock Incentive Plan

 

Neoprobe Corporation 2002 Stock Incentive Plan

 

Neoprobe Corporation 401(k) Plan

 

    	 

    	 

    

 

Schedule 9.05

to Term Loan Agreement

 

Existing
Investments

 

See
Section 9.05(e) (ii) and (iii) of the Term Loan Agreement.

 

    	 

    	 

    

 

Schedule 9.10

to Term Loan Agreement

 

transactions
with affiliates

 

Services provided to R-NAV pursuant to
Master Services Agreement

 

Borrower will provide in-kind services for
'back office' activities related to project accounting, finance, bookkeeping, and general office management related to TcRA Imaging,
Inc. (“TcRA”), to be credited against the preferred stock allocation for in-kind services. From time to time, Borrower
may also assist with and SnRA Theragnostics, Inc., Canine Osteoarthritis Theragnostics, Inc. and Pediatric Hemophilic Arthropathy,
Inc.

 

In consideration for Services performed
by Borrower in connection with general corporate, financial, accounting, human resources and administrative activities, TcRA shall
issue to Borrower 500,000 Series A Preferred Units of TcRA (the "Stock") on the effective date of this Statement of Work
subject to the terms of the Series A Preferred Unit Purchase Agreement. As of the effective date of this Statement of Work, the
Series A Preferred Units have a value of $1.00 per unit. Borrower shall render the in-kind services on an ongoing, periodic basis
over a three year period at a level of effort commensurate with the issuance of the 500,000 Series A Preferred Units. On an annual
basis, Borrower shall calculate the fair market value of the Services provided to TcRA for the preceding 12-month period and shall
provide to TcRA a reasonably detailed invoice setting forth a description of the Services and the fair market value for such Services.
If the fair market value of such Services is equal to an amount less than $500,000 for the Term, then TcRA shall have an irrevocable
option (the "Repurchase Option") to repurchase from Borrower at a price of $0.01 upon the expiration or termination of
the Agreement, up to but not exceeding the number of shares of Stock that have not vested in accordance with the provision set
forth below as of such date.

 

One
hundred percent (100%) of the Stock shall initially be subject to the Repurchase Option. On each successive one (1) month anniversary
of the effective date of this Statement of Work, one-thirty sixth (1/36th) (13,888 shares) of the Stock subject to the Repurchase
Option shall vest and be released from the Repurchase Option, provided that Borrower is continuing to provide Services to TcRA,
until all the Stock is released from the Repurchase Option. Borrower and TcRA can mutually agree to accelerate the vesting of the
Stock if the Services are accelerated or if the project plan accelerates.

 

    	 

    	 

    

 

Schedule 9.14

to Term Loan Agreement

 

Permitted
Sales and Leasebacks

 

None.EX-4.3

 Exhibit 4.3 

OVERALLOTMENT COMMON STOCK PURCHASE RIGHT 

RXI PHARMACEUTICALS CORPORATION 
  

					
	Overallotment Shares:            		 	Initial Exercise Date:            , 2015	  

 THIS OVERALLOTMENT COMMON STOCK PURCHASE RIGHT (the “Overallotment Purchase Right”) certifies
that, for value received,              or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter
set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the date that is thirteen (13) months following the Initial Exercise Date (the “Termination
Date”) but not thereafter, to subscribe for and purchase from RXi Pharmaceuticals Corporation, a Delaware corporation (the “Company”), up to              shares
(as subject to adjustment hereunder, the “Overallotment Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this
Overallotment Purchase Right shall be equal to the Exercise Price, as defined in Section 2(b). 
 Section 1.
Definitions. In addition to the terms defined elsewhere in this Overallotment Purchase Right, the following terms have the meanings indicated in this Section 1: 

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or
is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. 
 “Board of
Directors” means the board of directors of the Company. 
 “Business Day” means any day except any Saturday, any
Sunday, any day which is a federal legal holiday in the United States or any day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close. 

“Commission” means the United States Securities and Exchange Commission. 

“Common Stock Equivalent” means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common
Stock. 
 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder. 
 “Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive
right or other restriction. 
 “Person” means an individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. 

  
 1 

 “Proceeding” means an action, claim, lawsuit, investigation or proceeding
(including, without limitation, an informal investigation or partial proceeding, such as a deposition), whether commenced or threatened. 

“Purchase Agreement” means Securities Purchase Agreement, dated as of
            , 2015, between the Company and purchasers signatory thereto. 

“Registration Statement” means the effective registration statement on Form S-1 (Commission File No. 333-203389). 

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or
interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. 

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder. 

“Trading Day” means a day on which the principal Trading Market is open for trading. 

“Trading Market” means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on
the date in question: the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, OTCQB or OTCQX (or any successors to any of the foregoing). 

“Transfer Agent” means Computershare Trust Company, N.A., the current transfer agent of the Company. 

Section 2. Exercise. 

a) Exercise of Overallotment Purchase Right. Exercise of the purchase rights represented by this Overallotment Purchase
Right may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of the Company as it may designate by notice in
writing to the registered Holder at the address of the Holder appearing on the books of the Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto and within three (3) Trading Days
of the date said Notice of Exercise is delivered to the Company, the Company shall have received payment of the aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank or, if
available, pursuant to the cashless exercise procedure specified in Section 2(c) below. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise form be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Overallotment Purchase Right to the Company until the Holder has purchased all of the Overallotment Shares
available hereunder and the Overallotment Purchase Right has been exercised in full, in which case, the Holder shall surrender this Overallotment Purchase Right to the Company for cancellation within three Trading

  
 2 

 
Days of the date the final Notice of Exercise is delivered to the Company. Partial exercises of this Overallotment Purchase Right resulting in purchases of a portion of the total number of
Overallotment Shares available hereunder shall have the effect of lowering the outstanding number of Overallotment Shares purchasable hereunder in an amount equal to the applicable number of Overallotment Shares purchased. The Holder and the Company
shall maintain records showing the number of Overallotment Shares purchased and the date of such purchases. The Holder and any assignee, by acceptance of this Overallotment Purchase Right or any partial assignment of this Overallotment Purchase
Right, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase or assignment of a portion of the Overallotment Shares hereunder, the number of Overallotment Shares available for purchase hereunder at any
given time may be less than the amount stated on the face hereof. 
 b) Exercise Price. The exercise price per
share of the Common Stock under this Overallotment Purchase Right shall be $            , subject to adjustment hereunder (the “Exercise Price”). 

c) Cashless Exercise. If at the time of exercise hereof there is no effective registration statement registering, or the
prospectus contained therein is not available for the issuance of the Overallotment Shares to the Holder, then this Overallotment Purchase Right may only be exercised, in whole or in part, at such time by means of a “cashless exercise” in
which the Holder shall be entitled to receive a number of Overallotment Shares equal to the quotient obtained by dividing ((A-B) x (X)) by (A), where: 
  

	 	(A)  =	the VWAP (as defined below) on the Trading Day immediately preceding the date on which Holder elects to exercise this Overallotment Purchase Right by means of a “cashless exercise,” as set forth in the
applicable Notice of Exercise; 

  

	 	(B)  =	the Exercise Price of this Overallotment Purchase Right, as adjusted hereunder; and 

  

	 	(X)  =	the number of Overallotment Shares that would be issuable upon exercise of this Overallotment Purchase Right in accordance with the terms of this Overallotment Purchase Right if such exercise were by means of a cash
exercise rather than a cashless exercise. 

 If Overallotment Shares are issued in such a cashless exercise,
the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act, the Overallotment Shares shall take on the registered characteristics of the Overallotment Purchase Rights being exercised, and the holding period
of the Overallotment Purchase Rights being exercised may be tacked on to the holding period of the Overallotment Shares. The Company agrees not to take any position contrary to this Section 2(c). 

“VWAP” means, for any date, the price determined by the first of the following clauses that applies:
(a) if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or 

  
 3 

 
the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to
4:00 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is
not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported in the “Pink Sheets” published by OTC Markets, Inc. (or a similar organization or agency succeeding to its functions of reporting
prices), the most recent bid price per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as mutually determined by the Company and the Holder, provided that, if the Company and
the Holder are unable to agree upon the fair market value of such security, then the fair market value will be determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then
outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. All such determinations will be appropriately adjusted for any stock dividend, stock split, stock combination or other similar
transaction during such period. 
 d) Mechanics of Exercise. 

i. Delivery of Overallotment Shares Upon Exercise. Overallotment Shares purchased hereunder shall be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is
then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Overallotment Shares to or resale of the Overallotment Shares by Holder or (B) this Overallotment Purchase Right
is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Overallotment Shares to which the Holder is
entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is three Trading Days after the delivery to the Company of the Notice of Exercise (such date, the “Overallotment Share
Delivery Date”), provided that the Holder has paid any required Exercise Price for the portion of this Overallotment Purchase Right being exercised on or prior to such Overallotment Share Delivery Date (including by cashless exercise, if
permitted pursuant to Section 2(c)). The Overallotment Shares shall be deemed to have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record of such shares for all
purposes, as of the date the Overallotment Purchase Right has been validly exercised, with payment to the Company of the Exercise Price (or by cashless exercise, if permitted) and all taxes required to be paid by the Holder, if any, pursuant to
Section 2(d)(vi) prior to the issuance of such shares, having been paid. If the Company fails for any reason to deliver to 

  
 4 

 
the Holder the Overallotment Shares subject to a Notice of Exercise by the Overallotment Share Delivery Date, and the Holder has paid any required Exercise Price for the portion of this
Overallotment Purchase Right being exercised on or prior to such Overallotment Share Delivery Date (including by cashless exercise, if permitted pursuant to Section 2(c)), the Company shall pay to the Holder, in cash, as liquidated damages and
not as a penalty, for each $1,000 of Overallotment Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $5 per Trading Day for each Trading Day after such second Trading Day
following the Overallotment Share Delivery Date until such Overallotment Shares are delivered or Holder rescinds such exercise. 

ii. Delivery of New Overallotment Purchase Rights Upon Exercise. If this Overallotment Purchase Right shall have been
exercised in part, the Company shall, at the request of a Holder and upon surrender of this Overallotment Purchase Right, at the time of delivery of the Overallotment Shares, deliver to the Holder a new Overallotment Purchase Right evidencing the
rights of the Holder to purchase the unpurchased Overallotment Shares called for by this Overallotment Purchase Right, which new Overallotment Purchase Right shall in all other respects be identical with this Overallotment Purchase Right. 

iii. Rescission Rights. In the event that the Buy-In remedy pursuant to section 2(d)(iv) below does not apply or is
otherwise not exercised, if the Company fails to cause the Transfer Agent to transmit to the Holder the Overallotment Shares pursuant to Section 2(d)(i) by the second Trading Day following the Overallotment Share Delivery Date and the Holder
has paid any required Exercise Price for the portion of this Overallotment Purchase Right being exercised on or prior to such Overallotment Share Delivery Date (including by cashless exercise, if permitted pursuant to Section 2(c)), then the
Holder will have the right to rescind such exercise. 
 iv. Buy-In Remedy. In addition to any other rights available
to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Overallotment Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the second Trading Day following
the Overallotment Share Delivery Date and the Holder has paid any required Exercise Price for the portion of this Overallotment Purchase Right being exercised on or prior to such Overallotment Share Delivery Date (including by cashless exercise, if
permitted pursuant to Section 2(c)), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Overallotment Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the 

  
 5 

 
Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including reasonable brokerage commissions, if any) for the shares
of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of Overallotment Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at
which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Overallotment Purchase Right and equivalent number of Overallotment Shares for which such
exercise was not honored (in which case such exercise shall be deemed rescinded, provided, however, that such right to reinstate or rescind shall only apply in the event that the rights pursuant to Section 2(d)(iii) above have not been
exercised) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a
total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of
such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the
Company’s failure to timely deliver shares of Common Stock upon exercise of the Overallotment Purchase Right as required pursuant to the terms hereof. Notwithstanding anything to the contrary in the foregoing, any amounts payable by the Company
to the Holder pursuant to this Section 2(d)(iv) shall be reduced by any amounts that have been paid or are required to be paid to such Holder by the Company pursuant to the last sentence of Section 2(d)(i). 

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the
exercise of this Overallotment Purchase Right. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final
fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share; provided that the Company shall not be required to make any fractional payments on exercise if the aggregate value of fractional
shares is less than $100 and any such lesser amount shall be deemed forfeited. 

  
 6 

 vi. Charges, Taxes and Expenses. Issuance of Overallotment Shares shall
be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of Overallotment Shares, all of which taxes and expenses shall be paid by the Company, and such Overallotment Shares shall be
issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that in the event that Overallotment Shares are to be issued in a name other than the name of the Holder, this Overallotment
Purchase Right when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any
transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for timely processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar
functions) required for timely electronic delivery of the Overallotment Shares. 
 vii. Closing of Books. The Company
will not close its stockholder books or records in any manner which prevents the timely exercise of this Overallotment Purchase Right, pursuant to the terms hereof. 

e) Holder’s Exercise Limitations. The Company shall not effect any exercise of this Overallotment Purchase Right,
and a Holder shall not have the right to exercise any portion of this Overallotment Purchase Right, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice
of Exercise, the Holder (together with the Holder’s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess of the Beneficial Ownership Limitation
(as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise of this Overallotment
Purchase Right with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Overallotment Purchase Right
beneficially owned by the Holder or any of its Affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents)
subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in the preceding sentence, for purposes of this Section 2(e),
beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such
calculation is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained in this Section 2(e)
applies, the determination of whether this Overallotment Purchase Right is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this Overallotment Purchase Right is exercisable shall
be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder’s 

  
 7 

 
determination of whether this Overallotment Purchase Right is exercisable (in relation to other securities owned by the Holder together with any Affiliates) and of which portion of this
Overallotment Purchase Right is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and will have no liability for exercises of
this Overallotment Purchase Right that are in non-compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as
reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the
Transfer Agent setting forth the number of shares of Common Stock outstanding as established by clauses (A), (B), or (C), as applicable. Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally and
in writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company,
including this Overallotment Purchase Right, by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the
number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Overallotment Purchase Right. The Holder, upon notice to the Company, may increase or decrease
the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock upon exercise of this Overallotment Purchase Right held by the Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective
until the 61st day after such notice is delivered to the Company and shall only be effective with regard to such Holder. The provisions of this Section 2(e) shall be construed and implemented
in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or
to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this Section 2(e) shall apply to a successor holder of this Overallotment Purchase Right. 

f) Call Provision. Subject to the provisions of Section 2(e) and this Section 2(f), if, at any time after the
sixth (6th) month following the Initial Exercise Date, the VWAP for each of 10 consecutive Trading Days (the “Measurement Period,” which 10 consecutive Trading Day period shall not have commenced until after the Initial
Exercise Date) exceeds $             (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and the like after the Initial Exercise Date), then the
Company may, within 5 Trading Days of the end of such Measurement Period, call for cancellation of all or any portion of this Overallotment Purchase Right for which a Notice 

  
 8 

 
of Exercise has not yet been delivered (such right, a “Call”) for consideration equal to $0.0001 per Overallotment Share. To exercise this right, the Company must deliver to the
Holder an irrevocable written notice (a “Call Notice”), indicating therein the unexercised portion of this Overallotment Purchase Right to which such notice applies. If the conditions set forth below for such Call are satisfied from
the period from the date of the Call Notice through and including the Call Date (as defined below), then any portion of this Overallotment Purchase Right subject to such Call Notice for which a Notice of Exercise shall not have been received by the
Call Date will be cancelled at 6:30 p.m. (New York City time) on the fifth (5th) Trading Day after the date the Call Notice is delivered to the Holder (such date and time, the “Call Date”). Any unexercised portion of this
Overallotment Purchase Right to which the Call Notice does not pertain will be unaffected by such Call Notice. In furtherance thereof, the Company covenants and agrees that it will honor all Notices of Exercise with respect to Overallotment Shares
subject to a Call Notice that are tendered through 6:30 p.m. (New York City time) on the Call Date. The parties agree that any Notice of Exercise delivered following a Call Notice which calls less than all the Overallotment Purchase Rights shall
first reduce to zero the number of Overallotment Shares subject to such Call Notice prior to reducing the remaining Overallotment Shares available for purchase under this Overallotment Purchase Right. For example, if (A) this Overallotment
Purchase Right then permits the Holder to acquire 100 Overallotment Shares, (B) a Call Notice pertains to 75 Overallotment Shares, and (C) prior to 6:30 p.m. (New York City time) on the Call Date the Holder tenders a Notice of Exercise in
respect of 50 Overallotment Shares, then (x) on the Call Date the right under this Overallotment Purchase Right to acquire 25 Overallotment Shares will be automatically cancelled, (y) the Company, in the time and manner required under this
Overallotment Purchase Right, will have issued and delivered to the Holder 50 Overallotment Shares in respect of the exercises following receipt of the Call Notice, and (z) the Holder may, until the Termination Date, exercise this Overallotment
Purchase Right for 25 Overallotment Shares (subject to adjustment as herein provided and subject to subsequent Call Notices). Subject again to the provisions of this Section 2(f), the Company may deliver subsequent Call Notices for any portion
of this Overallotment Purchase Right for which the Holder shall not have delivered a Notice of Exercise. Notwithstanding anything to the contrary set forth in this Overallotment Purchase Right, the Company may not deliver a Call Notice or require
the cancellation of this Overallotment Purchase Right (and any such Call Notice shall be void), unless, from the beginning of the Measurement Period through the Call Date, (1) the Company shall have honored in accordance with the terms of this
Overallotment Purchase Right all Notices of Exercise delivered by 6:30 p.m. (New York City time) on the Call Date, and (2) the Registration Statement shall be effective as to all Overallotment Shares and the prospectus thereunder available for
use by the Company for the sale of all such Overallotment Shares to the Holder, and (3) the Common Stock shall be listed or quoted for trading on the Trading Market, and (4) there is a sufficient number of authorized shares of Common Stock
for issuance of all Securities under the Transaction Documents, and (5) the issuance upon exercise of the Overallotment Shares subject to the Call shall not cause a breach of any provision of Section 2(e) herein. The Company’s right
to call the Overallotment Purchase Rights under this Section 2(f) shall be exercised ratably among the Holders based on each Holder’s initial purchase of Overallotment Purchase Rights. 

  
 9 

 Section 3. Certain Adjustments. 

a) Stock Dividends and Splits. If the Company, at any time while this Overallotment Purchase Right is outstanding:
(i) pays a stock dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include
any shares of Common Stock issued by the Company upon exercise of this Overallotment Purchase Right or any other securities issued pursuant to the Registration Statement), (ii) subdivides outstanding shares of Common Stock into a larger number
of shares, (iii) combines (including by way of reverse stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common Stock any shares of capital stock of the
Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the
denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of shares issuable upon exercise of this Overallotment Purchase Right shall be proportionately adjusted such that the aggregate
Exercise Price of this Overallotment Purchase Right shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of stockholders entitled to receive
such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification. 

b) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the
Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common Stock (the “Purchase Rights”), then the
Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Overallotment Purchase Right (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of
such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the
Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial
ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder
exceeding the Beneficial Ownership Limitation). 
 c) Pro Rata Distributions. During such time as this Overallotment
Purchase Right is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, 

  
 10 

 
spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Overallotment
Purchase Right, then, in each such case, the Holder shall be entitled following partial or complete exercise of this Overallotment Purchase Right to participate in such Distribution to the same extent that the Holder would have participated therein
if the Holder had held the number of shares of Common Stock acquirable upon such partial or complete exercise of this Overallotment Purchase Right, as applicable (without regard to any limitations on exercise hereof, including without limitation,
the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the
participation in such Distribution (provided, however, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall
not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the
benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). In addition, to the extent that this Overallotment Purchase Right has not been partially or
completely exercised at the time of such Distribution, such portion of the Distribution will be held in abeyance for the benefit of the Holder until the Holder has exercised this Overallotment Purchase Right. 

d) Fundamental Transaction. If, at any time while this Overallotment Purchase Right is outstanding, (i) the
Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person (other than for the purpose of changing the name of the Company or changing the Company’s
jurisdiction of incorporation to another state within the United States), (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its
assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to
sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly or indirectly, in one or more related transactions
effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property, or
(v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of
arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or
party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a “Fundamental Transaction”), then, upon any subsequent exercise of this
Overallotment Purchase Right, the Holder shall have the right to receive, for each Overallotment Share that would have 

  
 11 

 
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section 2(e) on the
exercise of this Overallotment Purchase Right), the number of shares of Common Stock of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate
Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Overallotment Purchase Right is exercisable immediately prior to such Fundamental Transaction (without
regard to any limitation in Section 2(e) on the exercise of this Overallotment Purchase Right). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration
based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the
same choice as to the Alternate Consideration it receives upon any exercise of this Overallotment Purchase Right following such Fundamental Transaction. 

e) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if
any) issued and outstanding. 
 f) Notice to Holder. 

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section 3, the Company shall promptly mail to the Holder a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Overallotment Shares and setting forth a brief statement of the facts
requiring such adjustment. 
 ii. Notice to Allow Exercise by Holder. If, during the term in which this Overallotment
Purchase Right is exercisable by the Holder, (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption
of the Common Stock, (C) the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any
stockholders of the Company shall be required in connection with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or
any compulsory share exchange 

  
 12 

 
whereby the Common Stock is converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the
affairs of the Company, then, in each case, the Company shall cause to be mailed to the Holder at its last address as it shall appear upon the Overallotment Purchase Right Register of the Company, at least 10 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of
which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share
exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable
upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be
specified in such notice. To the extent that any notice provided in this Overallotment Purchase Right constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file
such notice with the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Overallotment Purchase Right during the period commencing on the date of such notice to the effective date of the event
triggering such notice except as may otherwise be expressly set forth herein. 
 Section 4. Transfer of Overallotment
Purchase Right. 
 a) Transferability. Subject to compliance with applicable securities laws, the Holder may
transfer this Overallotment Purchase Right and all rights hereunder (including, without limitation, any registration rights), in whole or in part, upon surrender of this Overallotment Purchase Right at the principal office of the Company or its
designated agent, together with a written assignment of this Overallotment Purchase Right substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the
making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Overallotment Purchase Right or Overallotment Purchase Rights in the name of the assignee or assignees, as applicable, and in
the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Overallotment Purchase Right evidencing the portion of this Overallotment Purchase Right not so assigned, and this Overallotment
Purchase Right shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Overallotment Purchase Right to the Company unless the Holder has assigned this Overallotment
Purchase Right in full, in which case, 

  
 13 

 
the Holder shall surrender this Overallotment Purchase Right to the Company within three (3) Trading Days of the date the Holder delivers an assignment form to the Company assigning this
Overallotment Purchase Right in full. The Overallotment Purchase Right, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Overallotment Shares without having a new Overallotment Purchase Right issued.

 b) New Overallotment Purchase Rights. This Overallotment Purchase Right may be divided or combined with other
Overallotment Purchase Rights upon presentation hereof at the principal office of the Company, together with a written notice specifying the names and denominations in which new Overallotment Purchase Rights are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Overallotment Purchase Right or Overallotment Purchase Rights
in exchange for the Overallotment Purchase Right or Overallotment Purchase Rights to be divided or combined in accordance with such notice. All Overallotment Purchase Rights issued on transfers or exchanges shall be dated the initial issuance date
of this Overallotment Purchase Right and shall be identical with this Overallotment Purchase Right except as to the number of Overallotment Shares issuable pursuant thereto. 

c) Overallotment Purchase Right Register. The Company shall register this Overallotment Purchase Right, upon records to
be maintained by the Company for that purpose (the “Overallotment Purchase Right Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Overallotment
Purchase Right as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. 

Section 5. Miscellaneous. 

a) No Rights as Stockholder Until Exercise. This Overallotment Purchase Right does not entitle the Holder to any voting
rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. 

b) Loss, Theft, Destruction or Mutilation of Overallotment Purchase Right. Upon receipt by the Company of evidence
reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Overallotment Purchase Right or any stock certificate relating to the Overallotment Shares, and in case of loss, theft or destruction, of indemnity or security
reasonably satisfactory to it, and upon surrender and cancellation of such Overallotment Purchase Right or stock certificate, if mutilated, the Company will make and deliver a new Overallotment Purchase Right or stock certificate of like tenor, in
lieu of such Overallotment Purchase Right or stock certificate. 
 c) Saturdays, Sundays, Holidays, etc. If the last
or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business Day. 

  
 14 

 d) Authorized Shares. 

The Company covenants that, during the period the Overallotment Purchase Right is outstanding, it will reserve from its
authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Overallotment Shares upon the exercise of any purchase rights under this Overallotment Purchase Right. The Company further covenants that its
issuance of this Overallotment Purchase Right shall constitute full authority to its officers who are charged with the duty of executing stock certificates to execute and issue the necessary Overallotment Shares upon the exercise of the purchase
rights under this Overallotment Purchase Right. The Company will take all such reasonable action as may be necessary to assure that such Overallotment Shares may be issued as provided herein without violation of any applicable law or regulation, or
of any requirements of the Trading Market upon which the Common Stock may be listed. All Overallotment Shares which may be issued upon the exercise of the purchase rights represented by this Overallotment Purchase Right will, upon exercise of this
Overallotment Purchase Right and payment for such Overallotment Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue
thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue). 
 Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Overallotment Purchase Right, but will at all times in good faith assist in the carrying out of all such
terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Overallotment Purchase Right against impairment. Without limiting the generality of the foregoing, the Company will
(i) not increase the par value of any Overallotment Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the
Company may validly and legally issue fully paid and nonassessable Overallotment Shares upon the exercise of this Overallotment Purchase Right and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or
consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Overallotment Purchase Right. 

Before taking any action which would result in an adjustment in the number of Overallotment Shares for which this Overallotment
Purchase Right is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. 

  
 15 

 e) Governing Law. All questions concerning the construction, validity,
enforcement and interpretation of this Overallotment Purchase Right shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflict of laws thereof. Each
party agrees that all legal proceedings concerning the interpretation, enforcement and defense of this Overallotment Purchase Right shall be commenced in the state and federal courts sitting in the City of New York, Borough of Manhattan (the
“New York Courts”). Each party hereto hereby irrevocably submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the
jurisdiction of such New York Courts, or such New York Courts are improper or inconvenient venue for such proceeding. Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury
in any legal proceeding arising out of or relating to this Overallotment Purchase Right. If any party shall commence an action or proceeding to enforce any provisions of this Overallotment Purchase Right, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred in the investigation, preparation and prosecution of such action or proceeding. 

f) Restrictions. The Holder acknowledges that the Overallotment Shares acquired upon the exercise of this Overallotment
Purchase Right, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. 

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of
Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies, notwithstanding the fact that all rights hereunder terminate on the Termination Date. Without limiting any other provision of this
Overallotment Purchase Right or the Purchase Agreement, if a party willfully and knowingly fails to comply with any provision of this Overallotment Purchase Right, which results in any material damages to the other party, the offending party shall
pay to the other party such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by such other party in collecting any
amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder. 
 h) Notices.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice of Exercise, shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized
overnight courier service, addressed to the Company, at             , Attention:             , facsimile number:
            , email address:                     ,

  
 16 

 
or such other facsimile number, email address or address as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be
provided by the Company hereunder shall be in writing and delivered personally, by facsimile, or sent by a nationally recognized overnight courier service addressed to each Holder at the facsimile number or address of such Holder appearing on the
books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile
number set forth in this Section prior to 5:30 p.m. (New York City time) on any Trading Day, (ii) the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number set forth
in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or
(iv) upon actual receipt by the party to whom such notice is required to be given. 
 i) Limitation of Liability.
No provision hereof, in the absence of any affirmative action by the Holder to exercise this Overallotment Purchase Right to purchase Overallotment Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any
liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the Company. 

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of
damages, will be entitled to specific performance of its rights under this Overallotment Purchase Right. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions
of this Overallotment Purchase Right and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. 

k) Successors and Assigns. Subject to applicable securities laws, this Overallotment Purchase Right and the rights and
obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Overallotment Purchase Right are intended
to be for the benefit of any Holder from time to time of this Overallotment Purchase Right and shall be enforceable by the Holder or holder of Overallotment Shares. 

l) Amendment. This Overallotment Purchase Right is one of a series of Overallotment Purchase Rights issued by the
Company pursuant to the Registration Statement (such series of Overallotment Purchase Rights, the “Offering Overallotment Purchase Rights”). Any term of this Overallotment Purchase Right may be modified or amended or the provisions
hereof waived with the written consent of the Company and the holders of at least 67% of the Overallotment Shares underlying the then outstanding Offering Overallotment Purchase Rights, provided that any such written consent must include the consent
of any holder of outstanding Offering Overallotment Purchase Rights that were purchased pursuant to the Purchase Agreement which had a Subscription Amount (as defined in the Purchase Agreement) of at least $1 million. 

  
 17 

 m) Severability. Wherever possible, each provision of this Overallotment
Purchase Right shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Overallotment Purchase Right shall be prohibited by or invalid under applicable law, such provision shall be
ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Overallotment Purchase Right. 

n) Headings. The headings used in this Overallotment Purchase Right are for the convenience of reference only and shall
not, for any purpose, be deemed a part of this Overallotment Purchase Right. 
 ******************** 

(Signature Page Follows) 

  
 18 

 IN WITNESS WHEREOF, the Company has caused this Overallotment Purchase Right to be executed by
its officer thereunto duly authorized as of the date first above indicated. 
  

			
	RXI PHARMACEUTICALS CORPORATION
		
	By:		  

	Name:		
	Title:		

  
 19 

 NOTICE OF EXERCISE 

 

	TO:	RXI PHARMACEUTICALS CORPORATION 

 (1) The undersigned hereby elects to purchase
             Overallotment Shares of the Company pursuant to the terms of the attached Overallotment Purchase Right (only if exercised in full), and tenders herewith payment of the exercise
price in full, together with all applicable transfer taxes, if any. 
 (2) Payment shall take the form of (check applicable box): 

 ̈  in lawful money of the United States; or 

 ̈  if permitted the cancellation of such number of Overallotment Shares as is
necessary, in accordance with the formula set forth in subsection 2(c) of the Overallotment Purchase Right, to exercise this Overallotment Purchase Right with respect to the maximum number of Overallotment Shares purchasable pursuant to the cashless
exercise procedure set forth in subsection 2(c) of the Overallotment Purchase Right. 
 (3) Please issue said Overallotment Shares in the
name of the undersigned or in such other name as is specified below: 
  

			
	  
		

 The Overallotment Shares shall be delivered to the following DWAC Account Number: 

 

			
	  
		
		
	  
		
		
	  
		

 [SIGNATURE OF HOLDER] 
  

			
	Name of Investing Entity:		  

			
	Signature of Authorized Signatory of Investing Entity:		  

			
	Name of Authorized Signatory:		  

			
	Title of Authorized Signatory:		  

			
	Date:		  

 EXHIBIT B 

ASSIGNMENT FORM 
 (To assign
the foregoing Overallotment Purchase Right, execute this form and supply required information. Do not use this form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Overallotment Purchase Right and all rights evidenced thereby are hereby assigned to 

 

			
	Name:		  

			(Please Print)
		
	Address:		  

			(Please Print)

  

					
	
Dated:                  ,   
      
		
			
	 Holder’s Signature:
		  
		
			
	 Holder’s Address:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]